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Abstract 
As society draws closer to the post-antibiotic era and the pipeline for alternatives dries, 
there is an urgent need for the development of novel antimicrobial therapies that do not promote 
bacterial resistance, particularly for immunocompromised chronic wound patients. Antimicrobial 
peptides (AMPs), including human-derived LL37, show considerable promise as broad spectrum 
alternatives that also have wound healing properties; however, few have been clinically 
implemented as novel antimicrobials due to their cytotoxicity stemming from a poor understanding 
of their mechanisms and low stability in vivo. It has been suggested that tethering, or attaching 
AMPs onto surfaces, is a viable strategy of delivering bioactive AMPs to surfaces while reducing 
cytotoxicity and improving stability. Thus, we designed new chimeric versions of LL37 with 
collagen-binding domains (CBD), derived from collagenase (cCBD-LL37) and fibronectin (fCBD-
LL37) for non-covalent tethering onto collagen, a prevalent biopolymer in commercially available 
wound dressings and scaffolds. Our overall hypothesis was that CBDs would mediate stable 
tethering of broadly active, non-cytotoxic CBD-LL37 onto collagen-based scaffolds. 
We first studied the loading, release and bioactivities (e.g. antimicrobial activity and 
cytotoxicity) of each CBD-LL37 on commercially available 100% collagen type I PURACOL® 
wound scaffolds. We found that both cCBD-LL37 and fCBD-LL37 bound highly to collagen, were 
active against relevant wound pathogens, demonstrated stable activity after 14 days of release, and 
were not cytotoxic to human fibroblasts. The addition of different CBDs onto LL37 also markedly 
altered their soluble bioactivities. Using similar methods, we then studied the loading, release and 
bioactivity of each CBD-LL37 on a commercially available FIBRACOL® wound scaffolds, 
comprised of 90% collagen type I and 10% calcium alginate biopolymers. We found that both 
cCBD-LL37 and fCBD-LL37 also bound highly to and retained on collagen for 14 days, but were 
xii 
 
only active against Gram-negative P. aeruginosa. This suggested that the presence other 
biopolymers in addition to collagen, which is common among commercial wound dressings, could 
cause significant differences in binding, retention and bioactivities of CBD-LL37.  
To better understand how CBD modification affected CBD-LL37 structure leading to 
different bioactivities, we studied the CBD sequence-, peptide structure-, concentration-, time-, 
and bilayer composition-dependent interactions of soluble CBD-LL37 and compared these 
findings with the properties of unmodified LL37. Using Molecular Dynamics (MD) simulations, 
circular dichroism (CD) spectroscopy, quartz crystal microbalance with dissipation (QCM-D), and 
fluorescent bilayer imaging we determined the structural basis behind CBD alterations in 
bioactivities. MD and CD, in addition to other intrinsic CBD properties (helicity, amphiphilicity, 
charge) we hypothesized that cCBD-LL37 utilized similar mechanisms as unmodified LL37 while 
fCBD-LL37 demonstrated based primarily on surface adsorption. 
We used QCM-D and Voigt-Kelvin viscoelastic modeling to determine the time- and 
concentration-dependent interactions of unmodified LL37 with model mammalian lipid bilayers, 
the mechanisms of which are still controversial in literature despite being widely studied. These 
results were used to propose a model for the interaction mechanism of LL37 with zwitterionic 
bilayers that aligned with its bioactive concentrations. LL37 adsorbed at concentrations where it 
is immunomodulatory until reaching a threshold which corresponded with its antimicrobial 
concentrations. The threshold was correlated to lipid bilayer saturation, after which LL37 formed 
transmembrane pores. We observed collapse of the bilayer into a rigid proteolipid film at 
concentrations higher than the reported cytotoxic threshold of LL37.  
The mechanistic and structural information for each CBD-LL37 and unmodified LL37 
provided a baseline for QCM-D and Voigt-Kelvin viscoelastic modeling to further elucidate the 
xiii 
 
time-, concentration-, lipid composition- and CBD sequence-dependent basis behind the observed 
bioactivities of cCBD-LL37 and fCBD-LL37. We found that similar to LL37, cCBD-LL37 
demonstrated pore formation mechanisms likely due to their similar charges, structural content 
and amphiphilicity. fCBD-LL37 demonstrated time-dependent, adsorption-based mechanism 
likely due to its anchoring aromatic residues, low charge, and low amphiphilicity. Knowledge 
gained from this study allowed mechanistic predictions of two newly designed hypothetical CBD-
LL37 peptides. 
Results from this study contribute to a better understanding of a new class of antimicrobial, 
non-cytotoxic therapies based on collagen-tethered CBD-LL37, bringing it closer to clinical 
implementation in chronic wound applications and demonstrate the viability of biopolymer 
tethering as a platform toward using AMPs to quench the resistance crisis. 
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1.1. Specific Aims 
Widespread microbial resistance, once just a looming possibility, has become a dangerous 
reality in today’s hospitals that severely threatens antibiotic effectiveness [1]. Chronic wound and 
burn victims in particular are immunocompromised and suffer a much higher chance of infection 
[2], thus requiring continuous antibiotic treatments that promote resistance. Wounded patients 
receive commercially available dressings or scaffolds, many of which are comprised of 
biopolymers such as collagen to enhance tissue regeneration and promote wound healing. 
Scaffolds promote a nutrient rich environment that, without adequate infection control, promotes 
diverse bacterial growth and biofilm formation [3]. Unfortunately, strategies used to combat 
infection on wound dressings and scaffolds either promote resistance or hinder tissue regeneration 
[4-6]. It is clear that alternative antimicrobial strategies are needed on biopolymer-based wound 
scaffolds that kill a wide range of bacteria and do not hinder healing while reducing the chance of 
bacterial resistance. 
Natural antimicrobial peptides (AMPs), specifically human-derived LL37, offer a 
promising alternative toward answering this need [7]. In addition to their broad antimicrobial 
activity [8] and pro-wound healing activities [9], AMPs such as LL37 prevent infection with a low 
likelihood of resistance due to their unique membrane-active mechanisms [10]. To date, few AMPs 
have been clinically implemented due to their narrow therapeutic ratio (defined as the ratio of 
antimicrobial to cytotoxic concentrations), a poor understanding of their specific mechanisms, and 
low degradation stability [11]. Tethering, or attaching, AMPs onto surfaces may improve these 
shortcomings [12]. Tethering strategies typically utilize covalent attachment [13]; however, we 
chose a biocompatible strategy of non-covalent AMP tethering onto collagen, a prevalent 
biopolymer in both the wound site and commercially available wound dressings. Thus, the goal 
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of this project was to evaluate the bioactivities, collagen-binding abilities, and biophysical 
mechanisms of two chimeric versions of human AMP LL37 with collagen-binding domains 
(collagenase-derived cCBD-LL37 and fibronectin-derived fCBD-LL37), compared with 
unmodified LL37, for their use in collagen scaffolds for chronic wound healing applications. 
To do this, we first studied the binding, retention and activities of the chimeric LL37 on 
collagen-based scaffolds [14]. Then, we studied soluble LL37, cCBD-LL37 and fCBD-LL37 
structures and interactions with model membranes to gain understanding of the molecular 
mechanisms behind the observed cytotoxicity and antimicrobial activities, which contribute to the 
peptides’ therapeutic ratios. These studies demonstrated collagen tethering as a viable strategy to 
deliver broadly antimicrobial, non-cytotoxic, and stable AMPs to chronic wounds, and provided 
insight to their structures and mechanisms. Results from this study will ultimately lead to new 
designs and the development of collagen-binding AMPs as a platform to combat the threat of 
antimicrobial resistance in chronic wounds. Toward this end, we: 
AIM 1: Evaluated the loading, release and bioactivity from CBD-AMPs in 3D collagen 
scaffolds. Two new chimeric versions of human LL37 were designed with C-terminal collagen-
binding domains (CBDs), derived from collagenase (cCBD-LL37) and fibronectin (fCBD-LL37). 
Chimeric cCBD-LL37, fCBD-LL37 and unmodified LL37 were then loaded onto commercially 
available, 100% collagen type I PURACOL® scaffolds and evaluated first for their collagen 
binding and retention using immunohistochemistry and enzyme-linked immunosorbent assays. 
Second, antimicrobial activity against multiple wound pathogens and cytotoxicity against human 
dermal fibroblasts were evaluated for soluble and tethered cCBD-LL37 and fCBD-LL37 compared 
with soluble and collagen adsorbed unmodified LL37 [14]. Third, similar methods were used to 
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determine CBD-LL37 and LL37 interactions with scaffold made of mixed biopolymers, 90% 
collagen type I and 10% calcium alginate (FIBRACOL®). 
AIM 2: Determined the interaction mechanism of human LL37 with model zwitterionic 
bilayers. Given that the specific mechanisms of cytotoxicity of unmodified LL37 leading to its 
narrow therapeutic ratio are still controversial in literature [15-19], we sought a clearer 
understanding of unmodified LL37 interactions with model mammalian lipid bilayers. We studied 
time- and concentration-dependent properties of LL37 interactions with model zwitterionic 
phosphatidylcholine (PC) bilayers using real-time quartz crystal microbalance with dissipation 
(QCM-D) [20]. We first evaluated concentration-dependent changes in LL37 adsorption and PC 
bilayer viscoelastic properties and used the Voigt-Kelvin model [21] to evaluate changes in bilayer 
thickness and density after interactions with different LL37 concentrations. Second, we studied 
the changes in these properties with time. Combined, these data allowed us to propose an 
interaction mechanism of LL37 with model mammalian membranes.  
AIM 3: Elucidated cCBD- and fCBD-LL37 mechanisms of cytotoxicity, stability, and 
antimicrobial activity. Based on the improved therapeutic ratio of CBD-LL37 peptides observed 
when tethered onto 3D collagen scaffolds (AIM 1), it appeared that the presence of CBDs onto 
LL37 altered its fundamental cytotoxic and antimicrobial mechanisms. We hypothesized that these 
changes were caused by the addition of unique CBD sequences, leading to changes in structure 
and specific interactions with both mammalian and bacterial lipids. We investigated structure of 
each CBD-LL37 using a combination of molecular modeling and spectroscopic techniques. Then, 
the concentration- and time-dependent biophysical interactions (in terms of adsorption and 
viscoelastic changes) with model zwitterionic and charged bilayers were studied using QCM-D. 
Additional information on thickness and density changes with concentration and with time was 
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gathered with Voigt-Kelvin modeling. After peptide interactions, fluorescent-labeled lipids were 
visualized using fluorescent microscopy. Together, these data allowed us to propose CBD 
structure-, lipid composition-, time-, and concentration-dependent mechanisms of CBD-LL37 
against lipid bilayers. New understanding of structure-function relationships gained in AIM 3 
allowed us to design two new CBD-LL37 peptides and predict their bioactivities based on CBD 
properties and structure. 
 
1.2. Broader Impact Statement 
Current ways to prevent infection of collagen-based wound dressings and scaffold 
materials for chronic wound patients, such as silver, antibiotic, or chemical antiseptic treatments, 
effectively kill bacteria but are often cytotoxic, may hinder healing and will promote bacterial 
resistance [1, 4, 22]. This is troublesome, since the longer a wound remains unhealed, the higher 
the chance of infection with resistant bacteria. The post-antibiotic era is fast approaching as the 
new antibiotic pipeline dries, and it is estimated that resistance will cost over $100 trillion dollars 
and kill more people than cancer by 2050 [23]. Antimicrobial peptides (AMPs), prominently 
human LL37, are among the most promising alternative antimicrobials due to their broad-spectrum 
antimicrobial activity, low likelihood of resistance and unique immunomodulatory activities [24]. 
If AMPs were successfully developed for the clinic, thousands of new protein-based antimicrobial 
alternatives could be introduced, halting the threat of antimicrobial resistance. Uniquely designed 
chimeric LL37 with added collagen-binding domains for tethering onto collagen-based wound 
scaffolds may become a platform approach to improving upon AMP shortcomings while taking 
advantage of their dual antimicrobial and pro-healing activities for chronic wound applications. If 
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successful, collagen-tethered AMPs could provide a foundation for the successful clinical 
implementation of thousands of new antimicrobial therapeutics. 
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Chapter 2: Introduction 
2.1. The threat of antibiotic resistance in chronic wounds 
Infections caused by antibiotic-resistant bacteria pose a serious and “catastrophic” threat 
to every part of today’s healthcare system [1]. It was recently estimated that by 2050, resistance 
will cause more deaths than prevalent diseases like cancer, and cost a devastating $100 trillion 
dollars per year [2]. A true crisis, some governments have incorporated resistance outbreaks into 
natural disaster planning [3]. The new drug pipeline for antimicrobials has been drying up; for 
example, only two new antibiotics were launched in 2015; thirty new antibiotics have been 
launched since 2000 [4]. 
Antibiotic resistance severely complicate the treatments of many conditions. A prominent 
example is in the treatment of chronic, non-healing wounds such as ulcers or burns. Infections of 
chronic wounds already cost over $24 billion per year in the United States [5]. The chronic wound 
environment, particularly those treated with wound dressings environment provides a moist, 
nutrient-rich environment conducive to bacterial proliferation and biofilm growth [6]; over two 
hundred different species can populate a single chronic wound, including resistant organisms such 
as Methicillin-resistant Staphylococcus aureus or Vancomycin-resistant Enterococcus species [7]. 
Unfortunately, current natural and synthetic wound dressings lack adequate infection control. The 
most common treatment are silver-based dressings, which effectively kill bacteria but hinder 
healing [8]. 
The need for new alternatives to fight resistant organisms is clear. The development of a 
suitable antibiotic alternative has four major requirements (Fig. 1): 
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1. broad activity (e.g. kill a broad range of Gram-positive, Gram-negative, and fungal 
species),  
2. biocompatibility (e.g. broad mechanisms of action that target bacterial membranes and not 
mammalian membranes; non-hemolytic and non-cytotoxic), 
3. effective delivery (e.g. it will allow stable delivery to the infected area in an appropriate 
dose that will not promote resistance [6], and 
4. low cost [9]. 
 
Figure 1: The four major requirements of antibiotic alternatives. 
 
For chronic wounds, the therapy must not hinder healing. Thus, there is a great need for 
the development of new, broad-spectrum antimicrobial treatments for chronic wounds that 
promote healing without promoting resistance. Such a development could be the foundation for 
replenishment of the drying pipeline. 
2.2. Antimicrobial peptides (AMPs) and cathelicidin LL37 
Among the most promising alternative antimicrobials currently in development are 
antimicrobial peptides (AMPs). AMPs are short (10 to 50), cationic (+2 to +9), amphiphilic and 
broadly antimicrobial proteins found in the innate immune systems of many species [10]. The 
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broad activity of AMPs is due to an ability to interact with bacterial membranes (which have a 
higher relative content of anionic lipids compared to mammalian membranes) using 
electrostatically driven, physical mechanisms of action. For this reason, there is a lower likelihood 
of the development of resistance against AMPs [11]. AMPs are classified according to their 
structural characteristics as well as their species derivation [12]. The diversity of AMPs holds an 
immense opportunity for the development of an entire new class of antimicrobials [13]. 
The class of mammalian AMPs, cathelicidins [14], contains a single human AMP called 
LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) [15-17]. Cathelicidins are 
characterized by a conserved N-terminal “cathelin-like domain” [18], and contain several unique 
structures and functions [19]. LL37 is the 37-amino acid active region of the hCAP-18 originally 
thought to be strictly expressed in the granules of neutrophils [16], but in reality is expressed in 
many other cell types [20]. hCAP-18 is inactive, but is cleaved into active LL37 by proteinase-3 
[21]. LL37 is broadly antibacterial, antifungal, antiviral, anti-biofilm, anti-parasitic and anti-
protozoan from 0.5 to 10 µM [22]. Uniquely, at concentrations below 1 µM, LL37 demonstrates 
both direct and indirect pro-wound healing activities [23]. Examples include neutralization of 
lipopolysaccharides (LPS) and endotoxins, control of apoptosis, and chemotactic activity [24]. The 
combination of antimicrobial and immunomodulatory activities make LL37 promising as a therapy 
for infection control in chronic wounds. 
Unfortunately, LL37 as well as other AMPs have not become clinically relevant to date, 
primarily due to its cytotoxicity at high concentrations and low degradation stability in vivo [10, 
25]. The cytotoxic threshold of LL37 is 13 µM [23, 24]; the therapeutic ratio (ratio of the 
antimicrobial to cytotoxic concentrations) must be widened by approximately an order of 
magnitude, to successfully reach the clinic. Such an improvement will stem from a better 
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understanding of LL37-membrane interaction mechanisms, which will support the design, 
development, and delivery of new AMPs [10].  
As with many other AMPs, the action mechanisms of human LL37 are still controversial. 
Generally, it is agreed that the LL37 is electrostatically driven to anionic membranes, given its +6 
charge (pH 7). Its amphiphilicity allows interactions with both the polar lipid head groups as well 
as the hydrophobic lipid cores. However, various specific mechanisms, including the detergent-
like carpet [26, 27], the non-pore carpet [28] and toroidal pore [20, 29] mechanisms have been 
proposed (Table 1). The carpet model involves initial adsorption of LL37 on the bilayer surface, 
usually facilitated by electrostatics. In this conformation, peptides align parallel to the bilayer with 
their hydrophilic face interacting with lipid head groups, creating a carpet of peptides covering the 
bilayer surface. At a threshold concentration, massive disruption occurs from “detergent-like” 
action of the peptides, which causes the formation of peptide-lipid micelles that lift from the bilayer 
surface. Peptide-lipid micelles have been rarely observed for LL37 [27, 30], leading to the 
proposed non-pore carpet model. The early stage of this model, much like the “sinking raft model” 
[31], involves peptide alignment parallel on the bilayer surface and intercalation within the lipid 
head groups. The increased accumulation of peptides causes a rigid transition in lipid phase from 
a natural fluid phase to non-natural cubic or hexagonal phases, following by full disruption of the 
bilayer [28]. A similar mechanism which is highly lipid composition-dependent is utilized by 
Pardaxin, an AMP derived from the Red Sea sole [32]. The toroidal pore mechanism is most 
commonly proposed for LL37 [20, 29]. In this mechanism, intercalation within polar lipid head 
groups and the formation of transient pores within the membrane also occurs at early stages and is 
characterized by induced positive membrane curvature, membrane thinning, leakage and bilayer 
disorder [33]. At a critical peptide-to-lipid ratio, transient pores transition into full transmembrane 
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pores, and peptide helices are thought to interact strongly with lipid head groups on both sides of 
the membrane, leading to toroid-shaped pores [31]. All of these mechanisms eventually lead to 
membrane disruption in the form of holes or pores, which in turn causes cell leakage, lysis and 
death. 
Table 1: Proposed mechanisms of LL37-membrane interaction 
Mechanism Description Schematica Ref. 
Detergent-
Like Carpet 
 Bilayer adsorption (electrostatic) 
 Insertion at a critical concentration 
 Formation of peptide-lipid micellular 
aggregates that lift off of bilayer 
 
[26] 
Non-pore 
Carpet 
 Bilayer adsorption (electrostatic) 
 Accumulation in a parallel orientation 
 Intercalation within lipid head groups 
 Rigid transition of bilayer into cubic phase 
prior to full disruption at a critical 
concentration 
 
[28] 
Toroidal 
Pore 
 Bilayer adsorption (electrostatic) 
 Induced positive curvature strain, leakage, 
membrane thinning, bilayer disorder 
 Transmembrane pores formed at a critical 
concentration 
 Pores are toroid-shaped due to interactions 
of peptides with both head groups 
 
[29] 
aLL37 peptides are represented by orange helices, lipid bilayers are represented in blue. 
 
In order to eliminate cytotoxic effects of LL37, many strategies have been studied. Most 
common are changes to its secondary structure, such as truncation and amino acid substitution. 
KR-12 (KRIVQRIKDFLR) is the shortest functional part of LL37 and has been widely studied 
[34]. Peptide hybridization has been used successfully for other peptides; however, both the C- 
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and N-termini of LL37 are responsible for cytotoxic or hemolytic function [35]. Another strategy 
has been co-delivery of LL37 with other, synergistic agents such as antibiotics [36] and silver [37], 
which require lower concentrations of LL37. Still, the presence of antibiotics or silver in the 
chronic wound environment is non-ideal, where an environment conducive to healing is required. 
Methods of controlled release, such as from poly(lactic)-co-glycolic acid microcapsules [38] or 
from within polyelectrolyte multilayers [39-41] are more promising methods for preserving the 
antimicrobial function of LL37 since they preserve the entire peptide structure until release is 
triggered. These strategies are still widely underdeveloped, suffer from large burst-like release 
profiles, which may be cytotoxic [39], and often require costly fabrication processes. New 
strategies must be developed for the use of LL37 to control infection of chronic wounds. 
2.3. Tethering of AMPs as a strategy for reducing cytotoxicity and degradation susceptibility 
AMP tethering, or the covalent attachment of AMPs onto surfaces, has been suggested as 
a possible strategy of reducing peptide cytotoxicity and reducing proteolytic degradation [42]. 
Covalent attachment of many different AMPs onto many different substrates using many different 
chemistries have demonstrated promising results toward creating non-cytotoxic, stable surfaces 
that actively kill bacteria, reduce bioburden and prevent the formation of biofilms (for a literature 
reviews, see [42-44]; Appendix 2, Table S1). The addition of linker molecules, such as 
poly(ethylene glycol) [45], block co-polymers [46], or other polymer brushes [47-49] has 
demonstrated the ability to preserve AMP flexibility, an attribute often required to maintain its 
antimicrobial function [50]. 
Many other parameters can vastly influence peptide activities when tethered. Important 
variables in tethering include surface charge density and concentration [42, 51], immobilization 
site [52, 53], time allowed for folding [54], linker type and length [45, 50, 55], peptide mode of 
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action [56], bacteria type [45], potential triggered release [39], flexibility [50, 57, 58], orientation 
and conformation [59, 60], peptide type, other peptide characteristics such as amphiphilicity [61, 
62], substrate [59, 63], and grafting method [64]. No simple correlations exist between the different 
tethering parameters to date, largely due to a lack of methods to study tethered peptides in a 
cohesive, yet simple way. Indeed, several methods have been used to study tethered AMPs, which 
has led to widely varying results over which parameters to emphasize toward achieving optimal 
bioactivities [42, 64].  
Overall, it appears that an improved, in depth knowledge of how tethering peptides 
influences structure and interactions with different lipid types, thereby influencing its different 
bioactivities, would considerably advance AMP development in the clinic. The development of 
novel techniques to study the relations between these different parameters would also catalyze new 
discoveries and add to currently limited fundamental knowledge of tethered AMP mechanisms. 
For chronic wound applications, care must be taken to avoid toxic tethering chemistries [39] and 
preserve the immunomodulatory function of AMPs. 
2.4. Design of chimeric LL37 with collagen-binding domains for chronic wound applications 
Based on the promise that tethering has in preserving the native activity as well as 
improving stability of AMPs, we were inspired to create a new tethering strategy for AMPs in the 
chronic wound environment. Toward designing a tethered peptide system for chronic wound 
healing applications, choice of the tethering strategy, peptide, and substrate were important. 
 We chose human AMP LL37 for four major reasons. First, due to its broad-spectrum activity 
against many of the bacteria and fungi found in chronic wounds [22]. Second, due to its 
promising wide array of in vitro immunomodulatory activities [23]. Third, due to its human 
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derivation, reducing the likelihood of immunogenicity. Lastly, Gabriel et al. tethered LL37 
onto titanium using flexible poly(ethylene glycol), and demonstrated promise for maintaining 
antimicrobial activity when immobilized [57]. 
 The choice of substrate was straightforward when we studied the chronic wound healing 
industry. It is common to dress wounds with either a superficial dressing or wound scaffold, 
depending on the severity of the wound. Many biomaterials are utilized for these scaffolds; 
however, one of the most widely available and biocompatible material for wound healing is 
type I collagen [65]. Thus, we chose biocompatible and natural biopolymer, collagen type I as 
a substrate for LL37 tethering. 
 The choice of tethering strategy was not as apparent. Tethering strategies of AMPs are 
typically covalent; however, we wanted to avoid potential cytotoxic side effects that covalent 
tethering could have in the chronic wound environment [39]. Thus, we turned toward other 
tethered molecules that had been “tethered” onto collagen and other biopolymers, e.g. growth 
factors. We identified a non-covalent strategy of tethering growth factors using short collagen-
binding domains (CBDs) derived from various sources [66-69]. This strategy demonstrated 
attenuated release profiles, thereby increasing stability, and demonstrated this for many 
different growth factors both in vitro and in vivo [70-74]. Thus, we chose CBDs to act as non-
covalent tethers for the retention of LL37 on collagen.  
The final design of chimeric LL37 peptides modified with CBDs (called, CBD-LL37) 
included the full, active region of LL37 with the CBD on the C-terminus (Fig. 2). Between the 
sequences was a FLAG™ octapeptide (DYKDDDDK). This common commercial sequence is 
used widely as an epitope tag [75], which we reasoned could be useful for biochemical and 
biophysical studies on CBD-LL37, given that LL37 does not have a fluorescent tryptophan residue. 
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FLAG™ was also added to act as a flexible linker sequence to preserve peptide flexibility and 
native mechanisms [45, 50, 58]. There are many possibilities for the choice of CBD sequence with 
different lengths, properties and binding affinities for collagen (Table 2). We hypothesized that 
the use of CBDs would allow for specific tethering of LL37 onto collagen substrates. Further, the 
CBD sequence and properties would affect the degree binding and retention as well as 
antimicrobial activity and cytotoxicity observed for LL37 when tethered to collagen substrates. 
 
Figure 2: The general design of CBD-LL37. From NC terminus, the design of CBD-LL37 
contains the active, 37 amino acid C-terminal domain of hCAP-18 (LL37), a FLAG™ linker, and 
collagen binding domain (various short sequences). 
 
Table 2: Possible collagen-binding domains for non-covalent AMP tethering 
Collagen Binding Domain* Chargea Reference(s) 
RRANAALKAGELYKSILYGCb +3 [76] 
RRANAALKAGELYKCILY +3 [77] 
RLDGNEIKRGCb +1 [68] 
AHEEISTTNEGVMGCb -3 [78] 
NGVFKYRPRYFLYKHAYFYPPLKRFPVQ +6 [79] 
CQDSERTFY (fCBD) -1 [69, 80, 81] 
TKKTLRT (cCBD) +3 [66, 71, 82] 
GLRSKSKKFRRPDIQYPDATDEDITSHM +1 [83, 84] 
SQNPVQP 0 [66, 82, 85] 
SYIRIADTNITGCb 0 [86] 
SYIRIADTNIT 0 [87] 
KELNLVYT 0 [88] 
KELNLVYTGCb 0 [78] 
GELYKSILYGCb 0 [77, 88] 
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GCGGELYKSILY 0 [89, 90] 
WREPSFCALS (vCBD) 0 [67, 71] 
RLDGNEIKR (fmCBD) 1 [68] 
*Bolded CBDs are those discussed within the chapters of this thesis. aCharge calculated using 
Heliquest (http://heliquest.ipmc.cnrs.fr/) [91]; bResidues ‘GC’ added to the sequences for purpose 
of cysteine-mediated covalent immobilization 
 
2.5. Chapter-by-chapter snapshot 
Described within these chapters is the story of the development and understanding of CBD-
LL37 peptides for potential implementation in chronic wound healing applications. Thus, it starts 
at the beginning with the design and bioactivities of collagen-tethered LL37 on different collagen-
based scaffold substrates. This is followed by in-depth mechanistic studies, with the goal of 
understanding how CBDs modulate both LL37 structure and bioactivities in soluble form. 
Together, results of this thesis demonstrate the promise of using biopolymer-tethered AMPs as a 
platform strategy for the design and delivery of non-cytotoxic and stable alternative antimicrobial 
therapeutics amidst the antibiotic resistance crisis.  
 
Chapter 3, describes the collagen tethering and bioactivities of two novel chimeric versions of 
LL37, designed with CBDs derived from collagenase (cCBD-LL37) and fibronectin (fCBD-
LL37). It was found that CBDs mediated stable binding and antimicrobial activity over 14 days on 
collagen scaffolds. CBDs also demonstrated different bioactivities in soluble form. Results from 
this study demonstrate proof-of-concept of CBD-mediated tethering of LL37 as a viable strategy 
for combatting chronic wound infection. 
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 Published in: Acta Biomaterialia, Special issue on extracellular matrix proteins and 
mimics, 2017, 52, 9-20. Authors: Lindsay D. Lozeaua, Jonian Groshab,c, Denis Kolec,d, 
Fioleda Prifid,e, Tanja Dominkof,e, Marsha W. Rollec, Terri A. Camesanoa 
Chapter 4, describes the tethering and bioactivities of cCBD-LL37 and fCBD-LL37 onto 
composite collagen and alginate scaffolds, providing insight to how the particular choice of 
biopolymers can significantly modulate CBD-LL37 binding and retention, antimicrobial activity 
and cytotoxicity when bound. 
 In preparation for submission. Authors: Lindsay D. Lozeaua, Ramona B. Bagoc, Mateo 
F. Frarec, Terri A. Camesanoa, Marsha W. Rollec 
Chapter 5, combines molecular modeling simulations and experimental techniques to study the 
influence of particular CBD sequences on the resulting structures of CBD-LL37 peptides in 
different environments leading to different interactions with model zwitterionic and charged lipid 
bilayers. Results from this study demonstrate that depending on the chosen CBD sequence, vastly 
different CBD-LL37 structures can result leading to differences in membrane activities that 
correlate with differences in bioactivities.  
 In preparation for submission to: Biomacromolecules. Authors: Lindsay D. Lozeaua, 
Sina Youssefiang, Nima Rahbarg, Terri A. Camesanoa, Marsha W. Rollec 
Chapter 6, describes the time- and concentration-dependent interactions of human LL37 with 
model mammalian bilayers using quartz crystal microbalance with dissipation (QCM-D), with the 
goal of understanding how LL37 implements cytotoxic functions and provide a baseline for the 
study of CBD-LL37 bilayer interactions. Results from this study suggest that methods to reduce 
time of interaction of LL37 with mammalian cells may be a strategy for reducing its cytotoxicity.  
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 Under review by Colloids and Surfaces B: Biointerfaces. Authors: Lindsay D. Lozeaua, 
Marsha W. Rollec, Terri. A. Camesanoa 
Chapter 7, provides an in-depth mechanistic study of concentration-, time-, lipid composition- 
and CBD sequence-dependent activities of two CBD-LL37 peptides using quartz crystal 
microbalance with dissipation (QCM-D), with the goal of understanding mechanistically why they 
demonstrated different in vitro bioactivities. In this study, predictions of sequence characteristics 
(hydrophobicity, charge, etc.) and expected QCM-D responses related to different mechanistic 
phenomena were also used toward proposing interaction mechanisms of the two peptides against 
different membrane types. New insight gained from this study toward CBD-LL37 structure-
function relationships was used to make mechanistic predictions of two hypothetical CBD-LL37 
designs. Results from this study demonstrate the potential of designing new and bioactive 
collagen-tethered CBD-LL37 and their use as platforms in chronic wound applications. 
 In preparation for submission. Authors: Lindsay D. Lozeaua, Marsha W. Rollec, Terri 
A. Camesanoa 
Chapter 8, provides two future directions (with preliminary data) for the study, design and 
development of collagen-tethered antimicrobial peptides. Part I provides an introduction overview 
for the chapter contents. Part II discusses a new technique, based on quartz crystal microbalance 
with dissipation as a platform to study the collagen-binding abilities of CBD-LL37 peptides, 
combined with an ex situ strategy of evaluating antimicrobial activity. Part III discusses the 
possible cost reduction of CBD-LL37 synthesis, by proposing an alternative, recombinant 
production strategy of bioactive CBD-LL37 peptides in a mammalian expression system. Lastly, 
Part IV presents a discussion of future directions, guided by insightful reviews provided by the 
author’s thesis committee.  
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 Part II of Chapter 8 is in preparation for submission. Authors: Lindsay D. Lozeaua, E. 
Berwin Jayapurnaa, Nicholas R. Bergstroma, Alexandra G. Connora, Mateo F. Frarec, 
Christine J. Lujuoc, Marsha W. Rollec, Terri A. Camesanoa 
 Part III of Chapter 8 is under further investigation by Dalia M. Shendic, and Marsha 
W. Rollec, and Michael Zimberh, in collaboration with Worcester Polytechnic Institute and 
Histogen, Inc. (San Diego, CA), NSF IIP 1660301. 
o Contributions to Part III were made by: Lindsay D. Lozeaua, Fioleda Priftid,e, 
Ray Gaspera, Chelsea R. Millerd, Denis Koled, Tanja Dominkod,f, Terri A. 
Camesanoa, Marsha W. Rollec 
Chapter 9, concludes this body of work with a final summary and statement of significance toward 
the use of CBD-LL37 peptides in wound healing applications and beyond, as we approach the 
post-antibiotic era. 
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ABSTRACT 
Wound infections, particularly of chronic wounds, pose a substantial challenge for 
designing antimicrobial dressings that are both effective against pathogens, and do not interfere 
with wound healing. Due to their broad-spectrum antimicrobial and immunomodulatory activities, 
naturally-occurring antimicrobial peptides (AMPs) are promising alternative treatments. However, 
their cytotoxicity at high concentrations and poor stability hinders their clinical use. To mitigate 
these undesirable properties, we investigated the effects of tethering human AMP cathelicidin 
LL37 to collagen, one of the main extracellular matrix proteins in wound sites, secreted by 
fibroblasts, and in commercially-available wound dressings. The active domain of human AMP 
cathelicidin, LL37, and two chimeric peptides containing LL37 fused to collagen binding domains 
(derived from collagenase – cCBD-LL37 or fibronectin - fCBD-LL37) were synthesized and 
adsorbed to PURACOL® type I collagen scaffolds. After 14 days, 73%, 81% and 99% of LL37, 
cCBD-LL37 and fCBD-LL37, respectively, was retained on the scaffolds and demonstrated 
undiminished antimicrobial activity when challenged with both Gram-positive and Gram-negative 
bacterial strains. Loaded scaffolds were not cytotoxic to fibroblasts despite retaining peptides at 
concentrations 24 times higher than the reported cytotoxic concentrations in solution. These 
findings indicate that biopolymer-tethered AMPs may represent a viable alternative for preventing 
and treating wound infection while also supporting tissue repair. 
 
STATEMENT of SIGNIFICANCE 
Over 6.5 million people annually in the United States suffer chronic wounds; many will 
become infected with antibiotic-resistant bacteria. Treatments used to prevent and fight infection 
are toxic and may hinder wound healing. To overcome treatments gaps, we functionalized collagen 
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scaffolds with chimeric antimicrobial peptides (AMPs) with collagen binding domains to create 
antimicrobial and non-cytotoxic scaffolds that may promote healing. AMPs are broad-spectrum 
antimicrobials that also promote healing; however, their instability and toxicity are major 
challenges. This is the first report of CBD-mediated, delivery of AMPs onto collagen scaffolds 
that demonstrates no cytotoxicity toward fibroblasts. This study also suggests that retention of 
antimicrobial activity is CBD-dependent, which provides foundations for fundamental studies of 
CBD-AMP mechanisms and clinical explorations. 
 
KEYWORDS 
Antimicrobial peptides; LL37; collagen; collagen-binding domain; tether; wound healing 
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GRAPHICAL ABSTRACT 
 
 
1. INTRODUCTION 
Wound infections, particularly of chronic wounds, pose a substantial challenge to patient 
health and quality of life, and cost billions of dollars each year to manage in the United States 
alone [1, 2]. Current approaches to combatting wound infections are insufficient and expensive 
due to bacterial resistance to conventional antibiotics [2-4]. Alternatively, silver- and chemical-
based compounds can prevent and treat infections, but are toxic to mammalian cells and may 
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impede tissue regeneration [4, 5]. Thus, there is a critical need for alternative approaches to wound 
care and infection control that eliminate pathogenic microbes and support functional tissue repair. 
Antimicrobial peptides (AMPs) have demonstrated promise as a class of broad-spectrum 
antimicrobial agents that may also promote wound healing. AMPs are short, naturally-occurring 
peptides that act by the general mechanism of membrane disruption, allowing antimicrobial 
activity against a wide variety of microbes, including antibiotic-resistant organisms [6, 7]. Further, 
AMPs are important components of host innate immunity, serving additional in vivo functions 
such as modulation of the inflammatory response [8], lipopolysaccharide (LPS) binding and 
neutralization [9], and chemotaxis [6, 7]. With over 2,600 natural AMPs discovered to date and 
thousands more being synthesized [10], this technology could provide a platform for the 
development of new antimicrobial agents and address the critical problem of antimicrobial 
resistance. Current AMP-based therapies have been limited to topical applications , despite their 
high potential and promise as alternative systemic antimicrobials [11].  
Several challenges have limited the use of AMPs in the clinic to date, primarily their toxicity 
to mammalian cells at high concentrations, in vivo instability, and their high cost of production [6, 
7, 11-14]. Low stability of AMPs in vivo leads to higher required dosages, which not only increases 
costs but also lowers their therapeutic index [14]. In some cases, slow release or covalent tethering 
of AMPs to various substrates such as resins [15, 16], titanium [17], silicon dioxide [18-20], gold 
[21, 22], polymer brushes [23], polystyrene [24-26], contact lenses [27] or synthetic polymer 
multilayers [28, 29] have been studied. However, few have focused on tethering or release from 
biopolymer scaffold materials [30]. Targeted delivery of AMPs using collagen scaffolds, including 
tethering to wound dressing materials, may improve AMP technology for broader clinical 
application.  
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Collagen is a component of the extracellular matrix (ECM) and a prevalent biopolymer in 
both regenerating tissues and commercially available wound dressings. Several previous studies 
have described the collagen-tethering of growth factors and other proteins via various collagen-
binding domains (CBDs), short sequences derived from molecules such as fibromodulin [31-33], 
von Willebrand’s factor [34, 35], collagenase [35, 36] and fibronectin [37, 38]. However, tethering 
and interactions of antimicrobial peptides with biopolymer materials such as collagen remains 
predominantly unexplored. 
We chose LL37, the 37 amino acid active antimicrobial peptide domain of human 
cathelicidin, as the model AMP for collagen tethering. Cathelicidins are a class of AMPs typically 
produced by neutrophils and consist of a precursor region, a highly conserved cathelin-like domain 
and the broadly-active, species-variable C-terminus domain [39]. The precursor molecule to 
human LL37, hCAP-18 [40], is cleaved extracellularly by serine proteinase-3 to yield the active 
C-terminus domain, LL37 [41]. Human cathelicidin has been widely studied and has demonstrated 
potent antimicrobial and healing activities [39, 40, 42-44], although its tethering and release from 
ECM scaffolds has only been studied very recently [30].  
The overall goal of the study was to generate and evaluate a new strategy for delivering 
AMPs via collagen-based scaffolds. For this, we designed two modified chimeric LL37 peptides 
with collagen binding domains (CBDs). Each has differing charges, amino acid compositions, 
lengths, and dissociation constants (KD) make them interesting models to study LL37 binding 
ability, structure, and antimicrobial activity as a function of binding domain sequence and 
structure. We hypothesized that the modification of LL37 with a CBD will enable its tethering to 
collagen substrates while reducing its cytotoxicity and preserving its antimicrobial activity. 
Further, the addition of a CBD would provide improved retention of LL37 to the collagen scaffold, 
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allowing for prolonged local bioactivities. To test this, we studied adsorption, antimicrobial 
activity and cytotoxicity of modified (cCBD-LL37 and fCBD-LL37) and unmodified LL37 while 
in solution and when applied to commercially-available 3D collagen scaffolds. These studies 
allowed us to observe how biopolymer tethering altered AMP bioactivity, compare the use of two 
different CBDs to tether LL37, and provide a foundation for future study of biopolymer-tethered 
AMPs for wound healing applications. 
 
MATERIALS and METHODS 
2.1. Synthetic Peptides 
Synthetic LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was 
purchased from Anaspec, Inc. (Fremont, CA) at >95% purity, confirmed by high-performance 
liquid chromatography (HPLC).  The modified LL37 peptides with a collagenase-derived CBD 
(cCBD-LL37) 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKTKKTLRT) and 
fibronectin-derived CBD (fCBD-LL37) 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKCQDSERTFY) were 
synthesized by New England Peptide, Inc. (Gardner, MA) at >90% purity, also confirmed by 
HPLC. A FLAG™ domain (DYKDDDDK) linker sequence was included between the LL37 and 
CBD sequences in each peptide to preserve flexibility [12, 15, 18, 19], and as an epitope tag [45]. 
The peptides were received at greater than 90% purity confirmed by high performance liquid 
chromatography. Stock solutions (0.67 mM) of each AMP were prepared according to 
manufacturer recommendations (LL37 in sterile PBS (pH 7.2) and cCBD- and fCBD-LL37 in 
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sterile water (pH 3.5), each supplemented with 5 mM ethylenediaminetetraacetic acid (EDTA)) 
and stored at -20°C.  
2.2. Bacterial Strains and Culturing 
Escherichia coli (B78) [46] was originally isolated from a woman with cystitis, provided 
by Dr. James Johnson (VA Medical Center, Minneapolis, MN), and Bacillus subtilis (R01792) 
was provided by Robert Stote (NSRDEC, Natick, MA). E. coli (ATCC 33694), Staphylococcus 
aureus (ATCC 48366), Staphylococcus epidermidis (ATCC 49461), Methicillin-resistant S. 
aureus (ATCC 33592), Gentamycin- and Methicillin-resistant S. aureus (ATCC 43300), and 
Pseudomonas aeruginosa (ATCC 29260) were purchased from the American Type Culture 
Collection, ATCC (Manassas, VA). Bacteria were cultured in 9.8 g/L Mueller Hinton broth (MHB; 
SigmaAldrich, St. Louis, MO). For all experiments, fresh cultures were prepared by choosing 
colonies on a Mueller Hinton agar (MHA; SigmaAldrich) stock plate (4-6 hours at 37°C). Cell 
turbidity was corrected to a McFarland Standard 0.5 to make 1x108 colony-forming units per mL 
(CFU/mL) and then diluted 100-fold in MHB to make 1x106 CFU/mL prior to inoculation. 
2.3. Minimum Inhibitory Concentration (MIC) Assays 
The MICs of each peptide (LL37, cCBD-LL37, fCBD-LL37) were determined using 
published methods [47], based on standards set by the Clinical and Laboratory Standards Institute 
[48] and the European Committee for the Antimicrobial Susceptibility Testing [49]. In short, two-
fold serial dilutions were tested for each sample in MHB. Each well, including a no-peptide growth 
control (GC) was inoculated with 1x106 CFU/mL fresh inoculum prepared as described in section 
2.2. A sterility control of MHB only was used as a negative control. After inoculation, plates were 
incubated at 37°C and absorbance at 590 nm, OD(590), was recorded using a Victor3 plate reader 
(Perkin Elmer, Waltham, MA) 12-16 hours after inoculation. GCs were diluted and plated on MHA 
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plates and counted after overnight incubation to ensure that the original inoculum size was 1x106 
CFU/mL. The MIC was determined as the concentration of peptide at which OD(590) was the 
same as the sterility control value, or where 100% visible growth was inhibited [47].  
2.4. AlamarBlue® Cell Viability Assay 
AlamarBlue® (Thermofisher, Waltham, MA) was used to determine the viability of CRL-
2352 dermal fibroblasts (ATCC) or CT1005 dermal fibroblasts (tissue distribution program, 
University of Massachusetts Medical School, Worcester, MA) after exposure to the AMPs in 
solution. The linear ranges of signal and cell seeding densities for AlamarBlue® reduction were 
determined by creating a standard curve. Cells were cultured in medium (1:1 Dulbecco’s modified 
eagle medium and Ham’s F-12 media supplemented with 10% fetal bovine serum) in 96-well 
plates seeded at 12,500 cells/cm2 for 12-16 hours. Medium was replaced with fresh medium 
supplemented with AMPs (1, 3, 5, 10, 15 and 20 µM) at pH 7.4 for 4 hours. AlamarBlue® solution 
(10% v/v) was then added to each well and incubated for another 4 hours. Plates were incubated 
at 37°C and 5% CO2. The fluorescent signal from AlamarBlue
® (excitation and emission at 540 
nm and 590 nm) after 4 hours were read on a Victor3 plate reader (Perkin Elmer). According to 
the manufacturer, the AlamarBlue® signal directly correlates to the number of viable cells. Medium 
was refreshed until the second addition of AlamarBlue® at 24 hours.  
2.5. Preparation, Handling and Loading of 3D Collagen Scaffolds 
PURACOL® collagen type I dressings (Medline Industries, Mansfield, MA) were cut into 
5 mm diameter disks using biopsy punches (Robbins Instruments, Chatham, NJ) under sterile 
conditions. Prior to additional testing, all scaffolds were sterilized with ethylene oxide. Each 
scaffold was loaded with peptides or sterile phosphate buffered saline (SigmaAldrich; PBS pH 
7.4) as a negative control. Scaffolds were loaded by adsorbing 5 µL of LL37 (1478 µg/mL), cCBD-
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LL37 (2078 µg/mL) or fCBD-LL37 (2178 µg/mL) diluted with PBS, pH 7.4. This volume was 
selected because it is the minimum volume required to hydrate a 5 mm diameter scaffold. The 
peptide concentration was chosen as the maximum mass required to fully saturate each 
PURACOL® disk. This theoretical mass was calculated assuming a 1:1 ratio of collagenase 
binding sites to collagen triple helices in each disk composed of 100% native collagen type I, a 
mass of 280 kDa per triple helix, and approximately 10x1014 collagenase binding sites per helix 
[36, 50-52]. Scaffolds were hydrated with the peptide or PBS control solution on hydrophobic 
polydimethylsiloxane (PDMS) mats, placed in a 37°C incubator for 2 hours, and rinsed twice with 
either MHB, release medium, or mammalian cell medium and studied for antimicrobial activity 
(section 2.7), cumulative release over 14 days (section 2.8), or cytotoxicity (section 2.10), 
respectively.  
2.6. Scanning Electron Microscopy (SEM) 
Scanning electron microscopy (SEM) images were collected of PURACOL® scaffold disks 
to visualize scaffold structure. Dry scaffolds were sputtered with an 8 nm coating of Pt/Pd 
(Cressington Scientific Instruments, Watford, England, UK). SEM images were taken at the 
University of Massachusetts Medical School Electron Microscopy Core (Worcester, MA) with an 
FEI Quanta 200 FEG MKII (FEI, Hillsboro, OR) SEM. Images were acquired at 300x 
magnification, 10 mm working distance, and 10kV under high vacuum condition.  
2.7. Antimicrobial Activity of Peptide-Loaded 3D Scaffolds 
To test the antimicrobial activity of peptides applied to 3D collagen scaffolds, a bacterial 
inoculation and growth assay based on medium turbidity was adapted from a prior study [53]. 
Under sterile conditions, scaffolds were loaded with peptides as described in section 2.5, placed 
in a 96-well plate and rinsed twice with MHB. Then, scaffolds were transferred with sterile forceps 
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into fresh MHB. Each well was inoculated with 1x106 CFU/mL bacteria prepared as described in 
section 2.2. A growth control, with no scaffolds or peptide, was also inoculated and sterile MHB 
only was used as a negative sterility control. The inoculated scaffolds and control samples were 
incubated 1 hour at 37°C.  
After 1 hour, bacterial solution was aspirated and scaffolds were rinsed twice with sterile 
MHB. Samples were then transferred into new wells with fresh MHB and incubated for 12 hours 
at 37°C. After 12 hours, scaffolds were removed from the wells and solution turbidity (indicating 
bacterial growth) in the form of OD(590) was recorded using a Victor3 plate reader (Perkin Elmer). 
All values were normalized to the average sterility control values; turbidities from peptide-loaded 
samples were compared with untreated, PBS-loaded samples. Antimicrobial activity was 
determined by the significant reduction of turbidity of peptide-loaded versus unloaded scaffolds. 
2.8. Peptide Adsorption and Release 
After loading and incubating the scaffolds with peptide or PBS control solutions, scaffolds 
were rinsed twice with release medium (sterile PBS pH 7.4 supplemented with 1% wt/v bovine 
serum albumin (BSA)) and rotated on a Labquake Tube Rotator (Thermofisher) at 37°C. At 
specific time points (1 hour, 4 hours, 1 day, 4 days, 7 days and 14 days), release medium was 
collected from each tube and replaced with fresh medium under sterile conditions. This time period 
of 14 days provides a peptide release period that matches the majority of the duration of the two 
critical phases of wound healing – inflammatory and proliferative – where LL37 may have the 
most impact on infection prevention and wound healing [54]. ELISA (section 2.9) was used to 
measure peptide concentrations in the collected aliquots, as well as in the initial scaffold rinses to 
determine cumulative release and initial peptide adsorption, respectively. Scaffold replicates from 
day 14 of the release study were also used for the antimicrobial assay (section 2.7) versus E. coli 
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followed by IHC (section 2.11) and additional replicates were collected for IHC to visualize LL37 
on the scaffolds without bacterial exposure. 
2.9. Enzyme-Linked Immunosorbent Assay (ELISA) 
A direct ELISA for determining AMP release was designed and validated. Aliquots from 
the release study were placed into ELISA plates (BrandTech Scientific, Essex, CT) and incubated 
12 hours at 4°C. Wells were then rinsed with Tween-20 in PBS (0.05% v/v), twice, followed by 
PBS pH 7.4, twice. All subsequent “rinses” were carried out the same way. BSA in PBS (1% wt/v), 
was added for 2 hours at 37°C, followed by rinsing. Then, 0.4 µg/mL, primary rabbit polyclonal 
anti(human)-LL37 antibody (Anaspec; cat. no. AS-55927) was added for 1 hour at 37°C. After 
another rinse, 0.3 µg/mL horseradish peroxidase-conjugated goat anti-rabbit antibody (Bio-Rad, 
Hercules, CA; cat. no. 1706515) was added for 1 hour at 25°C. Another rinse was followed by the 
addition of TMB-ELISA developer (ThermoFisher). The reaction was stopped at 30 min with 2M 
H2SO4, and absorbance at 450 nm, OD(450), was recorded using a Victor3 spectrophotometer 
(Perkin Elmer). 
To analyze these data, the OD(450) for each sample was compared to standard curves, 
created by constructing OD(450) versus concentration curves of serial dilutions for each peptide, 
LL37, cCBD-LL37 and fCBD-LL37. The concentration of peptide in each aliquot was calculated 
using these standard curves, total protein released at each time point was calculated, and the 
cumulative release profiles were constructed. 
2.10. Cell Viability on Peptide-Loaded 3D Scaffolds 
AlamarBlue® was also used to measure the cytotoxicity of peptide-loaded scaffolds 
(prepared as in section 2.5) when seeded with human dermal fibroblasts, cultured as described in 
section 2.4. Non-tissue treated, low binding Corning 96-well plates (Corning, NY) were used. The 
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chosen cell density to seed over the scaffolds, as determined by a standard curve, was 114,000 
cells/cm2, or 80,000 cells per scaffold. Loaded scaffolds were rinsed twice with fresh medium, 
seeded with cells and incubated at 37°C and 5% CO2. All wells were rinsed with fresh medium at 
4 hours to wash away non-adhered cells. After 24 hours, wells were rinsed twice with medium and 
refreshed with 10% v/v AlamarBlue® in medium. The fluorescent signal was read as described in 
section 2.4. A group of unloaded scaffolds without cells, wells with cells only, and medium only 
were included as negative controls.  
2.11. Immunohistochemistry (IHC) and Staining 
Immunohistochemistry (IHC) using anti(human)-LL37 was performed on sections of 
scaffolds harvested at different release times (described in section 2.9) both exposed to E. coli for 
12 hours and unexposed to bacteria. Scaffold replicates collected immediately after rinsing and 
after 14 days of release were exposed to bacteria and stained. Scaffold replicates at 1 hour, 1 day, 
4 days, 7 day and 14 days of release were stained without exposure to bacteria. 
All IHC images were taken with a Leica Upright Fluorescence Microscope, DMLB2 
(Wetzlar, Germany). Scaffolds were transferred into histology cassettes, fixed in 10% v/v 
formaldehyde in for 24 hours, processed (ATP1 tissue processor, Triangle Biomedical Sciences, 
Durham, NC) and embedded in paraffin. Scaffolds were cut into 5 µm sections, de-paraffinized in 
xylene, hydrated in a series of 100% to 70% ethanol, and left in water for 5 minutes. 
Samples were then probed for the presence of peptide using anti(human)-LL37 primary 
antibody (Anaspec; cat. no. AS-55927), by first boiling under pressure with an antigen retrieval 
solution (SigmaAldrich) followed by blocking with 5% v/v goat serum in PBS for 30 min at 25°C. 
Samples were incubated overnight at 7°C with 10 µg/mL primary rabbit polyclonal anti(human)-
LL37 (Anaspec) in 3% v/v goat serum. Then, AlexaFluor®488 goat-anti-rabbit antibody 
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(LifeTechnologies, Carlsbad, CA; cat. no. A11008), diluted 1:50 in 3% v/v goat serum was added 
for 1 hour at 25°C prior to dehydration, xylene clearance, and adding coverslips. 
IHC was also performed on peptide-loaded scaffolds collected 24 hours after fibroblast 
seeding (described in section 2.10). Scaffolds were first stained as described above with 
anti(human)-LL37 and then counterstained with Hoechst 33342 (LifeTechnologies; diluted 
1:6,000 in water) for 6 minutes to stain nuclei. 
2.12. Statistical Analyses 
For MIC and cytotoxicity assays in solution and scaffold cytotoxicity assays, all 
experiments were performed in triplicate with n=3 replicates per sample group. For MIC, statistics 
were performed to compare cCBD-LL37 and fCBD-LL37 to LL37 and for viability assays, 
statistics were performed to compare peptide-treated samples versus untreated controls; all were 
performed using one-way ANOVA and post-hoc Tukey Tests. For all experiments with 
antimicrobial activity applied to scaffolds, n=4 replicates per sample group were measured in 
triplicate for S. aureus and P. aeruginosa and in quadruplicate for E. coli; statistical significance 
of peptide-treated scaffolds versus PBS-treated scaffolds negative controls was determined using 
one-way ANOVA and a post-hoc Dunnett Test. For cumulative release studies, experiments were 
performed in duplicate for n=3 replicates per sample group; statistical significance of the release 
between two time points for each peptide was determined using a one-way repeated measures 
ANOVA and post-hoc Tukey Test. 
 
3. RESULTS 
3.1. Chimeric CBD-LL37 design 
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The active human AMP LL37 [44] was functionalized on its C-terminus with a CBD, and 
separated by a FLAG linker (DYKDDDDK) [45]. The peptides (Fig. 1a) were named cCBD-LL37 
(for collagenase-derived CBD) and fCBD-LL37 (for fibronectin-derived CBD). The cCBD [35] 
and fCBD [37] domains were chosen for their abilities to bind to collagen and for their short, 
unique sequences (Fig. 1b). 
 
Figure 1: Design of chimeric CBD-LL37. The LL37 antimicrobial peptide sequence at the N-
terminus, followed by a flexible FLAGTM linker domain, and collagen binding domain (CBD) on 
the C-terminus (a); Sequence and properties of CBDs (b); KD – dissociation constant. 
 
3.2. Peptides retain broad-spectrum antimicrobial activity after CBD modifications 
The minimum inhibitory concentrations, or the lowest concentrations of agent that reduce 
visible growth of bacterial strains, were determined against several Gram-negative and Gram-
positive bacterial species (Table 1; µg/mL values are also provided in Table S1). The MICs of 
LL37 and cCBD-LL37 were within an order of magnitude of the reported values for LL37 [42]. 
cCBD-LL37 showed similar antimicrobial activity to LL37, and was slightly more effective 
against Gram-negative organisms E. coli (both laboratory and clinical isolates) and P. aeruginosa 
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compared to LL37. However, the mean MIC values for cCBD-LL37 compared to LL37 against 
Gram-negative bacteria were not significantly different (Table 1). cCBD-LL37 also showed equal 
potency to LL37 against the biofilm-forming S. epidermidis strain at a very low concentration of 
0.53 µM. 
Table 1: Minimum inhibitory concentrations of LL37, cCBD-LL37 and fCBD-LL37 against 
different bacteria strains.  
 Microbe 
Published 
MIC for 
LL37 
(µM) [42] 
LL37 
(µM) 
cCBD-LL37 
      (µM) 
fCBD-LL37 
     (µM) 
 
E. coli HB101 0.42 0.77 ± 0.12 0.67 ± 0.20 2.92 ± 1.10* 
 E. coli B78 -- 1.67 ± 0.42 1.15 ± 0.10  6.46 ± 3.03 
 P. aeruginosa 1.27 0.69 ± 0.07 0.49 ± 0.06 9.17 ± 1.67* 
 S. epidermidis 0.56 0.50 ± 0.04 0.53 ± 0.22 10.0 ± 2.50* 
 S. aureus 0.80 0.45 ± 0.05 0.64 ± 0.27 6.67 ± 0.83* 
 Methicillin-resistant 
S. aureus (MRSA) 
0.76 0.68 ± 0.07 8.13 ± 0.68* 5.83 ± 0.83* 
 
Methicillin-, 
Gentamycin-resistant 
S. aureus (M/GRSA) 
2.34 7.50 ± 0.00 8.33 ± 0.83 5.83 ± 0.83 
 B. subtilis 0.60 0.53 ± 0.09 2.25 ± 0.49 5.83 ± 1.10** 
Mean is significantly different from mean for LL37; *p<0.001 or **p<0.05 (n=3). 
 
In general, fCBD-LL37 demonstrated weaker activity than cCBD-LL37 and LL37, 
particularly against E. coli, P. aeruginosa, S. aureus, MRSA and B. subtilis, suggesting that adding 
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the fCBD sequence to LL37 decreased its antimicrobial activity. Interestingly, fCBD-LL37 
demonstrated increased activity against multiple antibiotic-resistant MRSA and M/GRSA strains 
at 5.83 µM versus 8.33 and 7.50 µM for cCBD-LL37 and LL37, respectively. MIC values for 
fCBD-LL37 did not vary significantly against any Gram-positive organisms and were consistently 
between 5 and 10 µM. In contrast, cCBD-LL37 and LL37 demonstrated similar changes in MIC 
against Gram-positive compared to Gram-negative strains. Overall, all MICs were lower than 10 
µM, which suggests that adding CBDs had a minimal effect on the broad-spectrum antimicrobial 
activity of LL37 in solution.  
3.3. fCBD-LL37 is less cytotoxic in solution than cCBD-LL37 and LL37 
At 8 and 24 hours, LL37 and cCBD-LL37 cytotoxicity correlated well with the reported 
cytotoxic range [44] (Fig. 2a-b), with significantly reduced relative AlamarBlue® signals, directly 
correlated to the numbers of viable fibroblasts at peptide concentrations above 10 µM. fCBD-LL37 
followed a similar profile at low concentrations but had significantly attenuated cytotoxicity 
compared to LL37 and cCBD-LL37 at concentrations up to 20 µM for both 8 and 24 hours. By 24 
hours (Fig. 2b), there was no statistically significant difference between the cCBD-LL37 or LL37 
samples and the medium-only control (p<0.05) at the highest concentration (20 µM), which 
indicates that no viable cells remained. Similar cytotoxicity profiles were observed with AMP 
treatment for 8 hours in a primary human dermal fibroblast line CT1005, derived from the dermis 
of a woman undergoing panniculectomy (Fig. S1). 
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Figure 2: Antimicrobial peptide cytotoxicity. Relative fluorescent units (x103), correlate directly 
with the number of viable CRL-2352 human fibroblasts, given by AlamarBlue® reduction when 
exposed to LL37, cCBD-LL37 and fCBD-LL37 peptides in solution after 8 hours (a) and 24 hours 
(b). All values represent means ± S.D. from at least three experimental replicates. The dotted line 
represents the average medium-only fluorescence; the vertical line represents the reported 
cytotoxic threshold of soluble LL37 [11]. Difference between the means: *fCBD-LL37 is different 
from all other AMPs, p<0.001; **all samples are different from one another, p<0.05. 
 
3.4. All peptides bind to PURACOL® and are active against Gram-negative bacteria 
PURACOL® was selected as the wound dressing to study CBD-LL37 delivery from 
collagen scaffolds, for its 100% native bovine collagen type I composition and ease of handling as 
5 mm disks (Fig. 3a). SEM images (Fig. 3b) demonstrated high porosity of PURACOL®, 
consistent with its reported porosity of approximately 80% of scaffold volume [55], which is 
important for promoting cell adhesion and wound healing [56].  
LL37-, cCBD-LL37- and fCBD-LL37-loaded scaffolds significantly reduced E. coli 
burden after 12 hours (p<0.001 for LL37 and cCBD-LL37; p<0.05 for fCBD-LL37) compared 
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with PBS-loaded scaffolds (Fig. 3c). This suggests that all peptides retained antimicrobial activity 
when adsorbed to collagen. Peptide retention on collagen scaffolds was confirmed in all treatment 
groups, even after exposure to E. coli for 12 hours, by IHC staining for LL37 (Fig. 3d). 
 
Figure 3: Binding and activity of peptides on PURACOL® scaffolds. (a) PURACOL® scaffolds 
cut using a 5 mm biopsy punch; (b) SEM image of dry and sterilized scaffold disks taken at 10kV; 
bar = 200 µm; (c) Relative turbidity after loaded scaffold exposure to Gram negative E. coli, Gram 
positive S. aureus, or Gram negative P. aeruginosa for 12 hours. All values represent means ± S.E. 
from at least three experimental replicates. Statistical significance of peptide-loaded samples 
against PBS-loaded samples is indicated by: *p<0.01, **p<0.001 or ***p<0.007; Statistical 
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significance between peptide-loaded samples is indicated by +p<0.05; (d) representative 
immunohistochemistry images of scaffold sections stained using anti-human LL37 and visualized 
with AlexaFluor®488-conjugated secondary antibody after exposure to E. coli for 12 hours; bar = 
100 µm. 
 
The activity of cCBD-LL37 and fCBD-LL37 peptides against P. aeruginosa, a Gram-
negative pathogen commonly found in wounds, was similar to levels demonstrated against E. coli, 
with cCBD-LL37 demonstrating the highest overall activity against P. aeruginosa (Fig. 3c). LL37 
exhibited higher mean relative turbidity against P. aeruginosa than CBD-modified LL37 peptides, 
suggesting lower activity. In contrast, neither CBD-LL37 peptide showed significant antimicrobial 
activity against Gram-positive S. aureus, although LL37 exhibited antimicrobial activity against 
S. aureus compared with PBS-loaded control scaffolds (p<0.05). These data suggest that collagen-
tethered LL37 peptides are more effective against Gram-negative than Gram-positive organisms, 
and that CBD-LL37 peptide antimicrobial activity may have a higher sensitivity to differences in 
bacterial membrane structure.  
3.5. Modification with CBD improves peptide retention on collagen scaffolds 
We hypothesized that unmodified LL37 may be non-specifically adsorbed onto collagen 
and quickly released into the surrounding media, while CBD-LL37 peptides would have a slower 
release profile over time facilitated by specific binding of CBD to collagen type I [36, 57]. To test 
this hypothesis, we measured peptide release from collagen scaffolds and calculated the 
cumulative release profiles for each peptide (Fig. 4a). Overall, the total mean cumulative release 
of cCBD-LL37 and LL37 after 14 days was 18.5% and 26.9%, respectively. However, by 1 hour, 
12.9% of the adsorbed cCBD-LL37 was already released. Though LL37 release was only 8.36% 
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after 1 hour, its release was at a faster rate between subsequent time points, to 14.8% at 4 hours 
and 19.9% at 1 day, respectively. cCBD-LL37 release appeared comparatively slower at these later 
time points. Interestingly, significantly greater (p<0.05) amounts (micrograms) of LL37 were 
released between each time interval compared to cCBD-LL37 and fCBD-LL37. Cumulative 
fCBD-LL37 release from collagen scaffolds was significantly lower than LL37 and cCBD-LL37, 
with only 0.91% of the loaded peptide released over the course of 14 days. The concentration of 
fCBD-LL37 detected in the release medium was significantly different (p<0.001) compared to 
release medium-only negative control samples for each time point. Immunostaining of peptide-
adsorbed scaffold samples harvested at day 14 supports the observed retention of all peptides 
during the release assay (Fig. 4b). Scaffolds harvested at different time points during the release 
study (without performing an initial rinse) were stained in the same way and also suggest that 
peptides are retained on the scaffold (Fig. S2). 
 
Figure 4: The cumulative release profiles for LL37, cCBD-LL37 and fCBD-LL37, compared 
to a PBS-loaded negative control (depicted as the percent of total amount of loaded peptide) as a 
function of time. All values represent mean ± S.D. from two experimental replicates, n=3 scaffolds 
per treatment group. Statistically significant differences at each time point were found between 
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*all peptides, p<0.05 or **fCBD-LL37 and both LL37 and cCBD-LL37, p<0.001. fCBD-LL37 
release was significantly higher than the untreated, PBS-only control at all time points, p<0.001; 
(b) representative immunohistochemistry images of scaffold sections harvested at 14 days, stained 
using anti-human(LL37) antibody and visualized with AlexaFluor®488-conjugated secondary 
antibody; bar = 100 µm. 
 
ELISA analysis was also performed on the solution collected from preceding scaffold 
rinses to determine the percentage of peptide initially rinsed off the scaffold. Rinsing accounted 
for 2.83% ± 0.296%, 5.35% ± 0.305% and 0.023% ± 0.008% LL37, cCBD-LL37 and fCBD-LL37 
of the initial peptide adsorbed onto the scaffolds, respectively (mean of three rinses with n>3 
replicates per group ± S.E). Thus, for all peptides, greater than 94% (>310 µM) of the initial 
peptide is adsorbed to the collagen scaffolds. After 14 days, 73%, 81%, and 99% of LL37, cCBD-
LL37 and fCBD-LL37, or approximately 240, 270, and 325 µM, respectively are retained within 
the scaffold. This suggests that by using CBDs, LL37 can be initially retained at concentrations 24 
times higher than its cytotoxic threshold and released in increments at least 10x lower than its 
cytotoxic threshold between 1 hour and 14 days.  
3.6. CBD-LL37 peptides have improved retention compared to unmodified LL37 
The primary rationale for modifying LL37 with CBDs is to improve retention of the peptide 
over time on collagen-based scaffolds, thus improving its longer-term antimicrobial activity while 
reducing the total amount of peptide required to treat wound infections. Thus, after observing a 
high retention of all peptides after 14 days in release medium (Fig. 4a-b; Fig. S2), we tested 14-
day release scaffold activity against E. coli (Fig. 5a) and then probed for LL37 to assess peptide 
retention (Fig. 5b). After 14 days, both CBD-LL37 peptides were retained on collagen scaffolds 
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and exhibited similar levels of antimicrobial activity as samples tested after 12 hours in release 
medium. In contrast, LL37-loaded collagen scaffolds had lower antimicrobial activity at 14 days 
compared to 12 hours. IHC results showed lower LL37 staining on collagen scaffolds, whereas 
staining remained strong on collagen scaffolds treated with either cCBD-LL37 or fCBD-LL37 
(Fig. 5b). The reduction in LL37 staining is consistent with the observed loss of antimicrobial 
activity on LL37-treated collagen scaffolds after 14 days. Together, these data indicate that CBD 
modification facilitates retention of both binding and activity of LL37 on collagen scaffolds. 
 
Figure 5: Antimicrobial activity of peptide-loaded scaffolds over 14 days. Relative turbidity 
after scaffold exposure to E. coli for 12 hours (black) and 14 days (white) (a). All values represent 
means ± S.E. from at least four replicates. Statistically significant difference between means of 
peptide-loaded scaffolds and PBS-loaded scaffolds is indicated by: *p<0.01, **p<0.001, and of 
cCBD-LL37 versus LL37 at 14 days +p<0.05; (b) representative immunohistochemistry images of 
scaffold sections, harvested after 14 days of release, followed by 12 hour exposure to E. coli and 
stained using anti-human(LL37) antibody and visualized with AlexaFluor®488-conjugated 
secondary antibody; bar = 100 µm. 
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3.7. Collagen-bound peptides are non-cytotoxic, even at high concentrations 
An additional rationale for tethering AMPs to surfaces using covalent and non-covalent 
methods is to increase peptide stability and retain antimicrobial activity, while decreasing 
cytotoxicity [12]. Thus, we loaded peptides onto collagen scaffolds and assessed the viability of 
fibroblasts seeded on the scaffolds after 24 hours. CRL-2352 cell viability was not statistically 
different on peptide-loaded scaffolds compared to PBS-loaded scaffold controls (Fig. 6). These 
data suggest that the same concentrations of AMPs applied to collagen scaffolds that killed bacteria 
(Fig. 3c) were not cytotoxic to mammalian fibroblasts. To verify fibroblast seeding and verify 
peptide adsorption on collagen scaffolds, sections were immunostained for LL37 and counter-
stained with Hoechst to visualize nuclei. In all scaffold sample groups (peptide-adsorbed and 
unloaded controls), nuclei were observed along the edges of the scaffold, as well as within the 
scaffold material 24 hours after seeding. These data demonstrate the presence of cells on the 
scaffolds with or without peptide adsorption (Fig. S3). 
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Figure 6: Cytotoxicity of antimicrobial peptides tethered to collagen scaffolds. Relative 
fluorescent units (x103), correlated directly with the number of viable CRL-2352 human 
fibroblasts, given by AlamarBlue® reduction after 24 hours. All values represent mean ± S.E. from 
at least three experimental replicates. Statistically significant difference between PBS-, LL37-, 
cCBD-LL37- and fCBD-LL37-loaded scaffolds and medium-only, cell-only and no cells, PBS-
only scaffold controls, *p<0.001. 
 
4. DISCUSSION 
4.1. Considerations for AMP tethering 
Tethering AMPs such as LL37 to collagen could enable clinical application of broad-
spectrum AMPs to treat wound infections without cytotoxicity. Tethering or controlled release 
approaches may mitigate AMP cytotoxicity while retaining antimicrobial activity, and may serve 
to increase in vivo stability. While covalent tethering via flexible tether molecules could increase 
stability, a lack understanding of how tethering affects peptide structure and mechanisms could 
limit antimicrobial activity of these systems [12, 23]. For example, short tether lengths may not 
allow proper peptide structure and orientation to kill bacteria, but different lengths and properties 
are required for different peptides that utilize different mechanisms of action [17, 18, 26, 30]. 
Tethering may also cause alterations to AMP local charge and surface density [15, 18, 23, 26, 30, 
58], aggregation behavior and distribution [23], flexibility [17, 19], orientation [17, 20, 24, 25], 
conformation and secondary structure [20, 22, 23] which may all play roles in altering mechanisms 
required for antimicrobial activity [12, 15, 18, 20]. The complexity of these systems also limits 
their clinical use, requiring optimization of tether properties such as length [18], surface density 
[15, 23], and grafting method [30]. Some grafting methods may be cytotoxic [30] or involve highly 
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specific, complex, or costly synthesis [21]. These systems often have unclear clinical endpoints 
for regulatory pathways (e.g. FDA clearance) leading to trial failure [13]. At the fundamental level, 
there is a lack of consistent understanding of tethered AMP structure-function relationships, 
leading to varying success of AMPs in the clinic [21, 23]. Although several approaches have been 
developed for covalent and non-covalent tethering of AMPs to many different substrates, this is 
the first report of using a CBD to tether a chimeric AMP to an extracellular matrix biopolymer. 
More recently, Cassin et. al, investigated LL37 incorporation into collagen and hyaluronic 
acid biopolymer polyelectrolyte multilayers (PEMs) via physisorption and covalent 
immobilization, and characterized LL37 release, antimicrobial activity, and cytotoxicity [30]. All 
PEMs effectively reduced E. coli adhesion, but the exposure of mammalian cells to chemically-
immobilized LL37 resulted in morphological changes, which may indicate some degree of 
cytotoxicity [30]. Activity against other bacteria types was not investigated. This highlights one of 
the biggest challenges in the field of tethered AMPs today, choosing a tethering scheme that will 
allow the best balance of AMP properties to kill a broad spectrum of bacteria without 
demonstrating toxicity. By investigating a new non-covalent collagen tethering strategy using 
CBDs, we hope to provide additional insights to the use of tethering to reduce the cytotoxicity of 
peptides delivered from biopolymers.  
4.2. Effects of CBD addition on LL37 antimicrobial activity and cytotoxicity in solution 
LL37 is a short peptide that must adopt an alpha-helical conformation for its antimicrobial 
activity [59]. Thus, it is crucial for CBD-LL37 function that CBD modification does not interfere 
with the LL37 domain’s physical interaction with bacteria [15, 16, 18]. Peptide sequence and 
structure has been shown to influence AMP flexibility [17, 19], secondary structure [20, 22], 
orientation [17, 20, 22, 24, 25], and charge density [18, 58]. Previous work on CBD-mediated 
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collagen tethering has involved either high molecular weight, uncharged or globular molecules 
such as growth factors [34, 35, 60] and streptavidin [37], or peptides too small to adopt significant 
structure on their own, such as fibronectin-derived RGD peptides [61, 62]. In these cases, CBD 
acted like an anchor without influencing peptide activities. 
We found that cCBD-LL37 exhibited similar antimicrobial activity and cytotoxicity as 
unmodified LL37, which suggests that the cCBD modification does not adversely affect AMP 
function. In certain cases, we observed a trend toward enhanced antimicrobial activity with cCBD-
LL37 against Gram-negative microbes compared to LL37, although most of these differences were 
not statistically significant. However, this is consistent with reported observations of enhanced 
bioactivity of cCBD-modified, collagen-tethered proteins, which was attributed to the high content 
of charged and polar amino acids in the cCBD sequence [63, 64]. Indeed, its amphiphilicity and 
added charges (net +3) could extend the LL37 helix [17] and promote electrostatic interactions 
[63, 64] with negatively-charged bacterial membranes of various thicknesses.  
In contrast, fCBD caused reductions in LL37 antimicrobial activity and cytotoxicity 
compared to LL37 and cCBD-LL37. MIC values for fCBD-LL37 were consistent across Gram-
negative and Gram-positive organisms, suggesting that fCBD-LL37 is relatively insensitive to 
bacterial type. Its lower cytotoxicity could be related to decreased overall charge of LL37 caused 
by addition of fCBD (net -1), or structural alterations caused by aggregation of fCBD moieties [61, 
65]. Despite the observed reduction in antimicrobial activity, the minimum therapeutic index of 
fCBD is still 2x (> 20 µM cytotoxicity / 10 µM MIC). 
4.3. CBD-mediated peptide binding to collagen scaffolds 
CBDs may increase the stability and retention of AMPs on collagen, by limiting peptide 
exposure to proteases [12, 15, 17-19, 66] and providing high affinity [50], specific binding onto 
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collagen [50, 61, 67]. This increased stability is highly sought-after currently in both soluble and 
tethered AMP technologies [6, 12, 15, 66]. We tested both cCBD and fCBD sequences and 
hypothesized that they may differentially affect LL37 tethering and antimicrobial activity due to 
their variable structures and binding affinities. cCBD induces conformational changes in collagen 
type I in order to accommodate the small collagenase catalytic site (5Å binding site vs. 3000Å 
length and 15Å diameter of collagen) [67]. fCBD is less specific and has been shown to bind to 
collagen types I, III and V [37, 61, 62]  as well as gelatin [68]. fCBD has demonstrated disulfide 
bond formation, oxidation sensitivity [65] and aggregation leading to dimerization [65, 69], and 
also undergoes conformational changes upon binding to collagen [62], implying that its AMP-
tethering may also result in interesting structural alterations. 
Orientation of peptide binding and collagen scaffold structure are important design 
considerations for CBD-AMP-based antimicrobial collagen scaffolds. Surface-tethered and 
surface-adsorbed peptides have demonstrated conflicting results and variable success as 
antimicrobial agents [12, 15, 16, 18, 19, 58], but in all cases, the peptide structure when bound was 
important for its function [17-20, 24]. There are no reports of how (or if) CBDs affect AMP 
antimicrobial activity when tethered to collagen. However, it has been shown that cCBD [35, 60, 
70] and fCBD [37, 61] both improve collagen binding and retention of other molecules, leading to 
maintained or enhanced [63, 64] in vitro or in vivo bioactivity. 
4.4. Antimicrobial activity of collagen scaffolds loaded with CBD- and unmodified AMPs 
All of the LL37 peptides tested, CBD-modified or unmodified, adsorbed to PURACOL® 
collagen scaffolds, both initially and after 14 days in release medium. CBD-mediated tethering 
may increase peptide stability [15], reflected not only by greater retention of both cCBD-LL37 and 
fCBD-LL37 on collagen scaffolds after 14 days and exposure to bacteria, but also by retention of 
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scaffold antimicrobial activity compared to LL37-treated scaffolds. This non-covalent retention 
correlates well with the reported release profiles of physically-adsorbed and chemically-
immobilized unmodified LL37 from ECM materials and falls between the two reported profiles at 
96 hours [30]. Further, the negatively-charged fCBD domain may cause fCBD-LL37 aggregation 
on collagen [61, 65]. Since aggregation is the first step in the reported antimicrobial mechanism 
of LL37 [44, 59, 71], this could have contributed to fCBD-LL37’s stable antimicrobial action over 
the full 14 day period tested. The formation of intramolecular disulfide bonds by fCBD [68] could 
also play a role in altering the release profile for fCBD-LL37 compared to LL37 or cCBD-LL37.  
Reduction in LL37 antimicrobial activity after 14 days in vitro could have been the result 
of LL37 degradation, which has been reported to be relatively rapid [6]. Alternatively, it is possible 
that the negative charge of the E. coli membranes could have caused LL37 to change its 
conformation [59, 72, 73] and desorb from the surface [18]. 
LL37 is believed to act against bacterial membranes via the carpet model, which supposes 
that peptide molecules aggregate on the membrane surfaces until reaching a critical peptide-to-
lipid ratio, followed by intercalation within the membrane, pore formation, and lipid removal in 
the form of peptide-lipid aggregates [40, 44, 59, 71-73]. In solution, LL37 is globular until it adopts 
a helical structure in a lipophilic membrane environment [59, 72]. Thus, AMP adsorbed to collagen 
scaffolds may need to partially or fully desorb and interact with bacterial membranes to mediate 
effective killing, which has been observed for certain surface-adsorbed peptide systems [17-19, 
74]. Alternatively, we have demonstrated previously that tethered AMPs are still able to adopt 
non-native mechanisms of action (such as membrane charge destabilization) if unable to act 
through their primary mechanism of action [18].  
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In general, CBD-LL37 peptides displayed varying activities against different microbes 
when bound to collagen; for example, improved antimicrobial activity against Gram-negative P. 
aeruginosa but decreased antimicrobial activity against S. aureus. Fully permeating the thick 
peptidoglycan layer of Gram-positive organisms may require different structural considerations, 
such as CBD and peptide sequence composition [16], or linker sequence lengths [18]. 
4.5. Collagen-bound AMP reduction in cytotoxicity  
We hypothesized, based on findings for covalently-bound peptides [15], that collagen-
tethering would reduce peptide cytotoxicity. In our study, all peptide-loaded collagen scaffolds 
demonstrated biocompatibility based on fibroblast viability 24 hours after cell seeding, confirming 
this hypothesis and supporting the results of Cassin et. al, who observed cytotoxicity of 
chemically-immobilized LL37 at only 16 µM and suspected it was due to the immobilization 
strategy itself [30]. Unexpectedly, physical adsorption alone is enough to also reduce the 
cytotoxicity of LL37 that is retained on the surface.  
4.6. Implications for wound healing  
In addition to its antimicrobial properties, LL37 plays a role in wound healing (at 
concentrations between 0.1 and 5 µM) due to its synergy with other components at the wound site 
such as beta defensin 2 [11]. Preservation and survival of cells at the wound site may be important 
for the outcomes of the healing process and these activities of antimicrobial peptides, both in 
general and when tethered to collagen, need to be investigated further. 
Dosing optimization will need to be performed for each CBD-AMP prior to in vivo studies. 
Only a single peptide loading concentration was tested in this study. Although CBD-LL37-loaded 
collagen scaffolds were effective against Gram-negative bacteria at this concentration, higher 
doses may be required for activity against Gram-positive microbes. Clinical utility of AMP-loaded 
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wound dressings will depend on in vivo efficacy, as well as cost effectiveness. In ongoing studies, 
we are evaluating recombinant production of CBD-AMPs to reduce production costs and enable 
additional modifications to peptide sequences, including alternative CBD and ECM tethering 
domains, alternative AMP domains, and variable linker domain sequences and lengths. 
Recombinant protein production may be a promising approach for reducing peptide manufacturing 
costs in future studies [6, 75]. We initially chose the FLAG sequence between LL37 and CBD 
domains to serve as both a linker [17] and an epitope tag [45] that would provide the possibility of 
FLAG-based purification of CBD-AMPs. The addition of a linker sequence is important to 
maintain the flexibility required for membrane interactions of tethered peptides [15, 17, 19], and 
should be explored in future studies of CBD-AMP design and activity. 
Evaluation of the roles of alternative AMP, CBD, and linker sequences, as well as tethering 
to alternative ECM molecules prevalent in scaffold materials and healing wounds, will allow us to 
develop a versatile platform technology for treating infection while optimally stimulating tissue 
regeneration.  
 
5. CONCLUSIONS 
Herein, we demonstrated CBD-tethered LL37 binding to a collagen-based wound dressing, 
showed retention of antimicrobial activity (up to 14 days), and showed that scaffolds were non-
cytotoxic despite adsorbing AMPs at concentrations 24 times higher than their reported cytotoxic 
threshold. We show that when interacting with collagen, LL37 has a higher therapeutic index. 
Further, CBD addition and tethering to collagen modulate LL37 retention, release, antimicrobial 
activity and cytotoxicity. CBDs also allow retention and activity against Gram-negative E. coli for 
14 days, indicating that CBD mediates higher collagen binding affinity. Importantly, none of the 
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peptides (with or without CBD) demonstrated cytotoxicity against fibroblasts despite high loading 
concentrations, showing promise for collagen-tethering as a strategy to deliver effective, non-toxic 
doses of AMPs to kill bacteria and promote wound healing. 
Results from this study are important for not only demonstrating proof-of-concept of AMP 
binding to biopolymers and retaining their efficacy, but also making rational choices of AMP and 
CBD structures to allow effective and specific binding onto biopolymers without cytotoxicity. 
Collagen-tethering of AMPs without the harmful side effects of current approaches (e.g., bacterial 
resistance, general toxicity, scarring) and utilizing their wound healing functionality have 
important implications for the future of tethered AMPs. This includes elucidating structure-activity 
relationships and dosage concentrations to allow application-tailored design of biopolymer-
tethered AMPs, investigating novel production routes and delivery strategies, and exploring in vivo 
wound healing and antimicrobial abilities of biopolymer-tethered AMPs. 
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Abstract 
The collagen binding of human-derived antimicrobial peptide LL37 via collagen-binding 
domains (CBDs) has demonstrated promise as a viable strategy to improve the therapeutic ratio of 
LL37 for chronic wound healing applications. Recently, we found that chimeric LL37 with CBDs 
derived from collagenase (cCBD-LL37) and fibronectin (fCBD-LL37) bound to collagen-based 
scaffolds and retained antimicrobial activity against common wound pathogens. In this addendum, 
visualization of the scaffold surfaces after interactions with Gram-negative Escherichia coli is 
provided through scanning electron microscopy (SEM). SEM provided direct observation of both 
collagen and bacteria morphology after exposure to PBS-, LL37-, cCBD-LL37- and fCBD-LL37-
loaded scaffolds and allowed additional mechanistic observations suggesting that the bound 
peptides are surface-active. These observations demonstrate potential for anti-biofilm activity of 
CBD-LL37 peptides, an important attribute in clinical chronic wound healing applications. 
 
Keywords 
Scanning Electron Microscopy, LL37, Collagen Binding Domain, cCBD-LL37, fCBD-LL37 
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1. Introduction 
With the increasing prevalence of antibiotic resistance in the clinic, the development of 
new alternatives to prevent infection without promoting resistance are urgently needed [1]. Those 
suffering from chronic wounds in particular share this need, but also require alternative 
antimicrobials that do not hinder their healing, unlike those that are currently used (e.g. silver or 
chlorhexidine [2, 3]). 
Toward this need, antimicrobial peptides (AMPs) – particularly the human-derived 
cathelicidin LL37 [4, 5] – demonstrate promise toward providing broad-spectrum antimicrobial 
activity [6] that does not promote resistance [7] and immunomodulatory pro-wound healing 
activity to chronic wounds [8, 9]. Unfortunately, their low stability in vivo combined with narrow 
therapeutic ratios (defined as the ratio of antimicrobial to cytotoxic concentration) have prevented 
their clinical appearance [10]. 
Previously, we were able to significantly improve the therapeutic ratio of LL37 by tethering 
it onto collagen-based wound scaffolds via collagen binding domains (CBDs), one derived from 
collagenase (cCBD-LL37) and one derived from fibronectin (fCBD-LL37). cCBD-LL37 and 
fCBD-LL37 were highly retained on collagen and maintained their antimicrobial activity up to 14 
days [11]. However, unmodified LL37 appeared to desorb in the presence of bacteria after 14 days, 
suggesting that both stable attachment to collagen and antimicrobial activity were mediated by the 
presence of CBDs. The same was found for collagen scaffolds of different overall compositions; 
however, activity was limited to Gram-negative Pseudomonas aeruginosa (Chapter 4).  
The exact mechanism of antimicrobial action is not widely agreed upon for LL37. It is 
most often proposed to form transmembrane pores in lipid bilayers, causing leakage and eventual 
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cell death [5]. Further, LL37 has the ability to bind and neutralize endotoxins, lipopolysaccharides 
(LPS) and extracellular polymeric substances (EPS), all of which factors that increase the virulence 
of biofilms [12]. We postulated that tethered CBD-LL37 peptides could act via different 
antimicrobial mechanisms when tethered versus soluble, due to limited flexibility brought about 
by tethering. Flexibility has demonstrated great importance in other surface-tethered AMP systems 
[13-16]. Covalently tethered AMPs have exhibited alternative mechanisms due to limited 
flexibility [17-19]. However, it is also possible that the length of the FLAG (utilized as a short 
flexible linker sequence between the CBD and LL37 sequences) and CBD domains and the non-
covalent immobilization strategy provided CBD-LL37 a long enough length and flexibility to 
allow similar pore-forming mechanisms as unmodified LL37 [15, 20, 21]. 
In this addendum, we provide evidence toward membrane permeation, particularly in the 
case of cCBD-LL37, as well as possible aggregation mechanisms facilitated by fCBD-LL37 using 
scanning electron microscopy (SEM). SEM results suggested a protective, possibly anti-biofilm 
activity of both cCBD-LL37 and fCBD-LL37 versus scaffolds loaded with just phosphate buffered 
saline (PBS) and unmodified LL37. These results are qualitative, and highlight the need for 
additional studies of detailed CBD-LL37 mechanisms while tethered; however, they provide 
evidence of the potential for using CBD-modified AMPs as effective antimicrobial and anti-
biofilm therapies for chronic wound healing applications. 
 
2. Materials and Methods 
2.1. Synthetic peptides 
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All synthetic peptides were purchased and maintained as described previously [11]. Peptide 
sequences are listed in Table 1. 
Table 1: Synthetic LL37 and collagen-binding LL37 sequences* 
Peptide Sequence Ref. 
LL37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES [22] 
cCBD-LL37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-
DYKDDDDKTKKTLRT 
[23] 
fCBD-LL37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-
DYKDDDDKCQDSERTFY 
[24] 
*DYKDDDDK sequence: a commercially-recognized FLAG™ sequence was utilized as a flexible 
linking molecule as well as an epitope tag [25]. 
 
2.2. Loading of 3D collagen scaffolds 
PURACOL (Medline Industries, Mansfield, MA) scaffolds of 100% native bovine type I 
collagen were loaded with LL37 (1478 µg/mL), cCBD-LL37 (2078 µg/mL) and fCBD-LL37 
(2178 µg/mL), as descried previously [11, 26]. In short, 5 µL of each peptide was added on highly 
hydrophobic polydimethylsiloxane mats, incubated at 37°C for 2 hours, and then rinsed twice with 
sterile, Dulbecco’s phosphate buffered saline, pH 7.4 (PBS). Loading concentrations and volumes 
were calculated using the disk geometry and collagen properties, under the assumption of a 1:1 
ratio of collagenase binding sites to collagen monomers in each disk [27]. 
2.3. Bacterial strain and preparation 
Escherichia coli (HB101) was cultured in sterile, 9.8 g/L Mueller-Hinton broth (MHB) at 
37°C with agitation (250-300 RPM) for 4-6 hours. Immediately prior to experiments, the culture 
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was corrected to 1x108 colony-forming units (CFU) per mL using a 0.5 McFarland turbidity 
standard. Then, cultures were diluted 100-fold in MHB prior to inoculation to 1x106 CFU/mL. 
2.4. Peptide-loaded scaffold exposure to E. coli 
After loading and rinsing (Section 2.2), scaffolds were placed in fresh MHB and inoculated 
with 1x106 CFU/mL to a final concentration of 5x105 CFU/mL. In a procedure adapted from a 
published protocol [11, 28], scaffolds were incubated at 37°C without agitation at to allow bacteria 
to adhere onto the scaffolds. Then, scaffolds were rinsed well with MHB and returned to 37°C (no 
agitation) for 12 hours. Scaffolds were then collected and immediately fixed for microscopy. 
2.5. Scanning electron microscopy (SEM) 
The SEM preparation procedure was adapted from published protocols [29]. After bacteria 
exposure (Section 2.4), scaffolds were fixed for 1 hour in 2.5% glutaraldehyde in PBS and then 
transferred into cassettes and dehydrated in an alcohol series from 10 to 100%. Samples were dried 
in an Autosamdri 815 critical point dryer (Tousimis, Rockville MD) for 30 min with a 3 min purge, 
mounted onto SEM stubs with conductive tape, and painted around the edges with conductive 
silver paint (Sigma Aldrich, St. Louis, MO). Samples were then carbon coated with a Denton 
Vacuum 502b (Moorestown, NJ), followed by sputtering a 12 nm coating of Pt/Pd over the surface 
in three, 4 nm runs (Cressington Scientific Instruments, Watford England UK). SEM images (10 
kV) were collected at the University of Massachusetts Medical School Electron Microscopy Core 
(Worcester, MA), with an FEI Quanta 200 FEG MKII (FEI, Hillsboro OR). 
 
3. Results 
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Micrographs of dry PURACOL scaffolds (Fig. 1) were collected for comparison of 
peptide- and PBS-loaded scaffolds after bacterial exposure. Scaffolds were porous with dense 
collagen fibers. 
 
Figure 1: Dry scaffold disks at different magnifications. Representative images were taken at 
three magnifications, from left to right, 1 kx (left; bar = 50 µm) 10 kx (middle; bar = 5 µm) and 
25 kx (right; bar = 2 µm). 
 
PBS-, LL37-, cCBD-LL37- and fCBD-LL37-loaded scaffolds were imaged after exposure 
to E. coli for 12 hours and observed for signs of bacterial infiltration, fraying and any other surface 
“abnormalities” compared with dry scaffolds. Representative images were taken for the scaffolds 
at various magnifications, 1 kx (Fig. 2), 5 kx (Fig. 3), 10 kx (Fig. 4) and 25 kx (Fig. 5). 
Scaffold morphology after exposure to bacteria was observed using images with lower 
magnifications (Fig. 2, Fig. 3). Overall, the pore sizes and collagen fibers at the lowest 
magnification did not appear considerably different across samples (Fig. 2). However, scaffolds 
loaded with PBS only appeared “dirtier” than all of the other scaffolds; deposits covered the 
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surface. At slightly higher magnification, deposits were apparent on both PBS- and LL37-loaded 
scaffolds; some were very large (5 µM) in the case of LL37 and some were small (Fig. 3). At this 
magnification, rod-shaped E. coli were visible. PBS only-loaded scaffolds demonstrated the 
highest density of bacteria located on the collagen surface. Only a few areas on cCBD- and fCBD-
LL37-loaded scaffolds had small rods that resembled bacteria, and LL37 did not demonstrate any 
residing bacteria. Scaffolds loaded with cCBD- and fCBD-LL37-loaded were much “cleaner” 
overall than the PBS- and LL37-loaded scaffolds, more closely resembling the dry samples. 
 
Figure 2: PBS- and peptide-loaded scaffolds after exposure to E. coli at 1 kx. Representative 
1 kx images of PURACOL loaded with PBS, LL37, cCBD-LL37, and fCBD-LL37 and exposed 
to E. coli for 12 hours; bar = 50 µm. 
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Figure 3: PBS- and peptide-loaded scaffolds after exposure to E. coli at 5 kx. Representative 
5 kx images of PURACOL loaded with PBS, LL37, cCBD-LL37, and fCBD-LL37 and exposed 
to E. coli for 12 hours; bar = 10 µm. 
 
Upon further magnification (Fig. 4), the debris was much more apparent on both PBS- and 
LL37-loaded scaffolds. cCBD-LL37-loaded scaffolds had very small amounts of debris. There 
was also no evidence of debris on fCBD-LL37-loaded scaffolds; however, the structure of 
individual collagen fibers were morphologically different in fCBD-LL37 samples from the other 
samples and dry scaffolds. Fibers were thicker and made fewer pores, as if they were aggregated, 
and curled into winding shapes. 
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The morphology of individual bacteria was clearest at the highest magnification (Fig. 5). 
In PBS samples, E. coli were scattered among the debris, rod-shaped, smooth and ≈2 µm long. In 
contrast, the bacteria-like entities, with rough, shriveled surfaces that contorted into various 
shapes, resided on both cCBD- and fCBD-LL37-loaded scaffolds. With LL37-loaded scaffolds, 
the large debris that were prevalent across the entire scaffold did not resemble bacteria at all; 
however, appeared at the same relative density as individual bacteria (demonstrated by the same 
shade of gray in the micrographs). The difference in collagen fiber morphology of fCBD-LL37-
loaded scaffolds compared to all other samples was also most apparent at this magnification, 
showing large bundles with few pores that twisted together. 
 
Figure 4: PBS- and peptide-loaded scaffolds after exposure to E. coli at 10 kx. Representative 
10 kx images of PURACOL loaded with PBS, LL37, cCBD-LL37, and fCBD-LL37 and exposed 
to E. coli for 12 hours; bar = 5 µm. 
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Figure 5: PBS- and peptide-loaded scaffolds after exposure to E. coli at 25 kx. Representative 
25 kx images of PURACOL loaded with PBS (bar = 3 µm*) and LL37, cCBD-LL37, and fCBD-
LL37 (bar = 2 µm), and exposed to E. coli for 12 hours. Two representative images (top and bottom 
panels) are provided per sample. 
*Note that while the bars are different for PBS-loaded sample vs. all other samples, the scale and 
magnification are not. 
 
4. Discussion 
4.1. E. coli morphology on different scaffolds demonstrate different modes of activity among LL37 
and CBD-LL37 peptides 
E. coli bacteria were healthiest and most proliferative on PBS-only scaffolds; healthy E. 
coli should be smooth and devoid of membrane deformities, and are approximately 0.7 to 1.4 µm 
in diameter, 2 to 4 µm in length [30] which is what we observed. Further, surrounding them and 
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densely covering the collagen fibers were small deposits. Similar deposits were observed 
surrounding Staphylococcus epidermidis [31], Burkholderia cenocepacia [32], and polymicrobial 
biofilms [33], and suggested to be EPS produced during biofilm formation. During biofilm 
formation, EPS increases in number and with time, and can appear as early as 2 hours [34]. Thus, 
we might expect its presence after 12 hours on PBS-loaded scaffolds [11]. Interestingly, debris 
were also observed in LL37-loaded samples, despite effective antimicrobial activity, suggesting 
that bacteria are still able to attach and deposit EPS on LL37-loaded scaffolds. Indeed, it is possible 
that only soluble LL37 released from PURACOL retains effective antimicrobial activity thus 
allowing E. coli to still adhere onto the scaffolds. 
Once bacterial membranes become compromised as a result of interactions with AMPs, 
leakage of cellular contents and blebbing can result in large amounts of debris [35, 36]. Further, 
individual bacteria can become aggregated [32]. Thus, it is possible that the large aggregates 
observed on LL37-loaded scaffolds were aggregated cellular debris as a result of lethal interactions 
with soluble LL37. In the case of cCBD-LL37 and fCBD-LL37, bacteria were irregularly shaped 
and displayed surface roughness, both of which are evidence of damaged membranes, suggesting 
that membrane permeation was a cause of E. coli killing. Both E. coli and S. aureus demonstrated 
similar membrane morphologies after exposure to a different cathelicidin derived from sheep, 
SMAP-29 [37]. The twisted shapes of E. coli after interaction with fCBD-LL37 surfaces closely 
resembles those observed by Krahulec et al. in E. coli after interactions with soluble LL37 [38]. 
Shrinking, observed for bacteria on cCBD- and fCBD-LL37-loaded scaffolds is another indication 
that cells had been permeated. Gram-negative rod, P. aeruginosa demonstrated shrinking and 
membrane blebs in the presence of truncated version of Esculentin 1a from frog skin [39]. 
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4.2. Differences in scaffold morphology indicate different anti-biofilm and protective abilities of 
LL37 and CBD-LL37 
The interaction with bacteria did not appear to cause significant structural damage to the 
scaffolds. In some images, though inconsistently observed, there were some frayed fibers 
indicative of degradation [40]. This is not surprising, since the laboratory strain of E. coli used in 
this study does not produce proteases, such as collagenases from Clostridium histolyticum, that are 
strong enough to degrade the polymerized collagen in PURACOL. An interesting observation was 
what appeared like fiber aggregation and a lower porosity in the case of fCBD-LL37-loaded 
scaffolds, for which at this time we do not have a sufficient explanation. Crosslinking of 
biopolymers is not an unrealistic possibility; cationic AMPs have participated in biopolymer 
crosslinking before [41]. 
Biofilm formation is a predominant mode of enhancing bacterial infiltration, increasing 
resistance to antibiotics and creating highly virulent infections on biomaterial surfaces [42]. In 
many ways, simply reducing bacterial adhesion on biomaterials is more important than actively 
killing. The lack of EPS apparent in scaffolds loaded with cCBD- and fCBD-LL37 support possible 
anti-biofilm activities of these peptides when attached onto collagen. In this way, CBD-LL37 
peptides may also play a role in scaffold protection from bacterial degradation. LL37 has 
demonstrated anti-biofilm activity before [43] but did not demonstrate the same effect on collagen. 
More quantitative studies will be needed to fully understand the mechanistic reason behind this 
finding. 
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5. Conclusions 
In this short study, we used scanning electron micrographs to study the morphological 
changes in pure collagen scaffolds loaded with PBS, LL37, cCBD-LL37 or fCBD-LL37 after 
exposure to E. coli for 12 hours. We found that bacteria were healthy on PBS-loaded scaffolds, 
not present on LL37-loaded scaffolds, and demonstrated morphologies consistent with membrane-
permeated cells on both cCBD- and fCBD-LL37-loaded scaffolds. Further, the lack of EPS 
involved with pathogenicity of bacteria and biofilm formation, on both cCBD- and fCBD-LL37-
loaded scaffolds compared to PBS- and LL37-loaded scaffolds, demonstrated the possibility of 
anti-biofilm activity of collagen-tethered CBD-LL37. These qualitative results warrant additional 
studies on the mechanisms of collagen-tethered CBD-LL37, and demonstrate the promise of their 
use as effective antimicrobial and anti-biofilm therapeutics on collagen-based wound dressings. 
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Abstract 
The prevalence of chronic wound infection combined with the rise of antibiotic resistance 
has created a pressing need for alternative strategies to prevent infection that promote healing and 
combat resistance. Antimicrobial peptides (AMPs), including human-derived LL37, have broad-
spectrum antimicrobial activity and pro-wound healing functionality but do not promote 
resistance, making them promising for incorporation into chronic wound dressings. Previously, we 
found that new chimeric LL37 peptides with collagen binding domains derived from collagenase 
(cCBD-LL37) and fibronectin (fCBD-LL37) bound onto 100% bovine collagen type I dressings, 
maintained antimicrobial activity for 14 days and were not cytotoxic to human fibroblasts. 
However, commercial dressings are often manufactured with mixed biopolymers, not simply pure 
collagen. Thus to further study commercial applicability of CBD tethering, we investigated the 
cytotoxicity, retention, release, and antimicrobial activity of LL37, cCBD-LL37 and fCBD-LL37 
over 14 days on FIBRACOL scaffolds composed of 90% bovine type I collagen plus 10% calcium 
alginate, an anionic polysaccharide derived from brown seaweed commonly used in wound 
dressings. We found that LL37, cCBD-LL37 and fCBD-LL37 retained highly on FIBRACOL over 
14 days (90.3%, 85.8% and 98.6%, respectively) and were not cytotoxic. However, peptides 
demonstrated diminished antimicrobial activity against all strains tested except Pseudomonas 
aeruginosa. We attributed this the peptide inactivation and neutralization due to hydrophobic and 
electrostatic interactions with alginate biopolymer. This study demonstrates that biopolymer 
tethering is a viable strategy toward improving the cytotoxicity of AMPs, and stresses that 
biomaterial properties can modulate the activity and specificity of biopolymer-tethered AMPs. 
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1. Introduction 
Chronic wounds are a significant burden to the healthcare system, affecting over 6.5 
million people and costing over $25 billion per year in the United States [1]. Healing a chronic 
wound requires a warm, moist, nutrient-rich environment commonly provided by wound dressings 
or scaffolds [2]. Unfortunately, such an environment can also promote bacterial growth and many 
patients with chronic wounds such as burns or diabetic foot ulcers are immunocompromised, 
limiting their ability to combat infection [3]. Further, the “catastrophic” threat of antibiotic-
resistant bacteria [4] has increased the morbidity of chronic wound infection in these patients. 
Current options for preventing infections associated with wound dressings and scaffolds such as 
metal ions or chemicals (for example, silver and chlorhexidine) are toxic and do not aid the healing 
process [5, 6]. In this respect, new antimicrobial alternatives are needed to prevent chronic wound 
infections and promote healing. 
Antimicrobial peptides (AMPs), such as human cathelicidin LL37, are promising potential 
therapies for chronic wound healing due to their broad-spectrum antimicrobial activity [7] but also 
many immunomodulatory functions that aid in wound healing [8, 9]. For example, in the low 
micro-molar concentration range [10], LL37 has direct and indirect chemotactic activity, 
endotoxin (e.g. lipopolysaccharide) binding, blocks apoptosis in neutrophils, and is angiogenic [8]. 
Additionally, the unique physical membrane interactions of LL37 and many other AMPs do not 
promote resistance in bacteria [11]. Despite this promise, LL37 and other AMPs have not reached 
the clinic to date due to its low in vivo stability and cytotoxicity at high concentrations [12]. 
Tethering, or immobilization of AMPs onto surfaces is a promising method of mitigating 
cytotoxicity, improving stability and maintaining antimicrobial and anti-biofilm functionality [13].  
Indeed immobilization of LL37 onto commercial wound dressings, which are overwhelmingly 
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comprised of collagen-based biopolymers, appeared a viable strategy. However, the covalent 
attachment of LL37 onto biopolymer polyelectrolyte surfaces demonstrated signs of cytotoxicity 
[14]. Thus, we recently created modified chimeric version of LL37 with two collagen-binding 
domains (CBDs) on its C-terminus, one from collagenase (cCBD-LL37) and one from fibronectin 
(fCBD-LL37) for the non-covalent attachment onto PURACOL collagen scaffolds, and studied 
retention and release, antimicrobial activity and cytotoxicity of each compared with unmodified 
LL37 [15]. We found that cCBD- and fCBD-LL37 both remained adsorbed on PURACOL and 
antimicrobial up to 14 days [15]. The physicochemical properties of each CBD made a large impact 
on peptide bioactivities (Chapter 5). More importantly, we found that all peptides were not 
cytotoxic to human dermal fibroblasts, despite being loaded at a concentration 30 times higher 
than the reported toxic threshold of LL37, 13 µM [10, 15]. This study demonstrated that by non-
covalently tethering CBD peptides onto collagen, we could improve the therapeutic ratio of LL37 
(the ratio of antimicrobial to cytotoxic concentrations), bringing it closer to clinical application. 
PURACOL provided a suitable substrate to study the collagen-binding ability of CBD-
LL37 peptides; however, greater than ninety percent of commercial wound dressings are composed 
of something other than pure, native type I collagen. Many dressings are composites containing 
additional biopolymers and extracellular matrix proteins. A prominent example is alginate, an 
anionic polysaccharide derived from brown seaweed, which is often added to collagen-based 
scaffolds to maintain a moist healing environment [16, 17]. Its structure is comprised of 
consecutive and alternating (1,4)-linked β-D-mannuronate and (1,4)-α-L-guluronate, which gives 
it a highly anionic charge [16]. Alginate forms a gel in the presence of divalent cations such as 
Ca2+ [16]; thus, the combination of collagen and alginate creates scaffolds that do not require toxic 
crosslinking methods [18] and maintain high cellular attachment [19, 20]. Nearly twenty percent 
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of all scaffolds in the wound care products market, and eighty percent of biopolymer-based 
scaffolds for healing diabetic foot ulcers [21] are comprised of collagen, alginate or both (Table 
1). Interestingly, seven out of the ten companies listed in Table 1 incorporate silver or zinc ions 
into their wound dressings for infection control. 
Table 1: Major wound care companies and their collagen, alginate, or combined collagen 
and alginate wound products, comprising nearly 20% of the wound care products market. 
 
*Abbreviations: CA-ALG: calcium alginate; COL: collagen; ORC: oxidized-regenerated 
cellulose; Ag: silver; CMC: carboxymethylcellulose; ALG: alginate; GAG: incorporates 
glycosaminoglycans; Zn: incorporates zinc ions; PHM: incorporates polyhexamethylene 
antiseptic; (Ag), (Zn), (PHM), (CMC): indicates a separately sold version of the product that 
incorporates these agents. 
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 Toward the development of CBD-LL37 peptides as a platform tethering strategy for 
clinical applications in wound healing, their ability to bind, retain, and mediate preferred 
bioactivities on collagen scaffolds in the presence of other biopolymers must be studied in more 
depth. Given its common addition into collagen scaffolds and preferred moisture retention in 
chronic wounds we chose to study CBD-LL37 tethering and bioactivities on FIBRACOL (Acelity, 
San Antonio, TX), which adds 10% calcium alginate into an otherwise pure collagen type I 
scaffold as a first step toward this knowledge. We hypothesized that the presence of alginate could 
modify the ability CBDs to mediate binding and release from collagen over 14 days compared to 
pure collagen, as well as alter the bioactivities (e.g. broad-spectrum antimicrobial activity and low 
cytotoxicity) when bound. Results from this study demonstrate that the non-covalent collagen 
tethering of human LL37 is modulated by not only the type of CBD implemented, but also by the 
composition of the scaffold substrate. For wound healing applications, chimeric CBD peptides 
must be tested on more complex dressings composed of collagen with other biopolymers, and 
depending on the dressing composition, peptide and CBD modifications may need to be made to 
ensure retention of preferable bioactivities and mechanisms when bound. Importantly, this study 
further supports biopolymer tethering as a viable strategy for decreasing the cytotoxicity of AMPs 
such as human LL37, which is required for their clinical success. 
 
2. Materials & Methods 
2.1. Synthetic Peptides 
Synthetic modified LL37 from collagenase [22] (cCBD-LL37) and from fibronectin [23] 
(fCBD-LL37) were purchased from New England Peptide, Inc. (Gardner, MA) with sequences 
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LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKTKKTLRT and 
LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKCQDSERTFY, 
respectively. Each was purified at >90% using high-performance liquid chromatography (HPLC). 
The CBD-LL37 peptide included a common epitope tag, FLAG™ (DYKDDDDK) [24] to serve 
as a flexible linking sequence between LL37 and CBD when adsorbed onto collagen scaffolds [25, 
26]. For comparison, unmodified human LL37 (sequence, 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was purchased from Anaspec, Inc. 
(Fremont, CA) and purified with HPLC at >95% purity. All peptide stock solutions (0.67 mM) 
were prepared and stored at -20°C according to manufacturer suggestion, in sterile water (pH = 
3.5) supplemented with 5 mM ethylenediaminetetraacetic acid chelator (EDTA). 
2.2. FIBRACOL and PURACOL Scaffold Preparation and Peptide Loading 
All scaffolds were prepared and handled using sterile techniques and loaded in the same 
way. FIBRACOL Plus sheets of 26.01 cm2 were purchased from Acelity (San Antonio, TX). 3D 
scaffolds were cut into 5 mm circular disks using biopsy punches (Robbins Instruments, Chatham, 
NJ). Disks were sterilized with ethylene oxide gas (ETO) prior to use. PURACOL (Medline 
Industries, Mansfield, MA) was used as a comparison, prepared in the same way and as described 
previously [15]. 
 Scaffolds were loaded on highly hydrophobic mats of polydimethylsiloxane (PDMS) by 
adsorbing 5 µL of sterile Dulbecco’s phosphate buffered saline, pH 7.4 (PBS) negative control or 
peptides diluted in PBS (LL37 = 1478 µg/mL, cCBD-LL37 = 2078 µg/mL, or fCBD-LL37 = 2178 
µg/mL) and incubated for 2 hours at 37°C, under 5% CO2 and humidity. PDMS mats were used 
to ensure full hydration of the scaffolds. The loading volume (5 µL) was chosen because it was the 
minimum volume required to hydrate the 5 mm circular scaffold. Peptide concentrations used on 
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FIBRACOL were the same as those on PURACOL (details, [15]), which were calculated based on 
assuming a 1:1 ratio of collagenase binding sites per collagen monomer in the triple helices [22, 
27-29].  
After incubation, scaffolds were rinsed twice with different media depending on the assay: 
mammalian culture medium for viability assays (Section 2.4), release medium for cumulative 
release studies (Section 2.5), or Mueller-Hinton broth for antimicrobial assays (Section 2.6). A 
separate set of peptide- and PBS-loaded scaffolds, n=2 per sample group, was rinsed with PBS and 
immediately collected for processing and imaging (Section 2.7). 
2.3. Scanning Electron Microscopy (SEM) 
Scanning electron micrographs were collected at the University of Massachusetts Medical 
School Electron Microscopy Core facility (Worcester, MA) with an FEI Quanta 200 FEG MKII 
SEM (Hillsboro, OR). After ETO sterilization, FIBRACOL and PURACOL disks were sputtered 
with approximately 8 nm of platinum and palladium (Cressington Scientific Instruments, Watford, 
England, UK). Micrographs were acquired under high vacuum at 10 kV and 10 mm working 
distance. Micrographs were collected of n=2 FIBRACOL and PURACOL scaffolds.  
2.4. AlamarBlue® Scaffold Cell Viability Assay 
AlamarBlue® reagent (Thermofisher Scinetific, Waltham, MA) was used to assess 
cytotoxicity of LL37-, cCBD- and fCBD-LL37, and PBS only-loaded FIBRACOL against human 
dermal fibroblasts CRL-2352 (ATCC, Manassas, VA), as described previously [15]. According to 
the manufacturer, the AlamarBlue® signal directly correlates to a number of viable cells. CRL-
2352 cells were cultured in 1:1 Dulbecco’s modified eagle and Ham’s F-12 media (Hyclone, 
Logan, UT) supplemented with 10% v/v fetal bovine serum (Thermofisher). 
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In short, scaffolds were loaded with LL37, cCBD-LL37, fCBD-LL37 or PBS only (Section 
2.2) and then rinsed twice the sterile media. In non-tissue treated low binding Corning 96-well 
plates (Corning, NY), cells were directly loaded onto scaffolds at a density of 114,000 cells/cm2 
(80,000 cells per scaffold) and incubated for 4 hours at 37°C and 5% CO2. Scaffolds were rinsed 
twice more with medium followed by the addition and incubation of 10% v/v AlamarBlue® for 4 
hours at 37°C. Linear ranges of standard curves determined adequate cell seeding densities and 
AlamarBlue® reaction times. After 4 hours, the fluorescent signal (Ex/Em = 540 nm/590 nm) of 
50 µL aliquots from each sample was read with a Victor3 plate reader (Perkin Elmer, Waltham, 
MA). For additional time points of 24 hours and 7 days, the medium was refreshed every 36 hours, 
and the assay was repeated with fresh AlamarBlue® reagent. The 24-hour and 7-day samples were 
collected for processing and imaging (Section 2.7). Three independent release assays were carried 
out with n=3 scaffolds per sample group. 
2.5. Retention and Cumulative Release Studies 
2.5.1. Cumulative Release Assay 
The cumulative release of LL37, cCBD-LL37 and fCBD-LL37 from FIBRACOL was 
assessed over 14 days and compared both PBS only samples and PURACOL scaffolds. Scaffolds 
were loaded and incubated with peptides or PBS (Section 2.2) and then rinsed twice with “release 
medium,” comprised of sterile PBS supplemented with 1% w/v bovine serum albumin (BSA). All 
rinses were collected and stored at -20°C for ELISA (Section 2.5.2). Then, rinsed scaffolds were 
placed into release medium (1 mL) and constantly rotated (Labquake Tube Rotator, Thermofisher 
Scientific) at 37°C. At time points of 1 hour, 4 hours, 1 day, 4 days, 7 days and 14 days, 800 µL 
of release medium was collected under sterile conditions and stored at -20°C for ELISA (Section 
2.5.2). Before returning to the rotator, samples were replenished with 800 µL fresh release 
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medium. The study was chosen to be 14 days, because the majority of the inflammation and 
proliferation stages of wound healing occur within this time [30]. At day 14, scaffolds were rinsed 
twice with Mueller-Hinton broth and the antimicrobial activity of each sample against Gram-
negative P. aeruginosa (the only strain susceptible to peptides adsorbed onto FIBRACOL) was 
tested as described in Section 2.6. Then, scaffolds were harvested for processing and imaging 
(Section 2.7). Three independent assays were carried out with n=4 scaffolds per sample group. 
2.5.2. Enzyme-Linked Immunosorbent Assay (ELISA) 
 Cumulative release was quantified in 50 µL aliquots from all samples at all time points 
collected during the cumulative release assay (Section 2.5.1) using a direct enzyme-linked 
immunosorbent assay (ELISA), developed in-house and described in detail elsewhere [15]. The 
ELISA utilized a primary polyclonal rabbit-(anti)-human LL37, 0.4 µg/mL (Anaspec; cat. no. AS-
55927) for peptide detection and a secondary goat-(anti)-rabbit antibody conjugated to horseradish 
peroxidase (HRP), 0.3 µg/mL (Bio-Rad, Hercules, CA; cat. no. 1706515). HRP absorbance was 
read at 450 nm with a Perkin Elmer Victor3 spectrophotometer. Absorbance readings were fitted 
individually to standard curves of absorbance versus LL37, cCBD-LL37, and fCBD-LL37 
concentration to determine the total protein released at each time point, which allowed the 
calculation of percent cumulative release versus time. 
2.6. Scaffold Antimicrobial Activity Assays 
2.6.1. Bacterial Cultures and Preparation 
 Gram-negative strains Escherichia coli (ATCC 33694) and Pseudomonas aeruginosa 
(ATCC 29260), and Gram-positive strains Staphylococcus aureus (ATCC 48366) and 
Staphylococcus epidermidis (ATCC 49461) were purchased from ATCC. Broth cultures were 
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prepared in 9.8 g/L Mueller-Hinton broth (MHB) from Mueller-Hinton agar stock plates and 
shaken (250 – 300 RPM) for 4-6 hours at 37°C. Culture turbidity was matched to a 0.5 McFarland 
Standard (1.175% w/v BaCl2·2H2O and 1% v/v H2SO4 in sterile water), which corresponds to 
1x108 colony-forming units per mL (CFU/mL). Immediately prior to antimicrobial activity assays 
(Section 2.6.2), corrected cultures were further diluted 100-fold in MHB to 1x106 CFU/mL. All 
chemicals and media were purchase from SigmaAldrich (St. Louis, MO). 
2.6.2. Scaffold Antimicrobial Activity Assay 
 The antimicrobial activity of FIBRACOL disks loaded with LL37, cCBD-LL37 or fCBD-
LL37 was assessed using an assay based on bacterial attachment and solution turbidity and 
compared to PBS only samples. The assay was adapted from a previous study [31] and is described 
in detail elsewhere [15]. Briefly, scaffolds were loaded and incubated (Section 2.2) and rinsed 
twice with MHB. Bacteria (1x106 CFU/mL) were inoculated over the scaffolds and incubated at 
37°C for 1 hour to allow attachment to the scaffolds. Then, scaffolds were rinsed twice with sterile 
MHB, transferred into fresh sterile MHB and incubated for 12 hours at 37°C. Sterility (MHB only) 
and growth (MHB plus inoculum, no scaffolds) controls, n=3 replicates each, were included in 
each assay. At 12 hours, all scaffolds were harvested immediately for processing and imaging 
(Section 2.7). The remaining solution absorbance at 590 nm was read with a Victor3 
spectrophotometer (Perkin Elmer). Three independent assays were carried out per bacterial strain 
with n=4 scaffolds per sample group. 
2.7. Processing and Imaging of Collected Scaffolds 
Immediately following collection, all scaffolds were fixed in 10% v/v formaldehyde for 1 
hour in histology cassettes, followed by storage in 70% v/v ethanol. Tissues were processed in a 
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Tissue-Tek VIP® 6AI processor (Sakura Finetek, Torrance, CA), embedded in paraffin wax and 
cut into 5 µm sections. Paraffin was cleared in xylene, rehydrated in an ethanol series from 100% 
to 70%, and then prepared for imaging. All images (Section 2.7.1 and Section 2.7.2) were taken 
with a Leica Upright Fluorescence Microscope, DMLB2 (Wetzlar, Germany) and analyzed with 
ImageJ (https://imagej.nih.gov/ij/).  
2.7.1. Immunohistochemistry (IHC) 
Rehydrated scaffolds were rinsed with water and boiled under pressure with an antigen 
retrieval solution, rinsed with PBS and blocked with 5% v/v goat serum for 30 minutes. Rabbit-
(anti)-human LL37 primary antibody, 10 µg/mL in 3% v/v goat serum (Anaspec; cat. no. AS-
55927) was incubated at 4°C for 12 hours. After a PBS rinse, secondary goat-(anti)-rabbit 
AlexaFluor®488 antibody, diluted 1:1000 in 3% v/v goat serum (LifeTechnologies, Calsbad, CA; 
cat. no. A11008) was added for 1 hour at 23°C, rinsed again and coverslipped with ProLong™ 
Gold (ThermoFisher Scientific). 
 FIBRACOL scaffolds and PURACOL scaffolds exposed to bacteria for 12 hours were also 
stained for collagen, using a primary mouse-(anti)-collagen I antibody, diluted 1:500 in 3% v/v 
goat serum (Invitrogen, Rockford, IL; cat. no. MA1-26771). After LL37 staining, scaffolds were 
rinsed and blocked with 5% v/v goat serum again. The procedure above was repeated in the dark 
to minimize photobleaching. The secondary antibody used was goat-(anti)-mouse 
AlexaFluor®568, diluted 1:750 in 3% v/v goat serum (Invitrogen; cat. no. A11004). 
 For scaffolds collected after the AlamarBlue® viability assays, cell nuclei were visualized 
using a Hoechst 33342 counterstain (LifeTechnologies), diluted 1:6000 in sterile water and 
incubated for 6 minutes, rinsed in PBS, and coverslipped. 
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2.7.2. Colorimetric Staining 
 Rehydrated scaffolds were exposed to various colorimetric stains, followed by water rinses, 
dehydration in an ethanol series from 80% to 100%, xylene clearance and coverslipping. 
 To visualize collagen, FIBRACOL and PURACOL scaffold sections were stained with 
PicroSirius red (0.25 g Direct Red 80, 0.25 g Fast Green in picric acid) for 30 min. Collagen 
portions were thus stained red. All other parts of the scaffold that were not collagen were stained 
green. This stain was performed on sections collected from the cumulative release and 
antimicrobial activity assays. 
FIBRACOL and PURACOL were also visualized colorimetrically with Toluidine blue 
metachromatic stain. Rehydrated scaffolds were stained for 4 hours with 0.5 mg/mL Toluidine 
blue in 0.01 N HCl and 0.2% (w/v) NaCl. Toluidine blue metachromatic stain, at 5 mg/mL in 0.01 
N HCl and 0.2% (w/v) NaCl. Toluidine blue is a metrachromatic stain that specifically binds acidic 
components in a tissue sample, such as nucleic acids. Toluidine blue displays metachromasia, or 
dye aggregation in the presence of different materials, which leads to different colors in tissues 
that have free electronegative groups [32]. We hypothesized that Toluidine blue would have a 
higher binding affinity for alginate polysaccharides over collagen, thus providing an estimate of 
alginate localization in FIBRACOL. 
 To visualize collagen and cytosolic content of FIBRACOL scaffolds collected after 
AlamarBlue® viability assays, sections were stained with Gills III Hematoxylin for 4.5 minutes, 
rinsed and counterstained with Eosin for 24 seconds. Collagen portions were stained pink and 
cytosolic compounds were stained purple. 
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 To visualize bacteria within the FIBRACOL and PURACOL scaffold samples, a Hucker-
Twort (HT) staining procedure was used. HT is a version of Gram staining, which utilizes crystal 
violet and oxalate primary stain, iodine mordant, acetone decolorization and a 9:3 proportion of 
1% (v/v) Neutral red and 1% v/v Fast green counterstain. Gram-negative bacteria were stained red 
and Gram-positive bacteria were stained blue [33]. HT stained sections were imaged at 100x with 
oil immersion. 
2.8. Statistical Analyses 
For AlamarBlue® viability assays, statistics were performed comparing LL37, cCBD-
LL37, and fCBD-LL37 loaded scaffolds to PBS only control scaffolds with one-way ANOVA, 
p<0.05 (post-hoc Tukey test). For ELISA assays of cumulative release studies, statistics were 
performed with one-way ANOVA comparing LL37, cCBD-LL37 and fCBD-LL37 at each time 
point and fCBD-LL37 versus PBS only raw data (post-hoc Student-Newman-Keuls (SNK) test) as 
well as between time points for individual samples with a one-way repeated measures ANOVA 
(post-hoc SNK test). Statistics of antimicrobial activity assays at 12 hours and 14 days were 
performed comparing LL37, cCBD-LL37, fCBD-LL37 and PBS only samples with one-way 
ANOVA, p<0.05 (post-hoc SNK test). Whenever FIBRACOL versus PURACOL sample data 
were compared to one another, statistics were described with a t-test, p<0.05.  
 
3. Results and Discussion 
3.1. LL37, cCBD-LL37 and fCBD-LL37 bound to highly porous FIBRACOL scaffolds 
Morphologically, FIBRACOL disks were thicker and spongier than PURACOL disks (Fig. 
1A-B). The porosity of FIBRACOL may have attributed to the higher thickness; pores in 
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FIBRACOL were much larger than those in PURACOL (Fig. 1C-D). The porosity of FIBRACOL 
was thus much greater than the reported 80% for PURACOL [34]. Since porosity is critical for 
moisture retention, swelling of the biopolymers in the scaffold and cellular retention [16, 17, 20], 
we also calculated the swelling ratio (Q) of FIBRACOL vs. PURACOL, as the ratio of fully 
hydrated scaffold mass to dry scaffold mass [35]. Q for FIBRACOL was greater than two times 
larger than PURACOL, 53.9% and 20.4%, respectively. Different processing (e.g. crosslinking 
and decelluarization methods) utilized by manufacturers as well as the presence of 10% alginate 
could attribute to the different morphological features. This was apparent in both PicroSirius 
red/Fast green (Fig. 1E-F) and Toluidine blue (Fig. 1G-H) staining, where at the same 
magnification, PURACOL fibers were much denser than FIBRACOL. Unexpectedly, some fibers 
in PURACOL were stained green (Fig 1F) and blue (Fig. 1H). FIBRACOL demonstrated some 
areas with localized density of green (Fig. 1E) and Toluidine blue (Fig. 1G), which may indicate 
areas of a different composition, possibly areas with alginate. Lower magnification SEM images 
(Fig. S1A-B) and higher magnification colorimetric images (Fig. S1C-F) demonstrated the same 
morphological characteristics. 
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Figure 1: Morphological characteristics of FIBRACOL (left) and PURACOL (right) 
scaffolds. Photos of 5 mm cut disks of FIBRACOL (A) and PURACOL (B). Scanning electron 
micrographs of dry, sterile and sputter-coated FIBRACOL (C) and PURACOL (D) taken at 10 
kV; bar = 50 µm. Representative histological images of FIBRACOL (E,G) and PURACOL (F,H) 
scaffold sections first using PicroSirius red/Fast Green staining for collagen (E-F) and second with 
Toluidine blue staining for alginate (G-H); bar = 100 µM. 
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Importantly, despite the high porosity and presence of alginate, all peptides bound to 
FIBRACOL scaffolds (Fig. 2) in a similar way that was found previously in PURACOL [15]. The 
same loading concentrations of peptide were used for both FIBRACOL and PURACOL. Since 
FIBRACOL contains only 90% collagen, the estimation assuming a 1:1 ratio of collagen 
monomers to CBDs was a slight overestimate (see calculations in S2). Future studies are required 
to optimize the loading concentration on both FIBRACOL and PURACOL scaffold disks. 
 
Figure 2: Loading of cCBD-LL37, fCBD-LL37 and unmodified LL37 onto FIBRACOL. 
Representative IHC images of FIBRACOL immediately after loading with PBS and peptides 
followed by a rinse, visualized with (anti)-LL37 and Alexa®Fluor488 (anti)-rabbit antibodies; bar 
= 100 µm. 
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A notable difference between the two scaffolds was in peptide distribution on FIBRACOL. 
Consistently observed on loaded FIBRACOL scaffolds for all peptides were areas of bright and 
dense fluorescence, suggesting areas of a high peptide density. This was not observed in 
PURACOL, suggesting that the presence of alginate may have caused this distribution. Indeed, it 
was shown previously that anionic alginate caused charge-facilitated complexation and helix-
induction of cationic AMPs, which also promoted peptide self-association and highly localized 
peptide densities [36-38]. 
3.2. LL37, cCBD-LL37 and fCBD-LL37 were not cytotoxic when bound to FIBRACOL 
AlamarBlue® signals of peptide-loaded scaffolds after 24 hours were significantly higher 
than media-only and cell-only negative controls (*p<0.001), but were not significant from the PBS 
only loaded scaffolds (Fig. 2A). This suggests that the peptides were not cytotoxic when bound to 
FIBRACOL despite being loaded at a concentration much higher that reported for LL37 (329 µM 
loading vs. 13 µM soluble toxicity [10]). Similar results of fibroblast viability were found after 
exposure to peptide-loaded scaffolds for 8 hours and 7 days (Fig. S3A-B). Qualitatively, there 
appeared to be a trend toward LL37-loaded scaffolds having the highest relative viability compared 
to PBS-, cCBD-LL37- and fCBD-LL37-loaded scaffolds at all time points. 
At 24 hours after interaction with mammalian cells, all peptides remained on the scaffold, 
still localized around pore edges (Fig. 3B). Cells were attached primarily to the outer parts of 
FIBRACOL the scaffold given the short time period, which is also consistent results found with 
PURACOL [15]. At 7 days, all peptides remained on the scaffold and importantly, cells began to 
traverse within the scaffold, particularly those loaded with fCBD-LL37 and LL37 samples (Fig. 
4; Fig. S3C, higher magnification). A common drawback of pure alginate scaffolds is the lack of 
cellular attachment; however, it has been shown that both the addition of collagen [19, 39] and 
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grafting of short adhesive peptides [40] improve cellular retention on alginate, which may also 
be the case for the levels of cell infiltration observed here. 
 
Figure 3: Cytotoxicity of LL37, cCBD-LL37 and fCBD-LL37 on FIBRACOL against human 
dermal fibroblasts. (A) The relative fluorescent units (x103) produced by AlamarBlue® reagent 
reduction, correlated to the number of viable CRL-2352 fibroblasts after 24 hours’ exposure to 
peptide-loaded scaffolds. Bars represent the mean ± S.D of n=3 replicates. Statistically significant 
difference of PBS-, LL37-, cCBD-LL37- and fCBD-LL37-loaded scaffolds versus medium-only 
and cell-only controls, *p<0.001 (post-hoc Tukey test). (B) Representative IHC images of scaffold 
sections harvested after 24 hours’ exposure of fibroblasts to PBS only, LL37, cCBD-LL37 and 
fCBD-LL37, stained with LL37 (green) and DNA (blue); bar = 100 µm.  
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Figure 4: LL37, cCBD-LL37, fCBD-LL37 and cellular localization on the scaffolds after 7 
days in culture. Representative IHC images of scaffold sections harvested after 7 days’ exposure 
of fibroblasts to PBS only, LL37, cCBD-LL37 and fCBD-LL37 scaffolds, stained with LL37 
(green) and DNA (blue); bar = 100 µm. 
 
H&E staining of the scaffolds at 24 hours and 7 days also confirmed that most of the cells 
were located within the pores of the scaffolds next to collagen rather than directly on the collagen; 
however, had begun to traverse the scaffold at later time points (Fig. S4). 
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3.3. All peptides had a short burst cumulative release profile, but were highly retained overall 
on FIBRACOL after 14 days 
Despite the possibility of improved cellular retention due to the presence of collagen and 
grafted peptides, we wondered if lower cytotoxicity of peptide-loaded scaffolds was also due to 
successful non-covalent tethering, leading to low amount of peptide surface leaching into solution. 
The cumulative release profiles for all three peptides on FIBRACOL demonstrated a short burst-
like release, represented by an initial increase in cumulative release between 1 hour and 4 hours 
that was only statistically significant for LL37 samples (#p<0.05), followed by a plateau until 14 
days (Fig. 5A). Similar to PURACOL [15], fCBD-LL37 was retained the most (98.6%) through 
14 days; however, in contrast, cCBD-LL37 exhibited significantly higher release on FIBRACOL 
than LL37 and fCBD-LL37 (*p<0.005) while LL37 released the most from PURACOL. It should 
be noted that the release of fCBD-LL37 was significantly greater than the PBS only scaffold 
control signals (p<0.001). This could indicate different levels of specificity or binding coefficients 
(KD) of each CBD-LL37 peptide on the different biopolymers. Previously, we found that LL37 
adsorbed onto collagen despite the presence of a CBD [15]. It was also found to physically adsorb 
onto and release from other biopolymer mixtures, such as collagen and hyaluronic acid 
polyelectrolyte multilayers (PEMs) [14]. Physically adsorbed LL37 at 16 µM on PEMs completely 
released by 96 hours. A possible explanation for this difference in retention could be that the 
electrostatic interaction of LL37 with hyaluronic acid would not be as dominant as with alginate, 
which has nearly double the negative charge density [36]. 
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Figure 5: Cumulative release profiles of LL37, cCBD-LL37 and fCBD-LL37 on FIBRACOL 
up to 14 days. (A) The calculated percent cumulative release for LL37 (circles), cCBD-LL37 
(triangles) and fCBD-LL37 (squares) over 14 days. Values represent mean ± S.D of three 
experimental replicates, n=4 scaffolds per treatment group. Statistically significant differences at 
each time point were found between cCBD-LL37 vs. LL37 and fCBD-LL37 release (*p<0.005) 
and between 1 and 4 hours for LL37 (#p<0.05). fCBD-LL37 cumulative release was significantly 
greater than the untreated PBS only scaffolds (p<0.001) and lower than cCBD-LL37 and LL37 
release profiles at all time points (p<0.001), all one-way repeated measures ANOVA analyzed 
with a post-hoc SNK. (B) The overall percent cumulative release from FIBRACOL (dark bars) 
and PURACOL (light bars) scaffolds at 1 hour, 24 hours and 14 days. Values represent mean ± 
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S.D of n>3 experimental replicates. Statistically significant difference of FIBRACOL vs. 
PURACOL release with a t-test, *p<0.05 and **p<0.001. 
 
FIBRACOL generally released lower amounts of peptide at 1 hour, 24 hours and 14 days 
compared to PURACOL (Fig. 5B). The retention may be due to electrostatic interactions with 
anionic alginate, since LL37, cCBD-LL37 and fCBD-LL37 are all positively charged (+6, +6 and 
+2 overall predicted at pH 7). An exception was the release of fCBD-LL37 at 14 days, 1.7% vs. 
0.91% from FIBRACOL and PURACOL, respectively (**p<0.001). This may indicate that fCBD-
LL37 had a lower affinity for FIBRACOL, suggesting a lower affinity for alginate than collagen. 
This may also be due to electrostatics, since fCBD-LL37 has the highest proportion of negatively 
charged residues among the three peptides and lowest overall charge (+2). Alternatively, KD  for 
fCBD on collagen is 5 µM [23, 41, 42], which is more than an order of magnitude weaker than 
cCBD, 0.3 µM [22]; this could be a similar trend on other biopolymers. 
An interesting observation is the release of LL37 and its correlation to the higher viability 
observed in Section 3.2. The maximum release from FIBRACOL correlates to a concentration of 
0.8 µM, which falls in the concentration range reported for “wound healing” activity, 0.2 – 1 µM 
[8, 10]. On PURACOL, the overall 26.9% release corresponds to a concentration of 2.2 µM, which 
is still not toxic but is outside of the “healing” range. 
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3.4. LL37, cCBD-LL37 and fCBD-LL37 lost broad-spectrum antimicrobial activity when 
adsorbed onto FIBRACOL scaffolds 
With a low overall percent cumulative release, we hypothesized that higher concentrations 
of peptides would be available to kill bacteria on the surface FIBRACOL. Thus, antimicrobial 
activity of scaffolds with LL37, cCBD-LL37 and fCBD-LL37 was assessed against both Gram-
positive and Gram-negative bacteria using turbidity measurements compared to the PBS only 
loaded scaffolds (Fig. 6A). Unfortunately, the only strain that demonstrated reduced growth was 
Gram-negative P. aeruginosa (*p<0.05). 
Toppazzini et al. [36] reasoned that the difference in soluble LL37 activity against Gram-
negative vs. Gram-positive bacteria in the presence of alginate was due to the higher surface charge 
density in Gram-negative membranes allowing LL37 to dissociate from alginate. We further 
postulate that for surface adsorbed LL37, the concentration and charge of particular bacterial 
lipopolysaccharides (LPS; such as endotoxin A production) or number of LPS moieties in P. 
aeruginosa [43] are also important for this. Further, S. aureus and S. epidermidis produce 
molecules that can complex with AMPs and may neutralize their activity [44, 45]. All peptides 
remained adsorbed onto FIBRACOL after the interaction with P. aeruginosa (Fig. 6B) as well as 
all other strains tested (Fig. S5), suggesting that the activity is not the result of peptide surface 
displacement but instead may be due to neutralization [46]. 
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Figure 6: The antimicrobial activity of LL37-, cCBD-LL37- and fCBD-LL37-loaded 
FIBRACOL against common wound pathogens. (A) The relative turbidity at 590 nm, read after 
12 hours’ exposure to Gram-negative E. coli and P. aeruginosa and Gram-positive S. aureus and 
S. epidermidis bacterial strains. Statistical significance is demonstrated with a one-way ANOVA: 
(*p<0.05) peptide-loaded scaffolds versus PBS only scaffolds, (#p<0.05) relative turbidity of 
Gram-negative versus Gram-positive bacteria, and (##p<0.05) relative turbidity of P. aeruginosa 
vs. E. coli, all with a post-hoc SNK test. (B) Representative IHC images of scaffold sections after 
12 hours’ exposure to P. aeruginosa, stained with anti(human)-LL37 antibody; bar = 100 µm. (C) 
A comparison of the relative turbidities after 12 hours’ exposure of each bacterial strain to peptides 
loaded on FIBRACOL vs. PURACOL. Statistical significance, analyzed with a t-test of 
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FIBRACOL vs. PURACOL (*p<0.05). All relative turbidity values (A, C) represent mean ± S.E. 
of three experimental replicates and n=4 scaffolds per sample group. 
 
E. coli, S. aureus and S. epidermidis grew significantly less on PBS only FIBRACOL vs. 
PURACOL, suggesting that the presence of alginate in FIBRACOL caused reduced growth, or at 
least, adherence to the scaffold within the first hour (Fig. 6C). This has been noted before for E. 
coli and S. aureus strains [36] as well as mammalian cells [40] on alginate. P. aeruginosa growth 
appeared unaffected by FIBRACOL. Biocompatibility may stem from the fact that alginates are 
produced as extracellular polymeric substances (EPS) to aid in biofilm formation by P. aeruginosa 
[38]. 
The only cases where the turbidity was not significantly different on FIBRACOL vs. 
PURACOL scaffolds were: fCBD-LL37 vs. E. coli, fCBD-LL37 vs. S. epidermidis, and LL37 vs. 
P. aeruginosa. Thus under these conditions, the presence of alginate did not cause significant 
inactivation of the peptides. With the exception of S. aureus, which is not susceptible to fCBD-
LL37 in soluble form anyway [15], fCBD-LL37 mechanisms are more likely inhibited by the 
adsorption on the surface alone, and not by alginate. 
We also suspected that porosity could play a role in bacterial viability on FIBRACOL, and 
that planktonic bacteria could proliferate within its large pores of FIBRACOL without reaching a 
peptide-loaded surface. To test this, both scaffold types were Gram stained using the Hucker-Twort 
protocol and imaged for bacteria localization (Fig. S6). Indeed, some images suggest that 
planktonic bacteria localize to a higher degree in the pores of FIBRACOL versus PURACOL, 
which highlights a flaw of the turbidity-based antimicrobial assay design. In this respect, 
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implementing anti-biofilm studies may be useful, considering that LL37 prevents their formation 
at low concentrations against various bacteria types and biofilm formation often increases bacterial 
resistance to antibiotics [47, 48].  
3.5. CBD-modified peptides demonstrated activity against P. aeruginosa after 14 days of 
release 
The high retention of LL37, cCBD-LL37, and fCBD-LL37 over 14 days on FIBRACOL 
(Section 3.2) demonstrated promise for their antimicrobial activity over 14 days; however, all 
peptides appeared to be inactive against all strains except P. aeruginosa (Section 3.4). Thus, only 
P. aeruginosa was used to assess longer-term antimicrobial activity after 14 days of release. We 
found that the both of the CBD peptides were still effective against P. aeruginosa after 14 days 
(Fig. 7A), but LL37 no longer demonstrated activity. IHC images demonstrated a relatively 
reduced fluorescence for all of the peptides (Fig. 7B) compared to when initially loaded (Fig. 2) 
and after only 12 hours of exposure to P. aeruginosa (Fig. 6B). The reduced fluorescence was 
more apparent in cCBD-LL37 samples, which correlates with its higher overall relative release. 
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Figure 7: The antimicrobial activity and retention of LL37, cCBD-LL37 and fCBD-LL37 on 
FIBRACOL after 14 days of release. (A) The relative turbidity at 590 nm, read after 14 days of 
release and 12 hours of exposure to P. aeruginosa. Values represent the mean ± S.E. of three 
experimental replicates and n=4 replicates per sample group. Statistical significance of cCBD- and 
fCBD-LL37-loaded versus PBS only samples is represented by *p<0.05, post-hoc SNK test. (B) 
Representative IHC images of scaffold sections after 14 days of release and 12 hours of exposure 
to P. aeruginosa, stained with anti(human)-LL37 antibody; bar = 100 µm. 
 
The activity observed of the CBD peptides after 14 days demonstrates that despite limited 
broad-spectrum action, the CBDs mediated stable activity of cCBD-LL37 and fCBD-LL37 
specifically against P. aeruginosa. The mechanism of LL37 against lipid bilayers is reported to 
involved electrostatically driven surface adsorption, followed by transmembrane pore formation 
[49, 50]. Previously, we modeled the cCBD-LL37 and fCBD-LL37 thicknesses in helix-inducing 
trifluoroethanol solvent to be 8.46 and 9.05 nm, respectively using molecular dynamics (Chapter 
5); thus, both are long enough to allow the LL37 portion to span the outer bacterial membrane, 
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reported to be 5.39 nm [51]. We observed similar results against Gram-negative E. coli after 14 
days on PURACOL, but attributed it to the release of inactive or degraded LL37 that had been 
non-specifically adsorbed onto collagen [15]. In the case of FIBRACOL, alginate has been shown 
to induce a helical conformation in LL37, causing observed complexation and subsequent 
deactivation [37, 38]. Helix induction may not be as prominent for cCBD-LL37 and fCBD-LL37 
peptides given the possible electrostatic repulsions and linking length provided by the FLAG™ 
domain [26]. Further, with growth factors, it was observed that the highest alginate entrapment 
came with proteins that had the highest relative isoelectric point, pI [52]. When estimated using 
ExPASy (https://www.expasy.org/) [53], LL37 demonstrated the highest pI, 10.61, compared to 
cCBD-LL37 (pI=9.91) and fCBD-LL37 (pI=8.83), possibly explaining its higher degree of 
inactivity. For FIBRACOL and PURACOL, CBD tethering may have increased peptide stability 
by limiting exposure to proteases [13, 25, 54-56]. 
The interaction of alginate and LL37 (or other cationic AMPs) is not only driven by 
electrostatics alone but also driven by peptide hydrophobicity [44, 57]. A threshold hydrophobicity 
(H) was identified on the Liu-Deber Hydrophobicity scale [58], above which it was shown that 
alginate interacted with AMPs by inducing AMP helicity. Maximum helical content was induced 
by alginate in Magainin II (H=-0.59), which is less hydrophobic than LL37 (H=-0.54). Further, 
alginate induced some helicity in Cecropin P1 (H=-1.11) [38]. Cecropin P1 is also less 
hydrophobic than cCBD-LL37 (-0.99) and fCBD-LL37 (-0.82), suggesting that helix induction 
would also occur in both CBD-LL37 peptides, but perhaps not to as great of an extent as in LL37. 
Both N- and C-termini of LL37 adsorbed strongly and complexed with to alginate in FIBRACOL 
driven by electrostatic and hydrophobic interactions [59], respectively, leading to the inability to 
interact with bacteria over 14 days [37].  
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3.6. LL37, cCBD-LL37 and fCBD-LL37 may have localized differently on FIBRACOL 
compared to PURACOL 
It has been proposed that alginate promotes peptide self-association, which is another 
mechanism of peptide inactivation [37]. Given the interesting patterning of fluorescence in all of 
our IHC images, we asked whether alginate in FIBRACOL was doing the same. Thus, we labeled 
both peptides and collagen on FIBRACOL to investigate distribution. The distribution of peptides 
on collagen appeared similar regardless of bacterial strain, suggesting that the presence of different 
bacterial lipids did not visibly alter peptide distribution (Fig. S7A-D). In contrast, localized areas 
of high fluorescent highly fluorescent intensity were not observed on PURACOL after interaction 
with S. epidermidis (Fig. S7E) or any other strain (Fig. S8), indicating that the presence of alginate 
promoted this particular distribution. 
We hypothesized that the areas that demonstrated a high density of fluorescence on 
FIBRACOL were due induced peptide aggregation promoted by alginate in the scaffold [37]. 
Indeed, the green areas on PicroSirius Red and the very dark regions of Toluidine blue on 
FIBRACOL appeared concentrated in small, localized areas that matched approximately in size of 
the concentrated fluorescent areas observed with IHC. In contrast, differential areas of PicroSirius 
Red and Toluidine blue on PURACOL demonstrated very different overall distributions. While 
colorimetric staining of FIBRACOL and PURACOL scaffolds is purely qualitative, it does provide 
some evidence of possible alginate localization of LL37, cCBD-LL37, fCBD-LL37 on 
FIBRACOL, and warrants further quantitative studies. 
If the hypothesis of alginate-CBD-LL37 co-localization leading to aggregation is true (as 
it is for other cationic peptides [37, 38, 44]), it is interesting to speculate the possible mechanistic 
effect it has on cCBD-LL37 and fCBD-LL37 interactions with bacteria. Recently, we investigated 
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the role of CBD structure in determining mechanistic interactions of cCBD-LL37 and fCBD-LL37 
with different model lipid bilayers (Chapter 5). The overall bilayer interactions of cCBD-LL37 
peptide were similar to LL37, which suggests that it may form transmembrane pores [50]. 
Knowing this, one might expect cCBD-LL37 to be equally inactive as LL37 on FIBRACOL due 
to induced helical content; however, we did not observe that. An explanation may be based on H 
and pI discussed in Section 3.5, but also the relative cumulative release behaviors of cCBD-LL37 
observed on FIBRACOL versus LL37 between 1 and 24 hours, corresponding to approximately 
0.56 and 0.43 µM, respectively. This release corresponds to a concentration below Gram-negative 
MICs for LL37 (0.69 – 1.67 µM) but above the MIC of cCBD-LL37 against P. aeruginosa (0.49 
µM), suggesting that soluble cCBD-LL37 released from FIBRACOL, if still active, could 
effectively kill P. aeruginosa [15]. The mechanism of fCBD-LL37 involved surface adsorption 
and possible aggregation on membranes, due to the additional aromatic residues in fCBD acting 
as bilayer “anchors” [60], and the propensity of the cysteine in fCBD to form disulfide bridges 
leading to dimerization which occurs in other cysteine-containing AMPs [61, 62]. While these 
types of interactions typically inhibit peptide activities, the observed ability of soluble fCBD-LL37 
to effectively kill bacteria [15] suggests that aggregation is a part of its antimicrobial mechanism. 
If this were the case, then the presence of alginate in FIBRACOL may instead contribute to the 
observed activity of fCBD-LL37 vs. P. aeruginosa relative to PURACOL. 
 
4. Summary and Conclusions 
 In this study, we studied the adsorption, release and bioactivities of two chimeric versions 
of the human LL37 modified with collagen binding domains on 90% collagen, 10% alginate 
FIBRACOL scaffolds. We found that, despite being loaded and retained at concentrations far 
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exceeding the reported LL37 cytotoxic threshold, all peptides adsorbed onto the biopolymers did 
not exhibit cytotoxicity. Unfortunately, adsorbed peptides were only active against Gram-negative 
P. aeruginosa; the diminished activity on scaffolds with alginate versus those of just collagen was 
attributed to both electrostatic and hydrophobic interactions of anionic alginate with the cationic 
peptides, leading to peptide helix induction, aggregation, and inactivation. After 14 days of 
cumulative release, only CBD peptides demonstrated antimicrobial activity against P. aeruginosa 
while LL37 remained adsorbed, yet inactive on FIBRACOL, demonstrating that CBD mediated 
longer term, stable antimicrobial activity on biopolymer scaffolds. 
 The results from this study are important in supporting CBD tethering of LL37 as a viable 
strategy to reduce the cytotoxicity of LL37 against mammalian cells, which is important for its 
clinical success. However, it also demonstrates the important role that particular biopolymers play 
in mediating CBD-LL37 antimicrobial activity. Interestingly, the selectivity of CBD peptides 
toward specific types of bacterial membranes may be tailored simply by the use of particular 
biopolymers. A deeper understanding of the mechanisms of biopolymer-CBD-LL37 interactions 
and may allow the development many new collagen-based dressings that are both broad- and 
narrow-spectrum for preventing the infection of chronic wounds. 
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ABSTRACT 
Amidst the antibiotic resistance crisis, antimicrobial peptides (AMPs) such as human-
derived LL37, demonstrate promise as alternative antimicrobial therapies for wound healing due 
to their broad activity and immunomodulatory functions and low likelihood of resistance. To 
deliver LL37 to chronic wounds and overcome its major clinical challenges, two chimeric versions 
of LL37 were developed with C-terminal collagen binding domains (derived from collagenase, 
cCBD-LL37 and fibronectin, fCBD-LL37), as a strategy for tethering non-cytotoxic and broadly 
active LL37 onto collagen-based, commercially available wound dressings. The addition of CBDs 
to LL37 resulted in different cytotoxicity against human fibroblasts and antimicrobial ability 
against relevant wound pathogens. cCBD-LL37 exhibited similar bioactivities as unmodified 
LL37 and increased activity against Gram-negative pathogens, while fCBD-LL37 did not 
demonstrate cytotoxicity at 20 µM, but had reduced, though more consistent, activity against 
Gram-negative and Gram-positive bacteria. In this study, we sought to determine the sequence-, 
structure-, and concentration-dependent properties underlying these differences in bioactivity. 
Molecular Dynamics (MD) simulations and circular dichroism (CD) spectroscopy predicted that 
the LL37 portion of CBD-LL37 peptides was helical while CBD domains were not. Quartz crystal 
microbalance with dissipation (QCM-D) and imaging of fluorescent bilayers revealed unique, 
concentration-dependent interactions of each peptide with different lipid compositions. For 
example, fCBD-LL37 demonstrated higher affinity toward adsorbing onto anionic bilayers, while 
cCBD-LL37 and LL37 demonstrated similar bilayer interactions. This study demonstrates that the 
combination of MD, CD and QCM-D can be powerful in understanding the structural and 
mechanistic interactions of AMPs that lead to different antimicrobial and cytotoxic bioactivities. 
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1. INTRODUCTION 
Chronic wound infection has become a serious burden to the entire healthcare system, 
costing over $25 billion dollars per year and increasing patient morbidity [1], and has substantially 
increased with the threat of antibiotic resistance [2, 3]. The human-derived antimicrobial peptide 
(AMP) LL37 demonstrates therapeutic promise for chronic wound healing due to its broad 
antimicrobial [4] and immunomodulatory activities that aid in tissue regeneration while reducing 
infection without promoting resistance [5-7]. Unfortunately, clinical implementation of LL37 has 
been hindered due its low stability in vivo [8, 9] and its interactions with zwitterionic mammalian 
lipids leading to cytotoxicity [7, 10]. 
Previous work suggested that tethering AMPs onto surfaces specifically localizes, controls, 
and maximizes the effective antimicrobial dose of AMPs [11, 12]. This inspired the design and 
creation of a novel tethering strategy for controlling infection and enhancing tissue regeneration 
in chronic wound applications, by tethering human LL37 onto collagen-based wound dressings. 
To do this, we designed two new chimeric versions of human LL37 with collagen binding domains 
(CBDs), derived from collagenase (cCBD-LL37) [13] and fibronectin (fCBD-LL37) [14], and 
studied their bioactivity (antimicrobial minimum inhibitory concentrations [MICs [15]] and 
cytotoxicity) in soluble and collagen-bound forms [16]. CBD modifications appeared to cause 
significant, concentration- and peptide-dependent changes in LL37 activities in soluble form. For 
example, fCBD-LL37 did not demonstrate cytotoxicity up to the highest concentration tested, 20 
µM, compared to cCBD-LL37 and LL37, which were both toxic between 10-13 µM [16]. fCBD-
LL37 also demonstrated consistent MICs around 10 µM while cCBD-LL37 and LL37 
demonstrated low micro-molar MICs and slightly increased activity against Gram-negative 
organisms [16]. 
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Based on these observations, we hypothesized that differences in peptide sequence 
introduced by CBDs may have contributed to changes in structure that differentially affected its 
interactions with zwitterionic mammalian and charged bacterial bilayers. Indeed, even small 
changes in structure have led to large structural changes; for example, the addition of a C-terminal 
cysteine led to peptide aggregation in the case of ovine SMAP-29 [17] and porcine Cecropin P1 
[18]. Another example is the truncation of four amino acid residues on the C-terminal of Red sea 
bream-derived Chrysophsin-1, which led to marked changes in its ability to interact with 
mammalian membranes [19]. However, the effects of adding sequences such as cCBD or fCBD 
onto AMPs are studied less commonly due to relatively high costs of peptide synthesis. Overall, 
the combination of various peptide structural characteristics – charge, helicity, hydrophobicity, 
amphiphilicity and primary sequence – are all crucial to determining specific mechanisms of 
bilayer interaction. 
In this study, we tested this hypothesis by using a combination of Molecular Dynamics 
(MD) simulations and circular dichroism (CD) spectroscopy in different solvents to determine the 
structural features of each CBD-LL37 peptide in aqueous (100% water) and non-polar (50% TFE) 
solutions. To measure the interactions between CBD-LL37 peptides and zwitterionic and bacterial 
lipid bilayers, we used quartz-crystal microbalance with dissipation (QCM-D) of LL37, cCBD-
LL37 and fCBD-LL37 interactions with model mammalian (phosphatidylcholine; PC) and 
bacterial  (4:1 molar ratio of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-
2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol); 4:1 POPC:POPG) lipid bilayers. Then, we 
acquired images of fluorescent lipid bilayers treated with varying concentrations of peptides to 
visualize the effect of peptides on the bilayer. Combining modeling and experimental techniques 
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provided a useful platform for studying the structural basis for the observed bioactivities of LL37 
as a result of CBD sequence modifications. 
 
2. MATERIALS and METHODS 
2.1. MATERIALS 
2.1.1: Peptides 
Synthetic human LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was 
purchased from Anaspec, Inc. (Fremont, CA) at >95% purity as confirmed by high purity liquid 
chromatography (HPLC). LL37 peptides modified with collagen binding domains, cCBD-LL37 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKTKKTLRT; 
collagenase-derived cCBD underlined) and fCBD-LL37 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKCQDSERTFY; 
fibronectin-derived fCBD underlined) were custom synthesized at >90% purity, confirmed by 
HPLC, by New England Peptides, Inc. (Gardner, MA). Each sequence incorporated a FLAG™ 
domain (DYKDDDDK) between the LL37 sequence and CBD, to act as an epitope tag [20] and 
as a flexible linker sequence [11, 12, 21]. Peptide stock solutions were made according to 
manufacturer recommendations, at 0.67 mM in sterile water (pH 3.5) supplemented with 5 mM 
ethylenediaminetetraacetic acid (EDTA) and stored at -20°C. 
2.1.2: Lipids 
 Egg L-α phosphatidylcholine (PC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (POPG) and 1-palmitoyl-
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2(12-((7-nitro-2-1,3-benzoxadiazol-4-yl)amino)dodecanoyl)-sn-glycero-3-phosphocholine 
(NBD-PC) were purchased from Avanti Polar Lipids (Alabaster, AL). PC, POPC and POPG were 
stored at 100 mg/mL in ethanol, chloroform and chloroform supplemented with 3% v/v methanol 
(to help solubilize PG), respectively, and NBD-PC was stored at 1 mg/mL in chloroform, all at -
20°C. 
2.1.3: Other Reagents/Materials 
Tris (10 mM tris(hydroxymethyl)aminomethane with 100 mM sodium chloride, pH 7.8), 
MOPS(-) (10 mM 3-morpholinopropane-1-sulfonic acid with 100 mM NaCl, pH 7.0) and 
MOPS(+) (10 mM 3-morpholinopropane-1-sulfonic acid with 100 mM NaCl and 1 mM CaCl2, pH 
7.0), trifluoroethanol (TFE) and all other chemicals were purchased from Sigma Aldrich (St. Louis, 
MO). 
2.2. METHODS 
2.2.1: Molecular Dynamics (MD) Simulations 
 MD simulations were carried out using force field, COMPASS [22], allowing predictions 
of structural and conformation properties for LL37, cCBD-LL37 and fCBD-LL37 using Van der 
Waals and electrostatic energies of non-bonded interactions between atoms. The linear peptide 
structures were placed in periodic boundary conditions large enough to limit peptide-peptide 
interactions, dimensions of 6x6x8, 6x6x14, and 6x6x16 nm3 for LL37, cCBD-LL37 and fCBD-
LL37, respectively. Systems were immersed in simulated conditions of either 100% water or 50% 
water plus 50% trifluoroethanol, TFE (17:3 molar ratio). TFE is a non-polar solvent commonly 
used to induce helical structures in peptides [18, 23]. 
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 First, each structure was optimized with the steepest decent algorithm. Each optimized 
structure then underwent NVT dynamics (at 300K for 100ps) followed by NPT dynamics (at 350K, 
no pressure for 200ps). Lastly, the system was relaxed using NPT dynamics (at 300K, 1atm for 
100ps). An Anneal task was then used to reach the conformation with minimum energy [24]. In 
this process, NPT dynamics (1atm) were used, temperature was increased to 400K, then brought 
down to 300K at 0.25K/ps. Temperature and pressure were controlled by Nose thermostat and 
Berendsen barostat, respectively. The outcome of the Anneal process was subject to relaxation via 
NVT dynamics (at 300K for 2ns). Peptide structures are displayed from N- to C-terminal. Finally, 
the percent helicity of each peptide was calculated at the residue level from MD-generated ribbon 
diagrams. 
2.2.2: Circular Dichroism (CD) Spectroscopy 
 CD spectra were analyzed using similar methods as previous studies[25, 26]. Spectra were 
taken from 190-240 nm for solutions of 20 µM LL37, cCBD-LL37 and fCBD-LL37 at 23°C in 
MOPS(-) buffer alone (100% water) and MOPS(-) buffer plus 50% vol/vol TFE using a Jasco J-
1500 CD spectrometer (Oklahoma City, OK) and collected with Jasco SpectraManager v.2 
software. To reduce signal-to-noise ratio, 20 scans were accumulated for each replicate (3 total 
replicates per peptide) and NaCl was omitted from the MOPS(-) buffer [27]. CD data was analyzed 
for secondary structure components using the CDSSTR empirical model [28, 29] in DICHROWEB 
[30, 31]. 
2.2.3: Construction of Helical Wheel Diagrams 
To link the degree of amphiphilicity (measured by hydrophobic moment, µH) of each 
peptide to its structural characteristics measured by MD simulations and spectroscopy (described 
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in section 2.2.2), helical wheel diagrams [32] were constructed and µH was calculated with the 
Heliquest platform (heliquest.ipmc.cnrs.fr) [33]. 
2.2.4: Vesicle and Lipid Bilayer Formation 
Supported lipid bilayers (SLBs) of PC, 4:1 POPC:POPG (molar ratio), PC plus 1% wt/vol 
NBD-PC, and 4:1 POPC:POPG plus 1% wt/vol NBD-PC were formed in the quartz-crystal 
microbalance with dissipation (QCM-D) by the spontaneous bursting of small unilamellar vesicles 
(SUVs), a process characterized in previous studies [34, 35]. All SUV compositions were prepared 
using the same freeze-thaw, sonication and centrifugation procedure described by Wang, et al. [17, 
36, 37] and stored at 4°C under N2 for up to 1 month. Fluorescent SUVs (containing 1% wt/vol 
NBD-PC) were stored at 4°C under N2 for 1 week, to minimize photobleaching). 
2.2.5: Quartz-Crystal Microbalance with Dissipation (QCM-D) 
 SLBs of the compositions described in section 2.2.4 were formed over piezoelectric SiO2-
coated quartz crystal sensors in QCM-D (Q-Sense E4, Biolin Scientific, Stockholm, Sweden), as 
described previously [37]. QCM-D is an acoustic technique that measures changes in frequency 
(Δf) and energy dissipation (ΔD) of viscoelastic films deposited along different overtones, or 
multiples of the fundamental frequency (f0 = 5MHz) of the crystal sensors. Δf is inversely related 
to changes in mass adsorption on the crystal sensor surface; decreases in Δf indicate mass 
adsorption while increases in Δf indicate mass loss. ΔD is a measure of viscoelasticity; low ΔD 
suggests a rigid film while high ΔD indicates a more flexible, viscoelastic film on the crystal 
sensors. The overtones (1st, 3rd, 5th, 7th, 9th and 11th) describe phenomena that occur along different 
penetration depths (δ) into the viscoelastic film [37]. Higher overtones suggest phenomena 
occurring closest to the sensor surface, and lower overtones suggest phenomena occurring closer 
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to the bulk solution. The 1st overtone is a measure of f0 and was recorded but not analyzed due to 
oscillation interferences [38]. 
 The flow rate through QCM-D was set to 0.15 mL/min for all experiments. Stock SUVs 
were diluted in Tris or MOPS(+) buffers for PC or POPC:POPG bilayers, respectively, to 0.1 
mg/mL and flown through the QCM-D. SLBs spontaneously formed within minutes as a result of 
the SUVs bursting at a critical coverage over the crystal sensor surface, and settled at a Δf equal 
to -25 Hz and ΔD≈0. The SLBs were rinsed with buffer for 10 min. In POPC:POPG systems, this 
rinse was followed by a buffer exchange from MOPS(+) to MOPS(-), to rinse away excess calcium 
divalent cations [39, 40]. Buffer rinses were followed by flow of 1.5 mL LL37, cCBD-LL37 or 
fCBD-LL37, diluted in buffer (Tris or MOPS(-) for PC and POPC:POPG bilayers, respectively) 
to concentrations ranging from 0.01 – 20 µM. It is important to note that concentrations from 0.25 
– 10 µM are presented in section 3; 0.01 – 0.10 µM and 20 µM are presented as Supporting 
information. A 1-hour static incubation period, allowing peptide-SLB interactions was then 
followed by a final buffer rinse (Tris or MOPS(-) for PC and POPC:POPG bilayers, respectively). 
2.2.6: QCM-D Theory and Data Analysis 
To analyze QCM-D data along different overtones, bar plots of Δf and ΔD at each overtone 
were constructed by calculating the cumulative difference between Δf or ΔD at the end of the final 
buffer rinse and at the start of peptide introduction. For each peptide, each bar represents the mean 
± standard error (S.E.) of n>4 replicates per concentration.  
In rigid systems, Δf is inversely proportional to mass according to the Sauerbrey relation 
[41]. When formed over SiO2 crystal sensors, PC and POPC:POPG lipid bilayers are rigid systems 
[37], i.e. ΔD is approximately zero and Sauerbrey relation (Eq. 1) applies. 
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∆𝑓 = −
2𝑓0
2
𝐴√𝜌q𝜇q
Δ𝑚 = −𝐶Δ𝑚         Eq. 1 
Where the Sauerbrey constant (C) represents inherent properties of the crystal sensors: f0 (5 MHz), 
A, the active crystal surface area (0.785 cm2), ρq, the density of quartz (2.648 g/cm3), and µq, the 
shear modulus of the crystal (2.947x1011 g/(cm·s)). 
 The different overtones measured for Δf and ΔD are multiples of f0, are correlated to 
various depths of the film deposited on the crystal sensors, and are useful for determining peptide-
SLB interactions [42]. These penetration depths (δ) of the acoustic wave, discussed previous by 
Wang, et al. [37], can be determined for different overtone numbers, n, using Eq. 2. 
𝛿 = (
𝜂f
𝑛𝜋𝑓0𝜌f
)
1/2
          Eq. 2 
Where ηf and ρf are the viscosity and density of the film, respectively [43]. The depth into buffer 
systems is greater than that of a PC bilayer (for example, δ of the 7th overtone is 95 nm in water 
and 9.5 nm in PC, assuming ηf = 0.01 and 1 g/(cm·s) of water and PC, respectively, and an 
equivalent density, ρf = 1 g/cm3 [37]. The δ decreases from the 3rd to 11th overtones; thus, QCM-
D responses at lower overtones are more associated with bulk phenomena, and QCM-D responses 
at higher overtones are more associated with phenomena occurring closer to the crystal sensor 
surface.  
2.2.7: Fluorescent Imaging of Supported Lipid Bilayers (SLBs) 
 NBD-PC, or PC lipids with a fluorescent (Ex/Em = 460nm/534nm) nitrobenzoxidiazole 
added to the fatty acid chain, was mixed into each SLB at 1% wt/vol to allow for imaging of the 
SLBs after interaction with the peptides. In 4:1 POPC:POPG bilayers, the 1% wt/vol NBD-PC was 
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calculated as part of the PC proportion of the lipid mixture. After a final buffer rinse, crystal 
sensors were carefully extracted from the QCM-D without exposure to air or air bubbles. Then, 
images were obtained using a Leica Upright Fluorescence Microscope, DMLB2 (Wetzlar, 
Germany). 
 
3. RESULTS 
3.1: CBD sequence significantly influenced secondary structure, hydrophobicity and 
amphiphilicity of LL37 in aqueous and hydrophobic solutions 
The addition of cCBD (TKKTLRT) [13] and fCBD (CQDSERTFY) [14] onto the C-
terminus of LL37 markedly changed its antimicrobial activity and cytotoxicity profiles, which we 
attributed to changes in secondary structure brought about by the addition of each CBD with 
unique sequences and chemistries [16]. To predict whether the altered sequences led to different 
secondary structures in aqueous or non-polar solvent solutions, Molecular Dynamics (MD) 
simulations were performed for each peptide in 100% water and 50% v/v trifluoroethanol (TFE) 
solvents (Fig. 1). The 3D structure of LL37 in pure water has been characterized [44-46]. In water, 
LL37 and cCBD-LL37 had similar structures, with predominantly random coil conformations 
(Fig. 1A-B). Exposure to helix-inducing TFE solvent caused LL37 to conform into two helical 
regions connected by a bend (110°) between I13 and K15 residues, and cCBD-LL37 to have a 
similar bend (110°) between G11 and I13. Unlike LL37, cCBD-LL37 had several other bends at 
R7, V21, V32 and T46 residues, revealing an overall “W-like” structure when the molecule was 
oriented from CN (Fig. S1A-C). fCBD-LL37 had a “V-like” random coil structure in water with 
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a bend at N30 (Fig. 1C). This structure was not retained in TFE; instead, a new bend (90°) appeared 
between K10 and K12. The overall lengths each structure was also predicted by MD (Fig. S1D). 
 
Figure 1. MD Simulations of the CBD-LL37 structure. The final conformations (NC 
orientation) of LL37 (A), cCBD-LL37 (B) and fCBD-LL37 (C) in simulated 100% water (left) or 
50% v/v TFE (right) solutions. 
  
In 50 % v/v TFE, the simulated peptides all arranged in a way that distinctly created two 
separate faces of hydrophobic (orange) and hydrophilic (blue) residues, with hydrophobic residues 
positioned on the concave face of the molecules. This predicts amphiphilicity, which allows 
peptides to interact with both hydrophilic and hydrophobic parts of lipid bilayers. To further 
characterize the predicted amphiphilic peptide structure, helical wheel diagrams (Fig. 2) were 
constructed, to model the predicted amphiphilicity of these short peptides [32, 33]. For LL37 (Fig. 
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2A), the separation of polar (blue/red) and non-polar (yellow) resides was distinct, consistent with 
MD simulations. There was also separation of polar and non-polar residues in cCBD-LL37 (Fig. 
2B), but S-K-D-T-K-D-T on the right of the diagram starting with serine, introduced by cCBD and 
FLAG™ demonstrated a higher probability of bends or breaks in the helix [47], which was 
predicted by MD as a “W-like” shape. fCBD-LL37 (Fig. 2C) also had a series of residues (shown 
on the right side of the diagram) that are introduced by fCBD and FLAG™ (T-D-S-D-D-G) with 
alternating charges as well as an adjacent pair of threonine residues that could interrupt the helix. 
In fact, both CBD peptides have threonine residues that disrupt the hydrophobic face of the 
molecule (yellow). This is reflected in the lower values of µH observed for each CBD peptide 
(0.432 and 0.378 for cCBD-LL37 and fCBD-LL37, respectively) compared to unmodified LL37 
peptide. 
The hydrophobicity profiles for each molecule were constructed using MD simulations 
(Fig. S2), and further support the predicted amphiphilic helix formation. Despite the separation of 
hydrophilic and hydrophobic amino acids along the LL37 portion of the molecule, the FLAG™, 
cCBD- and fCBD- domains always appeared neutral or hydrophilic in all models. 
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Figure 2. Predictions of Peptide Amphiphilicity. The helical wheel plots drawn using Heliquest 
[33] (http://heliquest.ipmc.cnrs.fr/), showing charged polar (blue/red), uncharged polar 
(gray/pink/purple) and non-polar (yellow, green) residues, and the overall hydrophobic moment 
(µH, arrow) of LL37 (A), cCBD-LL37 (B) and fCBD-LL37 (C). The estimated overall charge at 
neutral pH and calculated µH for each peptide are indicated below each diagram. 
 
3.2: The addition of CBD sequences altered helicity of LL37 peptides in both aqueous and 50% 
TFE solutions 
The amphiphilic secondary structures predicted by helical wheel plots and MD simulations 
were investigated experimentally with CD spectroscopy (Fig. 3A). LL37 and cCBD-LL37 
demonstrated similar spectra in water; the steepest spectral peaks were observed with cCBD-LL37. 
fCBD-LL37 spectra were flatter and demonstrated very few peaks in water. However, all peptide 
spectra nearly overlapped in TFE, indicating similar secondary structures in membrane-like 
environments. DICHROWEB modeling was then used to identify the content of specific secondary 
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structures (helix, beta strand, turn, unordered) (Fig. 3B) [30, 31]. The largest change in structure 
from water to TFE was in fCBD-LL37 peptides, consistent with MD predictions. In water, fCBD-
LL37 had near-zero helical content (-0.5±2.1%), and had a significant proportion of unordered 
structure compared to LL37 and cCBD-LL37. The helicity increased significantly to 65±1.5%, 
68±0.6% and 66±6.6% for LL37, cCBD-LL37, and fCBD-LL37 from water to TFE environments. 
The only structural percentage that was not significantly altered by TFE was the content of turns 
in fCBD-LL37. Interestingly, no significant differences were calculated between any peptide 
secondary structures in TFE. The same structural results were found at 37°C (Fig. S3). 
 
Figure 3. Experimental Secondary Structure at 23°C. Representative CD spectra (θ, mdeg versus 
wavelength, nm) at 23°C for 20 µM LL37 (triangles), cCBD-LL37 (circles) and fCBD-LL37 
(squares) in 100% water (black) and 50% v/v TFE (white) environments (A). From CD spectra, 
the content of secondary structures in the form of helices, beta strands, turns and unordered 
percentages was determined using CDSSTR modeling [28] with SMP180 reference protein set 
[48] in DICHROWEB (B). Statistical analyses were performed to compare between peptides 
within 100% water and 50% v/v TFE groups, and also between 100% water and 50% v/v TFE. All 
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comparisons demonstrated statistical significance, one-way ANOVA, p<0.05, except for (1) the 
content of unordered structure of cCBD-LL37 and LL37 in 100% water, (2) all structural content 
between peptides in 50% v/v TFE and (3) the content of turn structures in fCBD-LL37 between 
100% water and 50% v/v TFE. 
 
The change in helicity modeled in DICHROWEB correlated well with MD ribbon 
diagrams constructed in simulated 50% TFE (Fig. 4A-C). The helical content in TFE, estimated 
from the ribbon diagrams, at the residue level was found to be 59.5%, 48.1% and 45.5% for LL37, 
cCBD-LL37 and fCBD-LL37 (Fig. 4D). The LL37 portion of cCBD-LL37 and fCBD-LL37 both 
demonstrated 67.6% helicity, which was increased compared to LL37 alone (59.5%). While the 
LL37 portion of all three peptides appeared similar, the cCBD, fCBD, and FLAG™ portions of 
the modified peptides introduced a large portion of disorder. Unlike LL37 (Fig. 4A) and fCBD-
LL37 (Fig. 4C), cCBD-LL37 (Fig. 4B) demonstrated a beta turn section of its structure on it N-
terminus. Ribbon diagrams were also constructed and helicity was estimated for the peptides in 
water (Fig. S4A-D). 
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Figure 4. Helicity Predicted using MD Simulations. Ribbon diagrams for LL37 (A), cCBD-LL37 
(B) and fCBD-LL37 (C) in TFE, constructed by MD simulations, highlighting helical resides in 
red, beta turn residues in green, and random coils in gray. Using the ribbon diagrams, the 
percentages of helical residues (D) in the whole peptides and just the LL37 portion of the peptides 
were computed. 
 
3.3: CBDs influenced the bilayer interactions of LL37 in a concentration- and lipid composition-
dependent manner 
QCM-D was used to determine the influence of CBD, peptide concentration and lipid 
composition on the interactions of cCBD-LL37 and fCBD-LL37 with zwitterionic PC (mammalian 
membrane model [17]) and charged 4:1 POPC:POPG (bacterial membrane model [39, 40]) lipid 
bilayers. Concentration-dependent changes in frequency (Δf) were observed in QCM-D for all of 
the peptides (Fig. 5). LL37 interactions with PC, analyzed in depth elsewhere [49], and 4:1 
POPC:POPG were included in the study as comparative baselines for determining the effect of 
adding cCBD- and fCBD- onto LL37. The negative Δf values increased with concentration for 
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both LL37 and cCBD-LL37 at all overtones between 0.25-1.0 µM. Interestingly, cCBD-LL37 
demonstrated significantly higher negative Δf (*p<0.05) on POPC:POPG at 0.25 µM, but not at 
0.50 or 1.0 µM. Against both bilayers at 1.0 µM, LL37 and cCBD-LL37 had similar magnitudes 
of Δf; LL37 had a statistically significant bias (*p<0.05, **p<0.001) toward PC bilayers, while 
cCBD-LL37 showed a similar trend. Larger magnitudes of Δf at lower overtones for LL37, 
indicated more surface adsorption, whereas cCBD-LL37 demonstrated equal Δf values across all 
penetration depths. For both LL37 and cCBD-LL37, there appeared to be a transition from mass 
adsorption to a state where there were no changes in mass (indicated by Δf) with increasing peptide 
concentration (between 2.0-10 µM). In this range, Δf was approximately -5 Hz (~70 ng) for cCBD-
LL37 against both bilayers, and Δf was more variable for LL37. For cCBD-LL37, the adsorption 
at 10 µM was significantly higher after interaction with PC versus POPC:POPG (*p<0.05). In 
contrast, fCBD-LL37 demonstrated a different progression of Δf with concentration than the other 
peptides, demonstrating a continuous, large adsorption of mass from 1.0-10 µM that reached nearly 
-60 Hz in the case of 10 µM vs. POPC:POPG bilayers. The Δf was significantly more negative 
over POPC:POPG bilayers at 2.0-10 µM, suggesting a stronger adsorption affinity for charged 
versus zwitterionic bilayers. 
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Figure 5. Frequency Changes due to Peptide-SLB Interactions. The overall changes in Δf (Hz) for 
the 3rd through 11th overtones for concentrations of LL37, cCBD-LL37 and fCBD-LL37 from 0.25-
10 µM against PC only (black bars) and 4:1 POPC:POPG (gray bars) bilayers. Statistically 
significant differences were analyzed of the mean ± standard error values (n>4 replicates) of PC 
vs. POPC:POPG bilayers, *p<0.05 and **p<0.001, one-way ANOVA. The data for LL37 vs. PC 
only bilayers is described in more detail elsewhere [49]. 
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Changes in energy dissipation (ΔD) of the bilayers during peptide interactions 
demonstrated differences in peptide-induced viscoelasticity and disorder in the bilayer (Fig. 6). At 
0.50 µM LL37 against PC, ΔD increased only at the 7th, 9th and 11th overtones, while at 1.0 µM, 
all overtones on both bilayers reflected increased ΔD due to LL37 interactions [49]. cCBD-LL37 
caused a cumulative increase in ΔD at all overtones against both bilayer types at 0.25 – 1.0 µM. 
Between 1.0 and 2.0 µM, there appeared to be a transition in the ΔD which corresponded to the 
observed Δf calculations. After the transition, ΔD responses were nearly zero, indicating that a 
highly rigid Sauerbrey film remained after peptide interactions with both bilayer types. For fCBD-
LL37, ΔD increased with increasing peptide concentration starting at 1.0 µM. The significant bias 
toward charged bilayers that had been observed in Δf was not as prevalent in the ΔD results. 
Against PC, fCBD-LL37 demonstrated larger ΔD in lower overtones compared with higher 
overtones, while against POPC:POPG, the ΔD across the different overtones were similar. 
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Figure 6. Dissipation Changes due to Peptide-SLB Interactions. The overall changes in ΔD (1E-
06) for the 3rd through 11th overtones for concentrations of LL37, cCBD-LL37 and fCBD-LL37 
from 0.25-10 µM against PC only (black bars) and 4:1 POPC:POPG (gray bars) bilayers. 
Statistically significant differences were analyzed of the mean ± standard error values (n>4 
replicates) of PC vs. POPC:POPG bilayers, *p<0.05, one-way ANOVA. The data for LL37 vs. PC 
only bilayers is described in more detail elsewhere [49]. 
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At concentrations lower than 0.25 µM, changes in Δf and ΔD (Fig. S5A-B) appeared 
negligible for all peptides on both bilayer types. At concentrations greater than 10 µM and 
exceeding the cytotoxic threshold for LL37, the trends of small Δf and ΔD responses for LL37 and 
cCBD-LL37 as well as large negative Δf and high ΔD responses for fCBD-LL37 were observed 
(Fig. S5C). 
3.4: Fluorescent lipid bilayers demonstrated concentration-dependent, peptide-induced changes 
in bilayer organization 
Fluorescent NBD-PC lipids were incorporated into each of the bilayer types to visualize 
changes in bilayer organization and structure following interaction with different concentrations 
(0.5-10 µM) of LL37, cCBD-LL37 and fCBD-LL37. Brighter areas observed on the bilayers were 
associated with areas of a relatively higher density of NBD-PC. QCM-D Δf and ΔD profiles for 
the formation of PC and POPC:POPG bilayers with 1% NBD-PC were identical to PC and 
POPC:POPG bilayers without NBD-PC (Fig. S6A-D). 
The bilayer images were similar for LL37 and cCBD-LL37 at different concentrations 
against PC (top and middle panels, Fig. 7). At lower concentrations (0.5-1.0 µM), dense, 
irregularly shaped patches of bright fluorescence covered the entire crystal sensor, and at high 
concentrations (2.0-10 µM) the images were comparatively darker. For cCBD-LL37, the transition 
from bright to dark images was observed at 1.0 µM (though bright patches were still apparent at 
this concentration), and at 2.0 µM for LL37. The complete disappearance of the bright patches for 
both peptides occurred at 2.0 µM, which corresponded with the transition observed in ΔD and Δf 
(Fig. 5-6). For fCBD-LL37 against PC (bottom panel, Fig. 7), all images were relatively dark at 
all concentrations; however, there were bright fluorescent spots of varying sizes, surrounded by a 
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circular “halo” of darker fluorescence scattered along the sensor, which became more prevalent as 
concentration increased (≥ 2µM). 
 
Figure 7. Visualizing peptide interactions with PC bilayers. Representative fluorescent images of 
PC bilayers with 1% NBD-PC after interactions with 0.5, 1.0, 2.0, 5.0 and 10 µM concentrations 
of LL37, cCBD-LL37 and fCBD-LL37. Bar = 200 µM. 
 
Against 4:1 POPC:POPG bilayers (Fig. 8), the fluorescent images were brighter overall 
but demonstrated similar patterns as images of PC. The most prominent difference between PC 
and POPC:POPG was in LL37, where it appeared to cause unique bright fluorescent patches 
aligned in long, string-like bundles on POPC:POPG at 1.0 and 2.0 µM which were not observed 
against PC. cCBD-LL37 demonstrated large irregular areas of bright fluorescence on POPC:POPG 
at low 0.5 and 1.0 µM. As with PC, there was a transition from bright to dark images for LL37 and 
cCBD-LL37, but against POPC:POPG, the transition occurred at 5.0 and 2.0 µM, respectively. 
For fCBD-LL37, the bright spots surrounded by dark “halos” as observed on PC were observed 
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on POPC:POPG. These bright spots were still visible despite an interesting transition between 2.0 
and 5.0 µM from brighter to darker images overall. 
 
Figure 8. Visualizing peptide interactions with 4:1 POPC:POPG mixed bilayers. Representative 
fluorescent images of 4:1 POPC:POPG bilayers with 1% NBD-PC (incorporated into the PC 
proportion) after interactions with 0.5, 1.0, 2.0, 5.0 and 10 µM concentrations of LL37, cCBD-
LL37 and fCBD-LL37. Bar = 200 µM. 
 
It is worth noting that PC only control bilayers were darker compared to 4:1 POPC:POPG 
control bilayers (Fig. S7A-B) and the peptides physically adsorbed onto SiO2 sensors did not 
produce fluorescent signals (Fig. S7C-E). 
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4. DISCUSSION 
4.1: Influence of cCBD and fCBD sequence and structure on LL37 bioactivities 
The bioactivities of AMPs are highly mediated by structural characteristics, which for 
LL37 were altered by the addition of cCBD or fCBD domain sequences. LL37 has a high 
amphiphilicity (µH = 0.521) and >50% helical structure demonstrated here by MD, CD, and helical 
wheel diagrams. Because of these properties, transmembrane pore formation has been commonly 
suggested as a route of its cytotoxicity and antimicrobial action [47]. Its insertion into the 
hydrophobic core of bilayers is driven by its disordered C-terminus [50]. Thus, by conjugating 
cCBD and fCBD domains onto the C-terminus, an intentional design strategy to add useful 
collagen-binding functionality, we may have also altered the structure and function of the toxic 
portion of LL37. However, here and previously [16] we observed that cCBD-LL37 demonstrated 
similar cytotoxic and antimicrobial activities at similar concentrations as LL37, whereas fCBD-
LL37 demonstrated significantly lower cytotoxicity compared to LL37 and cCBD-LL37. 
The similar bioactivities of cCBD-LL37 and LL37 were consistent with the similar 
structures between the two peptides. Further, cCBD added additional charge and disorder at the C-
terminus. This disorder could explain why we observed that cCBD-LL37 was slightly more 
cytotoxic to fibroblasts than LL37, as well as more antimicrobial against certain bacteria [16]. The 
bends introduced into the peptide structure by adding the cCBD sequence could play a role in 
membrane insertion, as has been demonstrated by the bend in LL37 [50, 51]. Two lysine residues 
in cCBD could play a role in reducing peptide-peptide interactions [52, 53] but also in the induction 
of membrane curvature upon adsorption, both leading to favorable peptide-bilayer interactions and 
cytotoxicity [45, 54].   
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Interestingly, no differences in structure (e.g. helicity) were calculated between any of the 
peptide secondary structures in TFE, yet three major differences were observed in fCBD-LL37 
bioactivities that have been attributed to its structure: attenuated cytotoxicity, lower antimicrobial 
activity, and similar activities against both Gram-negative and Gram-positive bacteria types. We 
attribute these characteristics to three structural features of the fCBD sequence. First, the flat 
structure and negative charges in both FLAG™ and fCBD render it unlikely that fCBD-LL37 
would insert into membranes and stably interact with polar head groups on both the surface and 
within the bilayer (required for toroidal pore formation [55]), particularly anionic membranes. 
Second, the cysteine in the fCBD sequence may be involved in promoting peptide-peptide rather 
than peptide-lipid interactions [17, 18]. Third, the aromatic phenylalanine and tyrosine residues in 
fCBD may be involved in membrane anchoring [47, 56]. This anchoring at the C-terminus may 
allow for the LL37 portion of the molecule to exert antimicrobial effects via alternative 
mechanisms, such as intracellular targeting [57, 58], membrane destabilization via positive cations 
[21, 59], or multiple simultaneous mechanisms [60, 61]. However, elucidating these specific 
mechanisms would require further testing with different model lipids and modified peptide 
sequences. 
4.2: Influence of electrostatics and membrane composition on LL37 bioactivities 
Adding cCBD onto LL37 did not change the overall charge of +6, indicating that both 
peptides should have an electrostatic affinity for anionic lipids prevalent in bacterial membranes 
[47]. However, neither LL37 nor cCBD-LL37 had consistent affinities for anionic lipid 
compositions over PC only. Previous studies on LL37 bilayer affinity concluded that the content 
of anionic lipid did not influence LL37 binding [62]; rather, the degree of lipid saturation was more 
important. PC, POPC, and POPG are all monounsaturated; thus, this finding is consistent what we 
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observed. For example, Shahmiri et al. observed long (>200 µM), tortuous, “tube-like” super 
structures in liposomes after interactions with 10 µM LL37, but only after 3 hours on saturated 
lipids (1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or DMPC with 1,2-dimyristoyl-sn-
glycero-3-phospho-(1’-rac-glycerol) (DMPG), but not on polyunsaturated lipids composed of 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC). It was suspected that tubular super structures were 
formed by slow lipid aggregation processes [62]. We observed similar structures on 
monounsaturated POPC:POPG after interactions with 1.0 and 2.0 µM LL37 (Fig. 8); thus, the 
kinetics of formation of these structures may depend on the amount of lipid saturation. We did not 
observe tubular structures caused by either cCBD-LL37 or fCBD-LL37, which may indicate that 
formation of such structures is propagated at the C-terminus of LL37, and is thus inhibited by 
CBDs conjugated on the C-terminus. 
Peptide surface adsorption to lipid bilayers is thought to be driven primarily by electrostatic 
interactions and salt-bridging [45, 62]. At low concentrations (from 0.25 to 1.0 µM) for all 
peptides, the increase in ΔD (Fig. 6) may indicate increased membrane fluidity, lipid area and 
disorder [63] induced by electrostatically-driven adsorption of peptides. Further, the influence of 
electrostatics was found to be enhanced in peptides with lower amphiphilicity, or µH [64]. This is 
illustrated in the case of fCBD-LL37, which had a lower µH than LL37 and cCBD-LL37, yet had 
considerably higher binding affinity POPC:POPG. This suggests that even though fCBD-LL37 
had lower overall charge of +2, the influence of electrostatic interactions were enhanced in the 
absence in cases where amphiphilicity was relatively low.  
4.3: Influence of concentration on LL37, cCBD-LL37 and fCBD-LL37 bioactivities 
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The in vitro bioactivities of LL37 are highly dependent on concentration [65]. The data 
presented here supports this for LL37 and both CBD-LL37 peptides, by demonstrating 
concentration-dependent changes in Δf and ΔD for each of the peptides against two different lipid 
bilayer compositions. In the case of LL37 and cCBD-LL37, adsorption of the peptides on the 
different bilayers at low concentrations (0.5-1.0 µM) demonstrated some affinity for both types of 
bilayers. In this concentration range, LL37 interacts with zwitterionic mammalian cells and 
exhibits immunomodulatory activity [7, 65]. The interaction appears to be primarily electrostatic 
adsorption [66]. The transition that occurred in Δf and ΔD between 1.0 and 2.0 µM for LL37 and 
cCBD-LL37 occurred at a concentration where both were found to effectively kill a broad 
spectrum of bacteria but not human fibroblasts [16], suggesting that mechanistic phenomena 
occurring at this transition results in antimicrobial activity but not cytotoxicity. For fCBD-LL37, 
concentrations as high as 20 µM did not demonstrate cytotoxicity but was able to kill bacteria [16]. 
In this study, QCM-D results up to this concentration demonstrated fCBD-LL37 adsorption with 
concentration, which implies that while surface adsorption is not cytotoxic to mammalian cells, it 
demonstrates toxicity to bacteria. Further studies are required to elucidate the mechanistic reason 
for this. 
4.4: Mechanistic predictions of peptide-lipid interactions for cCBD-LL37 and fCBD-LL37 
The structural characteristics of LL37, specifically cationic charge and amphiphilicity, 
drive electrostatic and physical interactions with negatively charged bacterial membranes that 
result in a low likelihood of bacteria developing resistance [67, 68]. However, the specific 
mechanisms of LL37-lipid bilayer interactions are still under investigation [47, 62]. Both the carpet 
and the toroidal pore mechanistic models have been suggested for LL37. In the carpet model, LL37 
peptides adsorb onto bilayers in a parallel orientation until a critical concentration whereby they 
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cause massive bilayer disruption in a “detergent-like” manner, lifting off large peptide-lipid 
micelles from the bilayer surface [60, 69]. A non-pore version of this mechanism has also been 
proposed, involving transient peptide insertion [45]. In the toroidal pore model, peptides adsorb 
onto the bilayer and intercalate within the polar head groups, causing increased bilayer disorder, 
positive membrane curvature, bilayer leakage and transient pores that eventually lead to the 
formation of full transmembrane pores [70, 71]. The pores are thought to be toroidal in shape, 
since transmembrane peptide helices interact with lipid head groups on both inner and outer parts 
of the bilayer. 
It is difficult to predict exact mechanisms of peptide-lipid bilayer interactions based on 
QCM-D results alone; however, general membrane behaviors can be speculated to direct future, 
more in-depth mechanistic studies. According to Wang et al., expected QCM-D responses 
associated with transmembrane pore formation would involve (1) mass loss of lipids geometrically 
excluded from the sensor crystal due to intercalation of peptide clusters and formation of water-
filled pores, and (2) similar Δf and ΔD values at all overtones due to similar phenomena occurring 
at all detectable penetration depths of the bilayer [17]. Further, pore formation occurs at a threshold 
concentration [55]. Some overall mass loss was observed for LL37 at high concentrations [49], 
but was not observed for cCBD-LL37 or fCBD-LL37. However for cCBD-LL37 compared to 
unmodified LL37, the similar bioactive concentrations, similar ΔD and Δf trends with 
concentration including a threshold concentration between 1.0 and 2.0 µM, and magnitudes of 
individual overtones after the threshold leads us to believe that both peptides may form 
transmembrane pores. No signs of membrane disruption were observed for fCBD-LL37 despite its 
ability to kill bacteria. Thus, we propose an alternative mechanism for fCBD-LL37 interaction 
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with lipid bilayers, which may require primarily surface adsorption such as the carpet mechanism, 
or by an entirely different route, such as intracellular targeting [56, 72]. 
 
5. CONCLUSION 
 In this study, we modified LL37 with two different CBDs on its C-terminus, one from 
collagenase (cCBD-LL37) and one from fibronectin (fCBD-LL37), and studied how adding these 
sequences altered LL37 structure and mechanistic properties leading to changes in bioactivities 
previously observed. The different CBD structures were found to alter LL37 structure and lipid 
bilayer interactions in a structure-, concentration- and lipid composition-dependent manner. This 
study emphasizes the importance of understanding how alterations in antimicrobial peptide 
primary structure can lead to vastly different membrane interactions. The combination of MD 
simulations, CD spectroscopy, QCM-D and fluorescent microscopy proved useful in predicting 
the structural bases behind different membrane interactions leading to different mechanisms of 
peptide antimicrobial activity and cytotoxicity. With this new understanding of chimeric CBDs, 
new CBD peptides can be designed that will both maximize antimicrobial activity and minimize 
cytotoxicity, to enable application of AMPs for infected wound treatment, and other clinical 
applications. 
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Abstract 
The human antimicrobial peptide LL37 is promising as an alternative to antibiotics due to 
its biophysical interactions with charged bacterial lipids. However, its clinical potential is limited 
due to its interactions with zwitterionic mammalian lipids leading to cytotoxicity. Mechanistic 
insight into the LL37 interactions with mammalian lipids may enable rational design of less toxic 
LL37-based therapeutics. To this end, we studied concentration- and time-dependent interactions 
of LL37 with zwitterionic model phosphatidylcholine (PC) bilayers with quartz crystal 
microbalance with dissipation (QCM-D). LL37 mass adsorption and PC bilayer viscoelasticity 
changes were monitored by measuring changes in frequency (Δf) and dissipation (ΔD), 
respectively. The Voigt-Kelvin viscoelastic model was applied to Δf and ΔD to study changes in 
bilayer thickness and density with LL37 concentration. At low concentrations (0.10 – 1.00 µM), 
LL37 adsorbed onto bilayers in a concentration-dependent manner. Further analyses of Δf, ΔD and 
thickness revealed that peptide saturation on the bilayers was a threshold for interactions observed 
above 2.00 µM, interactions that were rapid, multi-step, and reached equilibrium in a 
concentration- and time-dependent manner. Based on these data, we proposed a model of stable 
transmembrane pore formation at 2.00 – 10.0 µM, or transition from a primarily lipid to a primarily 
protein film with a transmembrane pore formation intermediate state at concentrations of LL37 
>10 µM. The concentration-dependent interactions between LL37 and PC bilayers correlated with 
the observed concentration-dependent biological activities of LL37 (antimicrobial, 
immunomodulatory and non-cytotoxic at 0.1-1.0 µM, hemolytic and some cytotoxicity at 2.0-13 
µM and cytotoxic at >13 µM). 
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Highlights 
 LL37 interactions with bilayers were both concentration- and time-dependent 
 At low concentrations, LL37 adsorbed to the bilayer surface 
 Pore formation was either a stable or intermediate state depending on concentration 
 LL37 saturation on the bilayer was critical for transition into a proteolipid film 
 
  
183 
 
Keywords 
Antimicrobial peptide, Cathelicidin LL37, Peptide-bilayer interactions, Quartz crystal 
microbalance with dissipation, Voigt-Kelvin Model 
 
1. Introduction 
Overcoming antimicrobial resistance presents a grand challenge in the healthcare industry, 
and requires the development of antibiotic alternatives [1]. Among current alternatives, 
antimicrobial peptides (AMPs) show significant therapeutic promise [2]. AMPs are short (10-50), 
cationic (+2 to +9), amphiphilic, and broad-spectrum antimicrobial proteins that are a part of the 
innate immune systems of many species [3], including humans [4]. Their diverse structures 
promote biophysical membrane interactions that are difficult for bacteria to develop resistance 
against [5]. 
LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) is the only human-
derived cathelicidin (a class of mammalian AMPs [6]), and is of clinical interest because of its 
broad antimicrobial activity [7, 8] and immunomodulatory properties [9-11]. These functions have 
been observed at different concentration ranges (Fig. S1): 
 Immunomodulatory, 0.05 – 1.0 µM [9], 
 Antimicrobial, 0.50 – 10 µM [7], 
 Hemolytic and cytotoxic, 2.50 – 13 µM [12], and 
 Cytotoxic threshold, >13 µM [13]. 
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Unfortunately, LL37 is not as selective as other cathelicidins toward charged bacterial membranes 
over neutral (or zwitterionic) mammalian membranes [14, 15]. Thus, improvement of its 
therapeutic ratio, defined as the ratio of antimicrobial concentration to cytotoxic concentration, is 
required for LL37 to achieve clinical utility. This will be enabled by an improved understanding 
of LL37 interaction mechanisms with zwitterionic lipids at different concentrations within its 
bioactive concentration range. 
At low concentrations, LL37 interacts with zwitterionic membranes via electrostatic 
interactions facilitated by its charge (+6 at neutral pH [15]) and amphiphilicity (demonstrated by 
the separation of its polar and non-polar residues in the peptide helix, Fig. S1). However, the exact 
mechanism of LL37-lipid interactions at hemolytic and cytotoxic concentrations are still debated. 
Proposed mechanisms include the carpet (“detergent-like” [14] and non-pore forming [16]) and 
toroidal pore [17, 18] models. In the detergent-like carpet model, LL37 adsorbs to the bilayer 
surface, followed by insertion at a critical concentration [14]. At high concentrations, massive 
bilayer disruption occurs by the formation of peptide-lipid micellular aggregates that lift off the 
surface [19]. Sevcsik et al. suggested that disk-like micelles, 270 Å in diameter, formed after 
exposure to 4 mol % LL37 under certain experimental conditions, such as bilayers composed of 
lipids with shorter acyl chain lengths [20, 21]. Porcelli et al. later suggested an alternative model 
due to the lack of evidence of peptide-lipid aggregates [16]. They proposed a non-pore carpet 
mechanism using nuclear magnetic resonance (NMR), in which concentration-dependent 
adsorption of LL37 in a parallel orientation occurred accumulatively, eventually causing a rigid 
transition of the bilayer into cubic phase prior to its full disruption [16, 22, 23]. Later studies using 
higher resolution NMR observed bilayer leakage, increased disorder, and induced positive 
curvature strain, and thus suggested that LL37 forms transmembrane pores [24, 25]. The toroidal 
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pore model has been proposed for LL37 [26, 27], a specific model of transmembrane pore 
formation defined by increased bilayer disorder, leakage, and importantly, membrane thinning, 
leading to a critical concentration where toroid-shaped pores are formed [28]. 
Both the carpet and toroidal pore models are concentration-dependent, and include aspects 
that are time-dependent, such as removal of disk-like aggregates or formation of unstable transient 
pores over time; however, it is difficult to measure these properties in a cohesive, non-destructive 
way using a single technique. Recently, Shahmiri et al. demonstrated the usefulness of quartz 
crystal microbalance with dissipation (QCM-D) in studying the real-time interactions of LL37 (at 
concentrations of 1.00 – 20.0 µM) with different lipid compositions [29]. In the current study, we 
further elucidated the real-time interactions of LL37 with zwitterionic phosphatidylcholine (PC) 
lipid bilayers by exploring a wider range of LL37 concentrations representative of its different 
functions, and implemented viscoelastic modeling of system properties with the overall goal of 
understanding the mechanisms directing the various functions of LL37. This study contributes to 
a better understanding of the concentration-dependent interaction of LL37 with zwitterionic lipids 
as models for mammalian membranes. Results from this study will allow a clearer understanding 
of LL37 cytotoxicity and new insight into creating clinically relevant LL37 peptides as 
antimicrobial alternatives that will aid in solving the grand challenge of antibiotic resistance. 
 
2. Materials and Methods 
2.1. Materials 
Cathelicidin LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) (Anaspec, 
Fremont, CA) was synthesized at >95% purity, as confirmed by high-performance liquid 
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chromatography, and stored according to manufacturer recommendations at -20°C. Egg L-α 
phosphatidylcholine (PC) lipids were purchased from Avanti Polar Lipids (Alabaster, AL) and 
were stored at 100 mg/mL in ethanol at -20°C. Experiments were performed in filter-sterilized Tris 
buffer (100 mM sodium chloride and 10 mM tris(hydroxymethyl)aminomethane), corrected to pH 
7.8. All other chemicals were purchased from Sigma Aldrich (St. Louis, MO).  
2.2. Methods 
2.2.1. PC vesicle preparation 
Stock solutions (2.5 mg/mL) of small unilamellar vesicles of PC were prepared in batches 
as described elsewhere [30], and stored under N2 at 4°C. PC vesicles were stable for up to 1 month. 
2.2.2. LL37-PC bilayer interactions monitored using QCM-D 
Supported lipid bilayers (SLBs) were formed over piezoelectric SiO2-coated quartz crystal 
sensors in QCM-D (Q-Sense E4, Biolin Scientific, Stockholm, Sweden), as described previously 
[30-32]. QCM-D is a real-time, acoustic method that measures changes in frequency (Δf) and 
energy dissipation (ΔD) of viscoelastic films deposited on the crystal sensors, along different 
overtones (multiples of the fundamental frequency, f0 = 5MHz). The Δf represents changes in mass 
on the sensor surface; mass adsorption and mass loss are reflected by negative Δf and positive Δf, 
respectively. The ΔD is a measure of film viscoelasticity; higher ΔD represents more flexible and 
viscoelastic films while lower ΔD represents more rigid films. The overtones (1st, 3rd, 5th, 7th, 9th 
and 11th) indicate phenomena occurring at different penetration depths into the viscoelastic film 
[30, 33]; high overtones suggest phenomena occurring closer to the sensor surface while lower 
overtones indicate phenomena occurring closer to the bulk solution. 
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All QCM-D experiments were performed as described previously [30-32], with a flow rate 
of 0.15 mL/min. Vesicles were diluted to 0.1 mg/mL in Tris and flown through QCM-D. SLBs 
spontaneously formed within minutes due to the bursting of the vesicles after reaching a critical 
coverage over the sensor surface, achieving a consistent equilibrium Δf = -25 Hz and ΔD≈0. This 
process has been well-characterized [34-36]. The SLBs were rinsed with Tris for 10 min, exposed 
to 1.5 mL LL37 (concentrations from 0.01 – 15.0 µM in Tris), incubated for 1 hour in a static 
condition to allow LL37-bilayer interactions, and rinsed with Tris again. A total of n>4 replicates 
were collected for all experimental conditions. 
Two variations in this experiment were studied. First, in order to differentiate Δf and ΔD 
responses specifically due to peptide-bilayer interactions, we compared the Δf and ΔD profiles of 
LL37 peptides physically adsorbed directly onto SiO2 crystal sensors. In these experiments, 1.5 
mL of LL37 (concentrations from 0.10 – 10.0 µM in Tris) were directly adsorbed onto SiO2, 
followed by the 1-hour static incubation and final Tris rinse as described above. 
In the second type of experiment, we were interested in determining the composition of the 
peptide-bilayer film after finding unique LL37-bilayer interactions at high LL37 concentrations 
(e.g. whether it was removed or still remained on the crystal sensor). To do this, we utilized 0.1% 
(w/v) sodium dodecyl sulfate (SDS), which completely removes lipid bilayers from QCM-D 
crystal sensors [37]. In these experiments, SLBs were formed, exposed to 10.0 µM LL37 and 
incubated for 1 hour. Then, the film was exposed to 1.5 mL SDS, and the resulting Δf and ΔD 
responses to SDS were compared with those of pure PC bilayers, pure films of physically adsorbed 
LL37 (10.0 µM), and bare SiO2 crystal sensors. 
2.2.3. Modeling viscoelastic film properties in QCM-D 
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2.2.3(1) QCM-D theory 
The viscoelastic properties of the deposited film (reflected by ΔD) influence the type of 
analyses that can be performed on QCM-D data. In the case of rigid systems, where ΔD≈0 and the 
different overtones nearly overlap, then Δf is inversely proportional to mass adsorption and the 
Sauerbrey constant (C), according to the Sauerbrey equation [38] (Eq. 1). The formation of PC 
bilayers falls within this applicable range [30, 35]; thus, the equilibrium Δf for a bilayer, -25 Hz, 
corresponds to approximately 445 ng/cm2 [31]. 
∆𝑓 = −
2𝑓0
2
𝐴√𝜌q𝜇q
Δ𝑚 = −𝐶Δ𝑚         Eq. 1 
Where C encompasses crystal sensor properties: f0 (5 MHz), A, the crystal sensor surface area 
(0.785 cm2), ρq, the density of quartz (2.648 g/cm3), and µq, the shear modulus of the crystal 
(2.947x1011 g/(cm·s)). 
The measured overtones are related to the penetration depth (δ) of the acoustic wave and 
film properties by Eq. 2, described in more detail for films comprised of PC bilayers compared 
with water by Wang et al. [30]. The δ increases from the 3rd to the 11th overtones; thus, lower 
overtones are more associated with bulk phenomena while higher overtones are more associated 
with sensor surface phenomena, the degree to which is dependent on film properties. For example, 
the higher the film viscosity (ηf), the lower the penetration depth. 
𝛿 = (
𝜂f
𝑛𝜋𝑓0𝜌f
)
1/2
          Eq. 2 
Where n is overtone number, and ηf and ρf are the viscosity and density of the film, respectively 
[39]. 
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 When the ΔD is not equal to zero (>5% of the Δf value at a given time point), other models 
must be utilized to study film properties that account for increased viscoelasticity. In this case, ΔD 
is described by Eq. 3. 
Δ𝐷 =  
𝐺′′
2𝜋𝐺′
           Eq. 3 
Where G’ is the storage modulus and G’’ is the loss modulus of the film. A commonly utilized 
model is the Voigt-Kelvin model [40], which considers the contribution of the viscoelastic 
properties of a film immersed in a Newtonian liquid using a continuum mechanics approach to 
calculate Δf (Eq. 4) and ΔD (Eq. 5), and is derived elsewhere [39]. The Voigt-Kelvin model has 
been used in previous studies to model viscoelastic changes in bilayer and vesicular systems [40, 
41].  
∆𝑓 ≈ −
1
2𝜋𝜌qℎq
{
𝜂l
𝛿l
+ ∑ [ℎ𝑗𝜌𝑗𝜔 − 2ℎ𝑗 (
𝜂𝑙
𝛿𝑙
)
2 𝜂𝑗𝜔
2
𝜇𝑗
2+𝜔2𝜂𝑗
2]𝑗=1,2   }     Eq. 4 
∆𝐷 ≈
1
2𝜋𝑓0𝜌qℎq
{
𝜂l
𝛿l
+ ∑ [2ℎ𝑗 (
𝜂𝑙
𝛿𝑙
)
2 𝜇𝑗𝜔
𝜇𝑗
2+𝜔2𝜂𝑗
2]𝑗=1,2   }      Eq. 5 
Where ηl, δl and ρl are the viscosity, penetration depth and density of the bulk liquid; hj, µj and ηj 
denote thickness, elastic shear modulus, and shear viscosity of viscoelastic overlayer films up to 
j=2 layers while hq is the thickness of the quartz crystal. Note that terms including film properties 
involve both real (storage modulus) and imaginary (loss modulus) parts of complex shear modulus 
[39]. In the case of a Sauerbrey film, then ΔD (Eq. 5) is approximately 0, and Eq. 4 reduces to Eq. 
1. 
2.2.3(2). Implementing the Voigt-Kelvin Viscoelastic Extended Model 
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The Voigt-Kelvin Viscoelastic Extended Model was applied to the raw Δf and ΔD data 
using Q-Tools software (Biolin Scientific) to estimate the film thickness and density [42]. 
According to physical constraints: reported PC bilayer thickness, ~5-7 nm [41], PC bilayer density, 
1060 kg/m3 [43], and LL37 peptide dimensions (Fig. S1) [15, 20, 27], the model step sizes and 
output ranges were chosen and iterated until the lowest chi-square (χ2) value was achieved. For 
improved accuracy of the model, all overtones were modeled simultaneously (excluding the 1st 
[33]).  
 
3. Results & Discussion 
3.1. Real-time QCM-D profiles of Δf and ΔD for LL37 are concentration-dependent, and exhibit 
a transition between 1.00 and 2.00 µM 
Δf and ΔD demonstrated characteristic changes with respect to LL37 concentration. The 
profiles were grouped at “low” (0.10 – 1.00 µM) and “high” (2.00 – 15.0 µM) concentrations in 
consideration of the biological activities of LL37. LL37 demonstrates both antimicrobial and 
immunomodulatory functions in the “low” concentration range [7, 9] and becomes hemolytic and 
cytotoxic in the high range [12, 13]. Thus, the concentration-based separation of the profiles 
observed in Fig. 1 may be linked to biological activity. At low concentrations (0.10 – 1.00 µM), 
Δf decreased and ΔD increased with concentration, consistent with adsorption of a viscoelastic 
film on the surface of PC (Fig. 1A). However, at “high” concentrations (2.00 – 15.0 µM), the 
profiles demonstrated a relatively rapid decrease in Δf and increase in ΔD until a threshold, upon 
which the reverse occured, and Δf and ΔD returned to the starting values (Fig. 1B). Full 
representative profiles for all overtones and including the final Tris rinses, are in Fig. S2. 
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Figure 1: Representative QCM-D Δf and ΔD profiles with time at different concentrations. 
Representative Δf (left) and ΔD (right) versus time profiles after the introduction of LL37 to PC 
lipid bilayers (at time 0) for A, low LL37 concentrations (0.10 – 1.00 µM) and B, high LL37 
concentrations (2.00 – 15.0 µM). C, Representative Δf (left) and ΔD (right) versus time profiles 
of LL37 (0.10 – 10.0 µM) physically adsorbed onto SiO2 crystal sensors. The 3rd overtone is 
shown, and is normalized to the equilibrated bilayer Δf and ΔD after rinsing.  
 
LL37 was also physically adsorbed directly onto SiO2 crystal sensors (with no lipid bilayer) 
spanning this concentration range (Fig. 1C; equilibrium values of Δf, ΔD and mass with LL37 
concentration, Fig. S3A-C). Comparing the behavior of physically adsorbed peptides with bilayer-
adsorbed peptides is helpful toward differentiating profiles that result specifically due to peptide-
bilayer interactions. Physical adsorption onto SiO2 caused an irreversible increase in mass with 
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concentration (negative Δf) and the deposited protein film was very rigid (ΔD≈0). Thus, the 
observed increases in ΔD over PC bilayers occurred due to the presence of PC. In previous QCM-
D study, lipid bilayers were found to promote self-association of adsorbed cationic peptides which 
caused ΔD to increase [44]. 
3.2. The LL37-PC bilayer interaction is concentration-dependent between 0.10 – 1.00 µM, 
illustrated by overall changes in Δf, ΔD, thickness, and density 
At each overtone the overall measurements of Δf and ΔD were calculated, following a 
previously published protocol [30-32]. The overall changes in Δf and ΔD at each overtone after 
LL37 introduction, static incubation and the final buffer rinse are shown for low (Fig. 2A) and 
high (Fig. 2B) peptide concentrations. At low concentrations, LL37 adsorbed to PC (negative Δf) 
with magnitudes that increased with concentration (Fig 2A). At 0.50 and 1.00 µM, Δf was 
significantly larger at the 3rd vs. the 9th and 11th overtones, suggesting that adsorption occurred 
closest to the bilayer surface. Adsorption of LL37 onto bilayers is required for many of its 
immunomodulatory functions at lower concentrations [8]. 
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Figure 2: Δf and ΔD overtone analysis. Overtone versus overall changes in Δf (blue) and ΔD 
(red) for A, low concentrations (0.10 – 1.00 µM) and B, high concentrations (2.00 – 15.0 µM). All 
values represent means ± S.E of n>4 replicates. *p<0.05 between the means Δf or ΔD overtones 
within each concentration; °p<0.001 between 1.0 µM sample means versus all other 
concentrations, using post-hoc Student-Neuman-Keuls (SNK) analysis.  
 
In contrast, Δf and ΔD were nearly zero for interactions of PC with high LL37 
concentrations indicating a highly rigid film (Fig. 2B). At all concentrations between 5.00 – 15.0 
µM, there was an overall loss of mass. All overtones demonstrated similar Δf and ΔD values, 
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indicating that the same type of interaction occurred throughout the penetration depth of the film. 
An overall low ΔD as a result of LL37 interactions has been observed before in both saturated and 
unsaturated bilayer systems, and was attributed to the adsorption of pre-assembled LL37 
aggregates [29]. Indeed, studies have demonstrated LL37 aggregates at concentrations as low as 
0.50 µM [45] and above [17, 46]; however, we did not observe an overall addition of mass that 
would accompany such aggregates. Another possibility at high concentrations is the formation of 
transmembrane pores, which has been observed for LL37 using other techniques [15, 24, 25] and 
is consistent with our observed overtone responses [30, 32]. We suspected that the former situation 
would cause increased film thicknesses, while the latter would not cause appreciable thickness 
changes.  
 Therefore, the overall changes in film thickness and density after interactions with LL37 
were modeled using the Voigt-Kelvin Viscoelastic Extended Model (Fig. 3). First, the PC bilayer 
alone (no peptide) was modeled; the resulting thickness and density were similar of those reported 
for PC [41, 43]. Thickness (6.84 ± 0.1 nm) was slightly higher than prior estimates (4-6 nm), due 
to the presence of a water layer existing between the PC bilayer and the SiO2 sensor surface, 
reported to be ≈10-16 Å [41, 47]. We observed a linear decrease in thickness from 0.05 to 0.25 
µM, followed by a linear increase from 0.25 to 1.00 µM (Fig. 3A). According to the toroidal pore 
mechanistic model, linear membrane thinning precludes the formation of pores [25, 27, 48]. The 
observed increased thickness (up to +4.06 nm at 1.00 µM) correlated with the observed decreased 
Δf and increased ΔD, indicating a surface layer of adsorbed LL37. Since this observed maximum 
thickness at 1.00 µM exceeded a single LL37 helix diameter (1.6 nm) and the thickness of 
physically adsorbed LL37 at 1.00 µM (~1.0 nm, Fig. S3D), LL37 may have a different orientation 
when adsorbed to PC bilayers than SiO2 rather than flat adsorption parallel to the bilayer surface. 
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With high concentration, thickness remains near SLB thickness. Interestingly, thickness was lower 
at 15.0 µM, which is past the cytotoxic threshold of LL37 (13 µM) [8]. The density of the film at 
different overtones was also modeled with concentration (Fig. 3B). There was an increase in 
density at the 3rd overtone between 0.25 to 1.00 µM. The increased density at the 3rd overtone 
suggests that the outermost parts of the bilayer (near the buffer interface) were denser relative to 
the rest of the bilayer. This could represent a dense, surface adsorbed protein film. At 2.00 µM the 
density was approximately that of the bilayer and then dropped further to ≈1000 kg/m3 from 5.00 
– 15.0 µM.  
 
Figure 3: Concentration-dependent thickness and density changes due to LL37-PC bilayer 
interactions. The modeled overall changes in A, thickness (nm) and calculated overall changes in 
B, density (kg/m3) at the 3rd and 11th overtones versus concentration of LL37 (µM). The PC bilayer 
thickness (6.84 ± 0.1 nm) and density (1060 kg/m3) prior to LL37 interactions are represented by 
dotted lines. 
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3.3. PC lipids remain on the sensor surface after interactions with high concentrations of LL37 
Based on overall Δf, ΔD, and thickness changes alone, we suspected three options for the 
interaction of high LL37 concentrations with PC bilayers: 
1. LL37 bound quickly onto PC as pre-assembled aggregates which were then later released 
leaving the original, intact bilayer, thus demonstrating no overall change in QCM-D data, 
2. There was an rapid “exchange event”, where LL37 formed pores and then adsorbed directly 
onto SiO2, thus displacing water from underneath the bilayer, removing all lipids and 
retaining a rigid and relatively thinner protein film, or 
3. A rapid “exchange event” occurred where LL37 formed pores and caused some removal 
of lipids while also rigidly adsorbing onto SiO2, leaving a proteolipid film on the surface. 
We investigated this further by studying the Δf and ΔD profiles after interaction with SDS 
detergent, which is commonly used for complete lipid removal from SiO2 [37]. The Δf 
(corresponding to amount of adsorbed SDS) and ΔD thresholds at the 3rd overtone required to 
completely remove the film after interaction with 10.0 µM LL37 was considerably higher (Δf = -
32.8 Hz, ΔD = 10.6x10-6) than films of pure PC (Δf = -9.6 Hz, ΔD = 6.1x10-6) or pure LL37 (Δf = 
-3.7 Hz, ΔD = 0.69x10-6) (Fig. 4). This indicates that a rigid proteolipid film remained adhered to 
SiO2 after high concentrations of LL37 interacted with PC. All of the overtones reflected a similar 
result (Fig. S4). The high amount of SDS required for removal of the proteolipid layer is surprising 
at first. However, we used the data collected from LL37 physically adsorbed onto the crystal sensor 
(Fig. 1C) to construct a Scatchard plot of the concentration of bound LL37 over the concentration 
of free LL37 versus the concentration of bound LL37 (Fig. S3D, inset). From the slope of this plot, 
we calculated the dissociation constant (KD) of LL37 on SiO2 to be 385 nM [49]. Our KD is similar 
in magnitude to previous reports of LL37 on SiO2 (600 nM [26]), in strength to antibody-antigen 
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binding, and is >10 times higher than the reported affinity of LL37 for PC lipids (5000 nM [26]). 
This suggests that an LL37 film would bind quite strongly to SiO2 and thus require more detergent 
and energy to remove from the crystal sensor. 
 
Figure 4: Removal of PC bilayers with detergent. The Δf and ΔD QCM-D versus time profiles 
after interaction of different film compositions with 0.1% (w/v) SDS. The Δf that predicts full SLB 
removal (25 Hz) is marked by a horizontal dotted line. Lines represent responses of the 3rd 
overtone; all overtones demonstrated similar Δf and ΔD (Fig. S4). 
 
3.4. High concentrations exhibit a three-step dynamic interaction with PC that appears less 
dependent on concentration 
While overtone analysis, thickness and density modeling provide insight to overall 
mechanistic phenomena (e.g. final, equilibrium states), QCM-D can also provide real-time 
dynamic analyses through ΔD vs. Δf plots, which create unique molecular signatures [31] for LL37 
at different concentrations (Fig. 5A-C) and physically adsorbed LL37 (Fig. 5D). In these plots, 
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changes in direction (labeled with arrows) suggest changes in molecular interactions between 
LL37 and PC [31-33, 44]. The x-axis is reversed (from +Δf to –Δf); thus, arrows pointing from left 
to right indicate increased mass adsorption (-Δf) and arrows pointing from right to left indicate 
mass loss (+Δf). While time is not explicit on these plots, each point is separated by approximately 
1s. Thus, the further the spacing between adjacent points, the faster the molecular process [31, 44]. 
 
Figure 5: Molecular signatures of LL37. Representative ΔD vs. Δf plots of the LL37-PC 
interactions at A, low concentrations (0.25 – 1.00 µM) and at high concentrations, B, 2.00 and 
5.00 µM and C, 10.0 and 15.0 µM. D, Representative ΔD vs. Δf plots of physically adsorbed LL37 
on SiO2 (0.10 – 10.0 µM). Numbered arrows indicate the progression of the interactions with time 
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and arrows labeled “R” indicate processes associated with the final Tris rinse. Signatures at the 3rd 
overtone are presented. 
 
From the QCM-D data and modeling calculations, we observed three distinct, 
concentration- and time-dependent interactions of LL37 with PC bilayers. At low LL37 
concentrations, the first process (orange arrow I, –Δf, +ΔD), indicated increased mass adsorption 
and film flexibility with increasing concentration (Fig. 5A). The first process also occurred at high 
concentrations, but at a faster rate (green/blue arrows I, Fig. 5B-C). A second mechanistic process 
observed at low concentrations (orange arrow II, +ΔD only) occurred relatively slower than the 
first. In order to create the most energetically favorable state on PC, surface-adsorbed LL37 
peptides may interact with one another [14], oligomerize [50], reorient [45] or partially insert into 
the bilayer [51], which would all cause increased ΔD. 
At high concentrations only, a third mechanistic process occurred (green/blue arrows III, 
+Δf, -ΔD), which represented rapid mass loss and increased film rigidity. Shahmiri et al. observed 
a similar transition from two- to three- steps between 2 and 3 µM over unsaturated 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) bilayers, but not over saturated 1,2-dimyristoyl-sn-glycero-
3-phosphocholine (DMPC) bilayers [29]. Since PC is monounsaturated and DOPC has two double 
bonds, the degree of unsaturation may correlate to the concentration at which the transition occurs. 
Interestingly, the third process ended at a much lower ΔD than observed here [29]. This may be 
due to a stronger proteolipid affinity for the gold QCM-D sensor substrate used by Shahmiri et al. 
compared with SiO2 substrate chosen in this study.  
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For reference, no changes in ΔD were observed in the case of physically adsorbed LL37 
on SiO2, (Fig. 5D); thus, the observed energy dissipation at the surface during LL37 adsorption 
only occurred due to the presence of a PC bilayer [29]. All overtones demonstrated similar 
molecular signature plots (Fig. S5A-C), and ΔD and Δf plots constructed at concentrations lower 
than 0.25 µM demonstrated negligible changes (Fig. S6). 
To gain more insight into viscoelastic changes of the film with time, we used the Voigt-
Kelvin Viscoelastic Extended model to study thickness with time (Fig. 6A). At low LL37 
concentrations, the PC bilayer-LL37 film thickness increased gradually with time before it reached 
an equilibrium. However, at high LL37 concentrations, a single rapid peak occurred in thickness, 
which reached a local maximum and returned close the starting thickness value before the system 
reached an equilibrium. Interestingly, the time required to reach the equilibrium thickness 
correlated with LL37 concentration at high concentrations, but was constant at low concentrations 
(Fig. 6B). The final Tris rinse caused very slight changes in the equilibrium thickness (Fig. S7A). 
The lowest LL37 concentrations tested (0.01 – 0.10 µM) demonstrated negligible changes in 
thickness with time (Fig. S7B). 
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Figure 6: Changes in film thickness versus time. A, representative profiles of thickness (nm) 
versus time (min) at different LL37 concentrations (0.10 – 15.0 µM) and B, the calculated time to 
achieve equilibrium thickness versus concentration of LL37. All values represent means ± S.E of 
n>4 replicates. 
 
3.5. Closer evaluation of maximum Δf and ΔD values at high LL37 concentrations reveals a flux-
dependent threshold required for membrane disruption 
The molecular signatures and thickness versus time plots demonstrate time-dependent 
LL37-PC bilayer interactions at LL37 concentrations between 2.00 – 15.0 µM. Thus, the local 
maxima demonstrated in thickness versus time (from Fig. 6A), local minima of Δf versus time and 
local maxima in ΔD versus time (from Fig. 1A-B) were calculated (Table 1, denoted by subscripts 
‘min’ or ‘max’). The local minima or maxima of Δf, ΔD, adsorbed mass, and thickness are also 
plotted in Fig. S8A-D, respectively. At low concentrations (0.10 – 1.00 µM), the changes in Δfmin, 
ΔDmax, Δmmax and maximum thickness up to 1.00 µM strongly correlated with concentration. At 
1.00 µM, we estimated ≈250 ng of adsorbed peptide on PC, which corresponded to 2.52x1013 
molecules on the surface. When LL37 physically adsorbed to SiO2, saturation was achieved 
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between 1.00 and 2.00 µM at ~200-250 ng (as demonstrated by a plateau in Fig. S3C), which 
corresponded to 2.17x1013 and 2.99x1013 adsorbed LL37 molecules, respectively (Table 1). When 
considering the surface area of the sensor and a molecular area of LL37 of 880 Å2 [20], the 
estimated number of molecules to saturate the bilayer surface would be ≈2.04x1013. This number 
is close to the estimations at 1.00 µM on both PC and SiO2, suggesting that the threshold observed 
at high concentrations could represent rapid bilayer saturation. Once saturation occurred, the time 
it took for LL37 to reach an equilibrium state as a surface-adsorbed proteolipid film depended 
strongly on concentration (Fig. 6B).  
Table 1: Numerical analysis of time-dependent QCM-D profiles with concentration. 
Conc. 
(µM) 
Δfmin 
(Hz)a 
ΔDmax 
(1E-06)a 
Δmmax 
(ng)b 
Max. 
Thickness 
(nm)c 
Moleculesd 
 
Physisorbed 
Moleculesd 
0.10 -0.057 0.0167 0.7949 6.978 7.45x1010 1.59x1012 
0.25 -0.805 0.3962 11.228 7.069 1.05x1012 --f 
0.50 -4.377 1.5164 61.051 7.992 5.73x1012 8.93x1012 
1.00 -19.28 6.5451 268.90 12.84 2.52x1013 2.17x1013 
2.00 -9.844 1.2552 137.61 10.13 --e 2.99x1013 
5.00 -13.30 3.7117 185.99 14.55 --e 3.10x1013 
10.0 -4.771 0.9796 66.702 8.620 --e 3.09x1013 
15.0 -2.367 0.4113 33.084 7.355 --e --f 
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aΔf and ΔD at the 7th overtone, all overtones demonstrated similar trends (Fig. S8A-C). bCalculated 
using the Sauerbrey equation (Eqn. 1) [38]. cThickness was modeled using the Voigt-Kelvin 
Viscoelastic Extended Model (Fig. 6A; [39]). dCalculated maximum number of molecules to 
saturate the bilayer surface, assuming molecular area of 880 Å2 [20] is 2.04x1013 molecules. 
eCalculations were not performed for 2.00 – 15.0 µM because the remaining mass is a proteolipid 
film of unknown final composition. fNot tested. 
 
Since the interaction mechanism of LL37 and PC bilayers appeared to be dependent on 
both the number of molecules as well as time, we wondered whether the Δf and ΔD vs. time profiles 
at one concentration would eventually transition to the Δf and ΔD vs. time profiles at the next 
concentration, given enough time. For example, would the gradual adsorption process at 1.00 µM 
eventually give rise to a transient peak like the one observed at 2.00 µM? To determine this in the 
QCM-D system, we calculated the Peclet number (NPe). Since the interaction of LL37 with PC 
bilayers in QCM-D is driven by both diffusion of LL37 molecules to the bilayer and flow of liquid 
through the QCM-D chamber, NPe, which is the dimensionless ratio between diffusional and 
inertial forces, would demonstrate which was dominant. For calculation of NPe, the diffusion 
coefficient (D) was first calculated with Eq. 6, the Einstein relation for relating diffusion of a 
spherical particle through a fluid and friction coefficient (γ) [52]. 
𝐷 (
𝑚2
𝑠
) =
𝑘B𝑇
6𝜋𝜂𝛼
          Eq. 6 
Where kB is Boltzmann’s constant, T is temperature (K), γ=6πηa is the relation between particle 
size and the friction coefficient, where we assume LL37 as a sphere of radius a moving through a 
fluid with viscosity η.  
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In both the x- and y-directions in QCM-D, NPe was very large (magnitudes of 10
10-1012), 
indicating that inertial forces were dominant, and diffusion was negligible (Fig. S9). However, we 
hypothesize that applying a high, constant flow rate would reduce NPe, requiring significantly 
lower times. Thus, for example, the interaction observed at 1.00 µM would eventually transition 
to the interaction observed at 2.00 µM. 
3.6. Suggested interaction mechanism of LL37 with zwitterionic PC lipid bilayers 
While QCM-D does not give direct evidence toward specific peptide-lipid interaction 
mechanisms (e.g. toroidal pore vs. carpet models), we can suggest mechanistic phenomena 
dependent on LL37 concentration and the formation of intermediates at high concentrations (Fig. 
7). Adsorption occurred at low concentrations (I), which eventually reached saturation at 1.00 µM 
(II). Adsorption caused membrane thinning, a requirement for toroidal pore formation [25, 27, 
48]. Thus, we propose the formation of transmembrane pores as a route of toxicity on PC bilayers 
(III), formed due to the number of molecules on the surface. Thickness calculations suggested that 
these pores were stable at high concentrations, between 2.00 – 10.0 µM. It is likely that the number 
of transmembrane pores increased with concentration. In the case of 15.0 µM, pores were an 
transient intermediate stage in the mechanism. Rapid interactions with the SiO2 substrate [44, 48], 
peptide-peptide interactions and possibly rapid attachment of pre-assembled aggregates [29] at 
toxic concentrations caused an “exchange event”, where the film went from being primarily lipid 
to primarily protein and remained strongly adsorbed onto SiO2 (IV). Achieving equilibrium 
correlated to time and concentration in the high concentration range, suggesting that after 
saturation on the membrane, a concerted “effort”, perhaps an energy threshold, by the LL37 
molecules bound to PC was required to achieve the pore-forming (III) and proteolipid film (IV) 
states. With different bilayer types – charged, zwitterionic, saturated, unsaturated – one might 
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expect that the concentration where saturation occurs (or the threshold between adsorption and 
concerted action) would be shifted [29]. 
 
Figure 7: Proposed mechanism of LL37 interaction with PC bilayers at different 
concentrations. The proposed mechanism is based on adsorption (I) and (II) saturation at low 
concentrations of LL37 (0.10 – 1.00 µM), followed by the formation of transmembrane pores (III) 
that are either stable (between 2.00 – 10.0 µM) or transient (>15.0 µM, dotted arrow) that 
equilibrates as a rigid proteolipid film adsorbed to SiO2 (IV). 
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This study demonstrates that saturation alone is not the threshold for cytotoxicity, but that 
the time of interaction is also important. Both must be considered during rational design of peptide-
based antimicrobial therapies that act through lipid bilayer disruption mechanisms. An example of 
this is in “tethered” systems whereby peptides are covalently or non-covalently attached to 
substrates. Tethering limits peptide surface concentration and therefore affects the ability of 
peptides to saturate cell surfaces. However, tethering also limits peptide flexibility, which we found 
is important for determining the time it takes to go from pore formation to membrane destruction, 
or to reach the equilibrium states observed in this study.  
 
4. Summary and Conclusions 
In this study, we used QCM-D to determine concentration- and time-dependent changes in 
mass adsorption, film rigidity, thickness, and density of zwitterionic bilayers after interactions with 
human LL37, at concentrations that represent its antimicrobial (low concentrations) and cytotoxic 
activities (high concentrations). The interactions of LL37 with PC lipid bilayers were found to be 
concentration-dependent, in a manner that correlated with its bioactive concentrations, and allowed 
us to propose a two-step mechanism with an intermediate state, depending on concentration. We 
found that bilayer saturation was a threshold for transmembrane pore formation. At 15.0 µM, pore 
formation was an intermediate state that reached equilibrium as a rigid proteolipid film adsorbed 
onto the crystal sensor in both a concentration- and time-dependent manner. Together, this 
indicates that while concentration is important at low concentrations (0.10 – 1.00 µM) for reaching 
saturation, the time of interaction is also important for cytotoxic functions (2.00 – 15.0 µM). 
Understanding the peptide-lipid interactions that lead to cytotoxicity will provide fundamental 
understanding of how to modify peptides for improving the therapeutic ratio, such as covalent or 
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non-covalent surface attachment. QCM-D is a powerful method of analyzing interactions between 
antimicrobial peptides and lipid bilayers, particularly when combined with viscoelastic modeling, 
in order to identify mechanisms of peptide-lipid interactions to a much greater extent. 
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Abstract 
LL37, a human-derived antimicrobial peptide (AMP), is promising as an alternative 
antimicrobial for chronic wound healing applications due to its broad antimicrobial and 
immunomodulatory functions; however, it has eluded the clinic due to cytotoxicity stemming from 
a poor understanding of its specific interactions with lipid bilayers. Recently, we designed chimeric 
LL37 by adding collagen binding domains derived from collagenase (cCBD-LL37) and fibronectin 
(fCBD-LL37) that were non-cytotoxic, antimicrobial and stable when tethered onto collagen-based 
scaffolds. Surprisingly, the addition of small CBD sequences mediated large changes in peptide 
structure and led to different bioactivities in solution (e.g. antimicrobial activity and cytotoxicity). 
In the current study, we aimed to understand the mechanistic basis behind the observation of 
different bioactivities. To do this, we studied time- and concentration-dependent interactions of 
cCBD- and fCBD-LL37 with different model bilayers at different bioactive concentrations by 
monitoring real-time changes in frequency (Δf) and dissipation (ΔD) in quartz crystal 
microbalance with dissipation (QCM-D). We also matched Δf responses to predictions for pore 
formation and surface adsorption mechanisms for cCBD- and fCBD-LL37, respectively. Our goal 
was to apply the Voigt-Kelvin viscoelastic model to the QCM-D findings to investigate overall 
and time-dependent thickness and density changes of the peptide-bilayer interactions and use these 
findings to develop a mechanism for each peptide interactions with the different bilayers, driven 
by CBD intrinsic sequence properties such as charge, helicity and amphiphilicity. The 
development of a structure-function relationship for cCBD-LL37 and fCBD-LL37 allowed 
mechanistic predictions for the bioactivities of new hypothetical CBD-LL37, which demonstrates 
promise for the broad, rational design of novel, antimicrobial and non-cytotoxic CBD-LL37 for 
clinical applications.
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1. Introduction 
Short, naturally-derived, and positively charged proteins called antimicrobial peptides 
(AMPs) [1], particularly human-derived LL37 [2, 3], are promising as alternative antimicrobial 
therapies for chronic wound healing applications. LL37 has broad antimicrobial properties [4, 5] 
and unique action mechanisms that cause a low likelihood of bacterial resistance [6], but also has 
immunomodulatory and healing activities [7, 8]. LL37 has not reached the clinic, due to its 
cytotoxicity and low in vivo stability, which stem from a lack of detailed structure-function and 
mechanistic knowledge [1, 2, 9, 10]. 
Sequence modifications of LL37 are made to tune LL37 structure to create new peptides 
with desired functionality. To decrease cytotoxicity, single amino acid substitutions [11] are 
common to systematically alter peptide charge, hydrophobicity, amphiphilicity and helical 
propensity, and uncover fundamental knowledge of which single amino acids are associated with 
particular functions. Truncation is a strategy pursued to find the shortest antibacterial segments of 
a peptide; for example, KR-12 [12], RK-31 [13] or LL-32 [14] derivatives of LL37 demonstrate 
antibacterial or antifungal activities but are not hemolytic. Hybridization of LL37 segments with 
segments from other natural [15-17] or synthetic [18] peptides is also a popular modification 
strategy. Substitution of D-amino acids [19] or cyclization [20] in similar peptides have 
demonstrated promising results toward improving stability. 
Alternative strategies to both improve stability and reduce toxicity of LL37 have also been 
studied; for example, through targeted delivery of LL37 using polylactic-co-glycolic acid 
microspheres [21] or polyelectrolyte multilayers of biopolymers [22], by conjugation to magnetic 
nanoparticles [23], or via tethering (e.g. covalent attachment to surfaces) [24]. Our group utilizes 
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non-covalent tethering onto collagen-based wound dressings as a strategy to reduce cytotoxicity 
and improve stability of LL37 for chronic wound applications [25]. We created chimeric versions 
of LL37 with C-terminal collagen binding domains derived from collagenase (cCBD-LL37) and 
fibronectin (fCBD-LL37) to achieve tethering, and found that the addition of CBDs demonstrated 
reduced cytotoxicity when tethered and improved antimicrobial stability after 14 days’ release 
[25]. Further, the primary sequence of each CBD tested affected both antimicrobial and 
cytotoxicity, particularly with fCBD-LL37 that did not demonstrate cytotoxicity to human 
fibroblasts in the range tested (up to 20 µM) [25]. We linked the differences in the observed soluble 
bioactivities to changes in peptide-bilayer interactions due structural changes induced by the 
addition of CBDs with different sequences using Molecular Dynamics (MD) simulations and 
circular dichroism spectroscopy (Chapter 5). Recently, we also found that real-time quartz crystal 
microbalance with dissipation (QCM-D) was a useful technique for studying the fundamental 
time- and concentration-dependent interactions of LL37 with model zwitterionic bilayers (Chapter 
6). 
Thus, our goal was to utilize QCM-D to study time- and concentration-dependent 
interactions of cCBD- and fCBD-LL37 with model mammalian and bacterial lipid bilayers 
compared to unmodified LL37 to develop a mechanistic model as it related to intrinsic CBD 
properties and observed in vitro bioactivities. In addition to changes in structure, our hypothesis 
in the current study is that CBDs modulate the specific interactions of cCBD- and fCBD-LL37 
with zwitterionic mammalian and charged bacterial lipid bilayers, leading to the observed changes 
in bioactivities. Results from this study are crucial to predict and implement novel bioactive 
chimeric CBD-LL37, contribute to knowledge base of collagen tethering as a platform, and 
provide a step toward clinical implementation of AMPs. 
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2. Materials and Methods 
2.1. Materials: Peptides and lipids 
Chimeric versions of human LL37 with C-terminal collagenase- [26] and fibronectin-
derived [27] collagen binding domains (CBDs) were custom synthetized by New England Peptide 
(Gardner, MA) to >90% purity and confirmed with high-performance liquid chromatography 
(HPLC) to create cCBD-LL37 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKTKKTLRT) and 
fCBD-LL37 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESDYKDDDDKCQDSERTFY). The 
CBD and LL37 sequences were separated by a FLAG™ octapeptide (DYKDDDDK), which is a 
commercial sequence that was strategically included as an epitope tag [28] and a spacer to improve 
flexibility of tethered peptides [29, 30]. For comparison, unmodified human LL37 was synthesized 
by Anaspec (Fremont, CA) at >95% purity, confirmed with HPLC. Peptides were stored at 0.67 
mM at -20°C according to manufacturer recommendations, in sterile water (pH 3.5) with 5 mM 
ethylenediaminetetraacetic acid (EDTA). 
Egg L-α phosphatidylcholine (PC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (POPG), 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-phospho-(1’-rac-
glycerol) (DMPG) were purchased from Avanti Polar Lipids (Alabaster, AL) and stored at 100 
mg/mL at -20°C. PC was stored in ethanol; POPC and DMPC were stored in chloroform and 
POPG and DMPG were stored in chloroform with 3% v/v methanol to help solubilize the charged 
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groups. Other materials, prominently buffers, were purchased from Sigma Aldrich (St. Louis, 
MO). 
2.2. Methods 
2.2.1. Lipid vesicle preparation 
Stock solutions of small unilamellar vesicles comprised of PC, 4:1 (molar ratio) 
POPC:POPG and 4:1 (molar ratio) DMPC:DMPG at 2.5 mg/mL (PC, POPC:POPG) and 0.5 
mg/mL (DMPC:DMPG) were all prepared in batches as described elsewhere [31], and stored at 
4°C under nitrogen. DMPC:DMPG vesicles were used within 1 week. 
2.2.2. Formation of supported lipid bilayers (SLBs) with QCM-D 
Supported lipid bilayers (SLBs) were formed via spontaneous rupture of the small 
unilamellar vesicles on piezoelectric silicon dioxide (SiO2)-coated quartz sensor crystals in real 
time, using quartz crystal microbalance with dissipation (QCM-D) (Q-Sense E4, Biolin Scientific, 
Stockholm, Sweden), as described previously [31-33]. QCM-D is a flow-based, acoustic method 
that measures changes in frequency (Δf) and dissipation (ΔD) of films deposited over the sensor 
crystals, corresponding to changes in mass deposition and viscoelasticity of the film, respectively. 
Specifically, Δf is negatively proportional to mass deposition (e.g. increased Δf indicates film mass 
loss), and ΔD indicates the degree of viscoelastic contribution to the film; films with high ΔD are 
flexible while films with decreased ΔD are rigid. Δf and ΔD are measured along different overtones 
(3rd through 11th), or multiples of the fundamental frequency (f0=5MHz), which also correlate to 
different penetration depths into the deposited film [31, 34]. Phenomena that occur closer to the 
film surface are indicated by changes in the lower overtones, while phenomena that occur deeper 
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within the film are indicated by changes in the higher overtones. SLB formation in QCM-D has 
been well characterized [35-37]. 
First, SLBs were formed on SiO2 sensor crystals in QCM-D at 0.15 mL/min according to 
previous methods [31]. PC bilayers were formed in tris(hydroxymethyl)aminomethane, pH 7.8 
(Tris) buffer. POPC:POPG and DMPC:DMPG bilayers were formed in 3-N-
morpholino)propanesulfonic acid, pH 7.0 (MOPS) buffer, supplemented with 1 mM CaCl2 [38, 
39]. To avoid interference of Ca2+ with peptides, charged bilayers were then rinsed with MOPS 
without CaCl2. Peptides (1.5 mL of concentrations from 0.10 to 20.0 µM) were then flown over 
the bilayers for 10 min, incubated for 1 hour under static conditions and rinsed with buffer for 10 
min while Δf and ΔD responses were collected with time. 
Peptides (concentrations 0.50 to 10.0 µM) were also directly flown over SiO2 sensor 
crystals in QCM-D in both MOPS (pH 7.0) and Tris (pH 7.8) using a similar method described 
above, to study the peptide physical adsorption behavior and to calculate binding coefficient (KD). 
2.2.3. Modeling viscoelastic film properties using the Voigt-Kelvin Viscoelastic Extended Model 
In the case of rigid systems (i.e. ΔD≈0), the Sauerbrey relation (Eq. 1) is used to directly 
relate Δf to mass changes (Δm) of the film using the Sauerbrey constant, C, and sensor crystal 
properties [40]. 
∆𝑓 = −
2𝑓0
2
𝐴√𝜌q𝜇q
Δ𝑚 = −𝐶Δ𝑚         Eq. 1 
Where ρq and µq are the density and shear modulus of the quartz crystal (2.648 g/cm3 and 
2.947x1011 g/(cm·s), respectively), and A is the crystal area (0.785 cm2). 
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In the case where ΔD is not 0 (a typical rule-of-thumb is greater than 5% of Δf at any given 
time), then the viscoelastic contribution of the film is significant, and more complex models must 
be used to study the film properties. A commonly used model for bilayer and vesicular systems is 
Voigt-Kelvin [41], which is a continuum mechanics approach to evaluating the contribution of 
viscoelasticity to Δf (Eq. 2) and ΔD (Eq. 3) of a film immersed in a Newtonian liquid [42].  
∆𝑓 ≈ −
1
2𝜋𝜌qℎq
{
𝜂l
𝛿l
+ ∑ [ℎ𝑗𝜌𝑗𝜔 − 2ℎ𝑗 (
𝜂𝑙
𝛿𝑙
)
2 𝜂𝑗𝜔
2
𝜇𝑗
2+𝜔2𝜂𝑗
2]𝑗=1,2   }     Eq. 2 
∆𝐷 ≈
1
2𝜋𝑓0𝜌qℎq
{
𝜂l
𝛿l
+ ∑ [2ℎ𝑗 (
𝜂𝑙
𝛿𝑙
)
2 𝜇𝑗𝜔
𝜇𝑗
2+𝜔2𝜂𝑗
2]𝑗=1,2   }      Eq. 3 
Where hq is the thickness of the quartz sensor crystal; viscosity, penetration depth, and density of 
the bulk liquid are represented by ηl, δl and ρl; and for j=2 film layers on the sensor crystal, the 
thickness, elastic shear modulus and shear viscosity are represented by hj, µj and ηj. In this model, 
the complex shear modulus involves real and imaginary parts corresponding to the storage and 
loss moduli, measured by ΔD. When ΔD=0, Eq. 2 reduces to Eq. 1 for a Sauerbrey film. 
To calculate the thickness and density changes with peptide concentration and time, a 
single-layer Voigt-Kelvin Viscoelastic Extended Model was applied to all overtones of Δf and ΔD 
(excluding the 1st [34]) using Q-Tools software (Biolin Scientific), in a similar manner as other 
studies [29, 41, 43]. Within the model, physical constraints of bilayer thickness (5-7 nm [43]), 
bilayer density (1060 kg/m3 for PC, 1080 kg/m3 for DMPC:DMPG [44]) and peptide dimensions 
calculated previously using MD simulations (Chapter 5) were used to iterate model step sizes and 
output ranges. When the lowest chi-squared, χ2, was achieved with respect to physical constraints, 
the model outputs were collected. 
2.2.4. Mechanistic predictions via calculations of expected ΔfMIN 
223 
 
To predict the possibility of pore formation or surface-association mechanisms for cCBD-
LL37 and fCBD-LL37 peptides, predictions of the minimum Δf (ΔfMIN) expected from each 
mechanism were calculated and compared to the actual Δf values observed in QCM-D [32, 45]. 
These calculations are modifications of the Sauerbrey calculation and have been described 
elsewhere [32]; thus, are summarized below for the insertion of single peptides or peptide clusters 
within the bilayers (Eq. 4), formation of water-filled transmembrane pores comprised of n peptides 
(Eq. 5) and the surface association of peptides in a “carpet-like” fashion (Eq. 6). 
∆𝑓𝑀𝐼𝑁 = −
𝜆
𝐶
[
𝑀𝑃
𝑎𝑃
− 2
𝑀𝐿
𝑎𝐿
]         Eq. 4 
∆𝑓𝑀𝐼𝑁 = −
𝜆
𝐶
[
𝑀𝑃
𝐴𝐻
𝑛
− 2
𝑀𝐿
𝑎𝐿
]         Eq. 5 
∆𝑓𝑀𝐼𝑁 = −
𝜆
𝐶
[
𝑀𝑃
𝐴𝑃
]          Eq. 6 
Where MP and ML represent the molecular masses of the peptides and lipids, respectively, and ap 
and aL are peptide and lipid areas, respectively, calculated assuming peptide dimensions as 
cylinders and the widely-accepted Δf recorded with QCM-D for SLBs, -25 Hz. AH is the estimated 
pore area that assumes cylindrically shaped pores of diameter DH formed by n peptides, and AP is 
the area occupied by a surface adsorbed peptide calculated assuming peptide dimensions estimated 
with MD simulations (Chapter 5). In Eq. 4-6, the fraction of peptides participating in a certain 
mechanism (λ) is set to 1 to calculate ΔfMIN [32]. 
2.2.5. Replicates and statistics 
All experiments were repeated at the various concentrations for n>4 replicates. Replicates 
were collected for 0.10-20 µM (PC), 0.25-10.0 µM (POPC:POPG), and 0.25-1.00 µM 
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(DMPC:DMPG). Representative plots are presented for Δf, ΔD, and thickness vs. time; bar and 
scatter plots represent the mean ± standard error (S.E.) of n>4 replicates for all bilayers and 
concentrations. For physically adsorbed peptides on SiO2, n>3 replicates for each concentration in 
each buffer were recorded. 
The 3rd overtone in the QCM-D is recorded for all figures unless otherwise noted, because 
it represented the maximum changes in Δf and ΔD occurring on the bilayer. In most cases, there 
were no significant differences between the overtones (tested using one-way ANOVA); however, 
differences between the 3rd through 11th overtones, if observed, are noted and discussed when 
necessary to describe mechanistically important phenomena occurring among different bilayer 
penetration depths. 
 
3. Results and Discussion 
3.1. Overall Δf and ΔD versus time profiles for cCBD- and fCBD-LL37 reflect their observed 
in vitro bioactivities 
Previously, we found similar cytotoxic (>10 µM) and antimicrobial (0.5 – 10 µM) 
concentration ranges [25] and similar structural composition (Chapter 5) of LL37 and cCBD-
LL37. In contrast to LL37 and cCBD-LL37, fCBD-LL37 demonstrated vastly different in vitro 
bioactivities, notably a lack of cytotoxicity up to 20.0 µM. It was thus unsurprising that Δf and ΔD 
versus time profiles with concentration of cCBD-LL37 against all bilayer types (Fig. 1) were quite 
similar to those for LL37 (Chapter 6, Fig. S1A-B), while fCBD-LL37 profiles were quite different 
(Fig. 2). 
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Against zwitterionic PC, cCBD-LL37 demonstrated two different profiles depending on 
the concentration. At “low concentrations” defined as 0.10 – 1.00 µM (Fig. 1A), mass adsorption 
increased with concentration (-Δf), suggesting a layer of surface-adsorbed peptides. At “high 
concentrations” defined as 2.00 – 20.0 µM (Fig. 1B), Δf and ΔD demonstrated an abrupt adsorption 
of mass and increase of viscoelasticity to a peak value (-Δf, +ΔD), after which both parameters 
reversed and equilibrated, Δf to -6 to -9 Hz and ΔD≈0. The two concentration ranges define 
bioactive ranges for LL37, which demonstrates immunomodulatory function at the “low 
concentrations” [46] and both antimicrobial and some cytotoxic function at the “high 
concentrations” [7, 47]. Though the immunomodulatory activities of cCBD-LL37 have not been 
tested, its antimicrobial and cytotoxic functions also correspond with the “high concentration” 
range. Against 4:1 POPC:POPG the general profiles for cCBD-LL37 were similar, but the 
transition between the two different profiles occurred at a lower concentration than against PC, at 
0.50 µM (Fig. 1C). This suggests that cCBD-LL37 imparts similar interactions with PC and 
POPC:POPG overall, but charge may allow increased mechanistic contribution of individual 
peptides. Against saturated 4:1 DMPC:DMPG membranes, adsorption at 0.25 µM (-Δf) was 
double that of unsaturated POPC:POPG (Fig. 1D). However, there were no clear trends of Δf or 
ΔD with concentration, similar to LL37 (Fig. S1C). Lipid saturation, which influences the packing 
density of lipid hydrophobic cores has been shown to highly influence LL37-bilayer interactions 
[48]. Based on Δf and ΔD, saturation level also appeared to influence interactions of cCBD-LL37. 
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Figure 1: Representative QCM-D Δf and ΔD profiles of cCBD-LL37 with time and 
concentration. Representative Δf (left) and ΔD (right) versus time profiles after the introduction 
of cCBD-LL37 to A-B, PC only, C, 4:1 POPC:POPG and D, 4:1 DMPC:DMPG (molar ratios). 
For PC only, the concentrations are separated into A, low cCBD-LL37 concentrations (0.10 – 1.00 
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µM) and B, high cCBD-LL37 concentrations (2.00 – 20.0 µM). The 3rd overtones only are shown 
normalized to the equilibrated bilayer Δf and ΔD values; all overtones had similar profiles. 
 
Against all bilayers and at all concentrations, fCBD-LL37 demonstrated similar Δf and ΔD 
vs. time profiles, increased mass adsorption and viscoelasticity (-Δf, +ΔD) (Fig. 2A-C). This 
suggests the presence of a viscoelastic film of fCBD-LL37 adsorbed to the bilayer surface. Against 
both PC and POPC:POPG bilayers, the adsorption was prominent at higher concentrations, 
between 1.00 and 20.0 µM (Fig. 2A-B). The Δf response due to 20.0 µM on PC was very large at 
approximately -100 Hz (Fig. S2). Relatively larger adsorption (-Δf) was observed on charged 
versus zwitterionic bilayers, suggesting that charge influenced the amount of adsorbed fCBD-
LL37 rather than its particular interaction mechanisms. Interestingly, fCBD-LL37 adsorbed the 
most at the lowest concentration (0.25 µM) against saturated DMPC:DMPG bilayers (Fig. 2C). 
For all concentrations, the 3rd overtone demonstrated significantly larger magnitudes of Δf than 
the 11th overtone (p<0.05, not shown), demonstrating that fCBD-LL37 adsorption was more 
significant at lower penetration depths. 
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Figure 2: Representative QCM-D Δf and ΔD profiles of fCBD-LL37 with time and 
concentration. Representative Δf (left) and ΔD (right) versus time profiles after the introduction 
of fCBD-LL37 to A, PC only, B, 4:1 POPC:POPG and C, 4:1 DMPC:DMPG (molar ratios). For 
PC only (A), an inset is provided to better visualize Δf changes. The 3rd overtones only are shown 
normalized to the equilibrated bilayer Δf and ΔD values; all overtones had similar profiles. 
 
3.2. ΔfMIN predictions for transmembrane pore- and adsorption-based mechanisms did not 
match well the observed Δf in QCM-D for cCBD-LL37 and fCBD-LL37, respectively 
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Based on the Δf and ΔD vs. time profiles, we hypothesized that cCBD-LL37 and fCBD-
LL37 interactions were based on the transmembrane pore formation and surface adsorption 
phenomena, respectively. To match these supposed interactions with expected Δf, we utilized a 
predictive tool [32] to calculate the expected minimum frequency change (ΔfMIN) associated with 
transmembrane pore formation (Fig. 3) and “carpet-like” surface association [10] (Fig. 4) for 
cCBD-LL37 and fCBD-LL37, respectively. 
Given the similarities of cCBD-LL37 and LL37 in terms of in vitro bioactivities [25] and 
Δf and ΔD profiles and our previous finding that LL37 formed transmembrane pores in PC bilayers 
(Chapter 6) similar to what has been proposed by others [49-52], we calculated ΔfMIN for two 
cases. First, we considered insertion into the bilayer as a monomer or cluster of peptides with no 
water association with Eq. 4 (Fig. 3A) and second, formation of cylindrical, water-filled pores 
with Eq. 5 (Fig. 3B). Then, the ΔfMIN predictions for each case were compared to the actual change 
in Δf in QCM-D, calculated as the difference in Δf from the beginning of peptide flow to after the 
final buffer rinse (Fig. 3C). According to Huang and colleagues [53], pore formation (i.e. the 
“inserted” state) typically occurs at a threshold concentration. The apparent threshold in the case 
of cCBD-LL37 may be the noted transition of Δf and ΔD vs. time profiles between “high” and 
“low” concentrations (Fig. 1A-B) and is thus separated by a dashed underline in Fig. 3C. 
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Figure 3: Predicted ΔfMIN versus actual overall Δf values for two different pore-forming 
mechanisms. The predicted ΔfMIN (Hz) for cCBD-LL37 inserting into bilayers as A, monomers or 
dimer clusters or B, water-filled transmembrane pores comprised of different participating 
numbers of peptides. These predictions may be compared to C, the overall average Δf observed in 
QCM-D. The 3rd overtone for Δf is presented to allow for maximum Δf magnitudes to be compared 
with predicted values. Other overtones are reported elsewhere (Chapter 5). 
 
Monomer or cluster insertion did not fit the observed Δf for cCBD-LL37 (Fig. 3A vs. Fig. 
3C). Indeed, the highly amphiphilic character of cCBD-LL37 (measured by a hydrophobic 
moment (µH), of 0.432 for cCBD-LL37 compared to 0.521 for LL37), makes it unlikely that 
cCBD-LL37 would conform within the bilayer as a single-spanning transmembrane helix. Further, 
transmembrane bundles are more common [54]. However, when additional cCBD-LL37 were 
added to the cluster, ΔfMIN was too large (-105.9 Hz for a dimer) to match any of the observed Δf. 
The formation of water-filled pores was an improved match (Fig. 3B vs. Fig. 3C). After the 
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threshold, cCBD-LL37 equilibrated to Δf ≈ -4 to -5 Hz against PC and POPC:POPG, which 
corresponded to pores comprised of 16-20 peptides. At 1.00 µM against DMPC:DMPG, Δf 
matched 14 peptides per pore, suggesting an influence of both charge and bilayer composition with 
pore formation. Using atomic force microscopy, Morgera et al. observed 10 nm pores, which if 
perfectly lined could comprise of 20 peptides per pore [50], suggesting that these estimations are 
within reason. 
The apparent adsorption of fCBD-LL37 represented by QCM-D (Fig. 2) and the large 
differences from overtone to overtone did not support the formation of transmembrane pores; thus, 
Eq. 6 was used to calculate ΔfMIN for a mechanism based on bilayer coverage in a “carpet like” 
fashion (Fig. 4). Unfortunately, the observed Δf and ΔfMIN did not correlate for fCBD-LL37, unless 
very large aggregates were assumed on the surface (Fig. 4A vs. Fig. 4B). At 1.00 µM, Δf matched 
ΔfMIN for monomers (PC only), dimers (POPC:POPG) and trimers (DMPC:DMPG), suggesting 
that fCBD-LL37 formed larger aggregates with lipid surface charge and degree of saturation. 
However, at larger concentrations the aggregates grew to be very large; for example, ΔfMIN 
predicted 10-25 peptides per aggregate at 10.0 µM, depending on bilayer charge. This is unlikely, 
since one may expect QCM-D to reflect either a continued increase of viscoelasticity (high ΔD) if 
self-association were occurring or near zero ΔD if pre-assembled aggregates were attaching all at 
once [48]. Since neither ΔD response was observed, these data suggest that a simple surface 
adsorption model does not describe the behavior of fCBD-LL37. 
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Figure 4: Predicted ΔfMIN versus actual overall Δf values for a carpet-like, surface adsorption 
model. A, The predicted ΔfMIN (Hz) for fCBD-LL37 adsorption onto bilayer surfaces. These 
predictions may be compared to B, the overall average Δf observed in QCM-D. The 3rd overtone 
for Δf is presented to allow for maximum Δf magnitudes to be compared with predicted values. 
Other overtones are reported elsewhere (Chapter 5). 
 
The Δf for cCBD-LL37 and fCBD-LL37 also did not match ΔfMIN associated with 
adsorption and pore formation mechanisms, respectively (Fig. S3, Fig. S4). We also made all 
corresponding ΔfMIN predictions for LL37 (Fig. S5). Overall, it appeared that additional 
mechanistic phenomena contributed to the bilayer interactions of cCBD-LL37 and fCBD-LL37 to 
cause the mismatches is Δf and ΔfMIN. In section 3.3 and section 3.4, the influence of other 
parameters such as time, concentration, thickness and density are studied for cCBD-LL37 and 
fCBD-LL37, respectively. 
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3.3. Time- and concentration-dependence of cCBD-LL37 interactions with different bilayers 
Time and concentration are highly influential for transmembrane pore formation; thus, we 
further evaluated these changes in Δf and ΔD, and also used the Voigt-Kelvin Viscoelastic 
Extended Model to study bilayer changes in thickness and density during cCBD-LL37 interactions. 
3.3.1. cCBD-LL37 and LL37 demonstrate subtle differences in thickness and density with 
concentration indicating different bilayer insertion and orientation preferences 
cCBD-LL37 caused higher overall changes in thickness against both PC and POPC:POPG 
than did LL37 (Fig. 5A-B), perhaps due to its relatively longer length. At low cCBD-LL37 
concentration, bilayer thickness increased with concentration until 1.00 µM against PC and 
POPC:POPG, while LL37 caused linear bilayer thinning indicated by decreased thickness. This 
indicates that the presence of cCBD causes the cCBD-LL37 peptide to localize primarily on the 
surface until 1.00 µM rather intercalating within the bilayer head groups. The maximum thickness 
of the cCBD-LL37-bilayer films were higher on zwitterionic PC than charged POPC:POPG, 15.4 
versus 9.4 nm total (8.0 and 2.8 nm above the original bilayer thickness). These values are similar 
to the modeled thicknesses of cCBD-LL37 (8.46 nm) and FLAG (2.8 nm) (Chapter 5).  
Interestingly, the physical adsorption of cCBD-LL37 and LL37 in buffers of different ionic 
strengths were similar to one another, but only demonstrated film thickness up to ≈4-5 nm on SiO2 
sensor crystals (Fig. S6). The discrepancy between this thickness and the maximum thickness on 
PC indicates possible re-orientation of cCBD-LL37 perpendicular to the bilayer prior to insertion, 
which is common for pore-forming AMPs [55]. Meanwhile, against charged POPC:POPG, a fully 
perpendicular reorientation may not be a requirement for insertion. This is also reflected in the 
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density, which increased abruptly between 0.25 and 0.50 µM against PC (Fig. 5D), yet gradually 
with concentration against POPC:POPG (Fig. 5E). 
 
Figure 5: Thickness and density changes as a function of cCBD-LL37 concentration against 
different bilayer compositions. The overall changes in A-C, modeled thickness (nm) for cCBD-
LL37 compared with unmodified LL37* and D-F, calculated density (kg/m3) at the 3rd (purple) 
and 11th (orange) overtones due to cCBD-LL37, all versus peptide concentration (µM) against PC 
only (A, D), 4:1 POPC:POPG (B, E) and 4:1 DMPC:DMPG (C, F) bilayers. Dotted lines represent 
original bilayer thicknesses and densities. All values represent mean ± S.E. of n>4 replicates. 
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*Note that the thickness values reported here for LL37 on PC bilayers were recently submitted for 
publication in Colloids and Surfaces B: Biointerfaces (Chapter 6). 
 
Bilayer thinning (i.e. thickness decrease with concentration) was apparent for both cCBD-
LL37 and LL37 against saturated DMPC:DMPG bilayers (Fig. 5C). Thinning occurs as a 
prerequisite for toroidal pore formation [53] and has also been associated with more recently 
proposed “sinking raft” mechanism, whereby peptides adsorb and cause thinning as they 
intercalate within bilayer head groups [56]. In this mechanism, it might be expected that at a 
threshold concentration, density would be disproportionate at different levels of the bilayer, which 
is what we observed in the overtones at 0.5 and 1.0 µM (Fig. 5F). Saturated bilayers are less fluid 
than unsaturated bilayers and thus require more energy, and possibly a higher concentration of 
AMPs for interactions to occur. Thus, it is possible that 1.00 µM is too low of a concentration to 
see the full spectrum of its interaction with cCBD-LL37, a notion that is supported by Shahmiri et 
al. who observed LL37 mass adsorption in QCM-D against DMPC:DMPG bilayers at 1.00 µM 
and above [48]. 
After the maximum, thickness was constant between 2.00 and 10.0 µM at 8.7 and 7.8 nm 
for cCBD-LL37 with PC and POPC:POPG, respectively (1.3 nm thicker than original bilayer 
thicknesses). At these concentrations, density was also constant along all detectable penetration 
depths (Fig. 5D-E). At 20.0 µM against PC, above the cytotoxic threshold of cCBD-LL37 [7], 
there was a further drop in thickness and density (Fig. 5A, D). For comparison, density changes 
due to LL37 interactions with different bilayers are presented in Fig. S7. 
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3.3.2. cCBD-LL37 interactions with different bilayers were rapid, concentration-dependent and 
multi-step processes 
The formation of transmembrane pores is a highly dynamic process. To investigate the 
influence of time with the different bilayer interactions of cCBD-LL37, we created unique 
molecular signatures of ΔD vs. Δf for cCBD-LL37 with concentration and bilayer type and 
compared to physically adsorbed cCBD-LL37 on SiO2 (Fig. 6). When reading these plots, it is 
important to note that the x-axis is reversed from +Δf to -Δf for intuitive interpretation [33]; thus, 
left to right on the x-axis represents mass adsorption. The y-axis, from -ΔD to +ΔD, represents 
changes in viscoelasticity. An interesting aspect of ΔD vs. Δf plots is that time is not an explicit 
parameter, but adjacent points are separated by ~1s so that faster interactions are indicated by 
further spaced apart adjacent points [57]. 
The first process (i) against all bilayers at all concentrations was the same (Fig. 6A-C): 
increased mass (-Δf) and ΔD, which indicates a surface-adsorbed viscoelastic protein film. 
Physically adsorbed cCBD-LL37 on SiO2 demonstrated constant ΔD≈0 between 0.50 – 10.0 µM 
in different buffers (Fig. 6D), which suggests that any increased ΔD on bilayers occurred strictly 
due to the interaction of cCBD-LL37 with lipids. Similar phenomena occurred for bilayer-
adsorbed versus SiO2-adsorbed LL37 (Fig. S8). At low concentrations 0.25 and 0.50 µM, the 
second process (red ii) demonstrated mass loss, suggesting some reversibility of adsorption. 
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Figure 6: Dynamics of cCBD-LL37 interactions with different bilayers. Representative ΔD vs. 
Δf plots of cCBD-LL37 at concentrations ranging from 0.25 – 10.0 µM against A, PC only, B, 4:1 
POPC:POPG and C, 4:1 DMPC:DMPG bilayers. D, representative ΔD vs. Δf plots of physically 
adsorbed cCBD-LL37 on SiO2 substrates (0.50 – 10.0 µM). Numbered and colored arrows indicate 
the progression of membrane interactions with time, and “R” represents the processes associated 
with the final buffer rinse. For simplicity, plots of the 3rd overtones only are presented; all 
overtones demonstrated similar ΔD vs. Δf signatures. For comparison, the molecular signature 
plots for LL37 are provided in Fig. S8. 
 
Against PC only and POPC:POPG (Fig. 6A-B), there was a transition between 0.50 and 
1.00 µM from a two-step to a three-step interaction, where there was a “turn” in the data (green 
ii), followed by large decrease in viscoelasticity back to that of the original bilayer (green iii). The 
three-step processes were the same shape for PC and POPC:POPG bilayers, suggesting that charge 
did not influence the overall interaction mechanism, which has been observed before for other 
charged membrane-spanning proteins [58]. Overall, there were higher ΔD and Δf magnitudes 
increased spacing between adjacent points against POPC:POPG and DMPC:DMPG compared to 
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PC bilayers (Fig. 6B-C vs. Fig. 6A), suggesting that charge influenced other aspects of the 
interaction such as number of peptides involved, orientation and interaction speed. All signatures 
at 1.00 µM (green), ended with a ΔD higher than the starting ΔD. This could indicate a viscoelastic 
state on the bilayers at this concentration important for antimicrobial activity, since it correlates 
with the transition between wound healing and antimicrobial concentration ranges for LL37 [46]. 
Against saturated DMPC:DMPG bilayers (Fig. 6C), cCBD-LL37 demonstrated rapid 
adsorption at all concentrations (green i). At both 0.50 and 1.00 µM, process (i) was followed by 
a “twist”, where relatively slower mass loss (+Δf) and -ΔD occurred (ii) prior to continued 
viscoelastic adsorption at a slower pace (iii). This “twist” also occurred for LL37 against 
DMPC:DMPG, but at higher ΔD (Fig. S8B). 
The “twist” pattern was not observed by Shahmiri et al. at 1.00 µM, who investigated LL37 
interactions with DMPC:DMPG bilayers on gold sensor crystals [48]. It is possible that either 
LL37 or DMPC:DMPG interact differently with gold and SiO2, propagating different interactions. 
3.3.3. cCBD-LL37 thickness demonstrated peaks in thickness with time that were different sizes 
depending on the bilayer composition and peptide concentration 
For cCBD-LL37, it was clear from Section 3.3.2 that with concentration and bilayer type, 
rapid and transient interactions play a major role in determining its bilayer interactions. Thus, we 
further explored the influence of interaction time on thickness (Fig. 7). At low concentrations, 
thickness increased gradually until reaching an equilibrium within 10 min, 0.10-1.00 µM vs. PC 
only (Fig. 7A), 0.25-0.50 µM vs. POPC:POPG (Fig. 7B) and 0.25 µM vs. DMPC:DMPG (Fig. 
7C). This reflects a buildup of cCBD-LL37 molecules on the bilayer surface up to 2 nm. If 
arranged parallel to the bilayer plane, this would be too thick for a single helix (1.1 nm); however, 
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may account for a cCBD domain of 2.2 nm (Chapter 5). Two charged residues in cCBD (two 
lysine residues) at its C-terminus may prevent the ability for cCBD-LL37 to traverse membranes. 
This inability may lead to a surface where cCBD domains remain on the outer portion of the bilayer 
in a perpendicular orientation, which has been shown before in domains containing adjacent 
charged arginine residues [58]. If this were the case, the length of the LL37 portion of cCBD-LL37 
would still allow pore formation, as it is a sufficient length to span a membrane. 
In contrast, LL37 demonstrated considerably smaller thickness with time profiles (small 
peaks with a maximum of 1 nm) against POPC:POPG (Fig. S9A), further supporting the 
possibility of cCBD contributing to the relatively larger thicknesses observed for cCBD-LL37. 
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Figure 7: Changes in film thickness with time due to cCBD-LL37-bilayer interactions. 
Representative profiles of thickness (nm) versus time at different concentrations of cCBD-LL37 
(ranging from 0.10 – 20.0 µM) against A, PC only, B, 4:1 POPC:POPG and C, DMPC:DMPG 
bilayers.  
 
At high concentrations, peaks appeared in the cCBD-LL37 thickness versus time profiles, 
consistent with Δf vs. time profiles which were most pronounced on charged POPC:POPG 
bilayers. Two different peaks were observed during cCBD-LL37 interaction with only PC bilayers 
upon close examination of the profiles at 2.00, 5.00 and 10.0 µM (Fig. 7A) but were not observed 
for LL37 (Chapter 6) which suggests that they are a consequence of cCBD present in a zwitterionic 
bilayer environment. Interestingly, the peak at 1.00 µM cCBD-LL37 against DMPC:DMPG 
similar in magnitude and rate to its profile at 5.00 and 10.0 µM versus POPC:POPG (Fig. 7C vs. 
Fig. 7B). Against DMPC:DMPG, LL37 rapidly (within ~2 min) caused a small peak in thickness 
at 0.25 and 1.00 µM (Fig. S9B), suggesting that the interaction of cCBD-LL37 and LL37 against 
saturated membranes were very similar.  
By 20.0 µM, no replicates of cCBD-LL37 demonstrated two peaks in thickness against PC. 
This may reflect another mechanistic phenomenon that occurred at concentrations that reflect the 
cytotoxicity of cCBD-LL37 (>10 µM [25]), for example, the collapse of a proteolipid film on the 
sensor crystal surface due to a very high density of cCBD-LL37. 
3.3.4. cCBD-LL37 local peaks in thickness and frequency reveal a better fit with predicted ΔfMIN 
for pore formation and a different influence of interaction time with bilayer charge 
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We further investigated the observed peak thickness and Δf values caused by cCBD-LL37 
against PC and POPC:POPG bilayers (Fig. 8), since for LL37 we recently found that bilayer 
saturation demonstrated by these peaks was a threshold for pore formation (Chapter 6). The peak 
thickness and peak frequency (denoted ΔfP) magnitudes did not correlate with concentration 
against any bilayer (Fig. 8A-B). ΔfP remained relatively constant at concentrations higher than 
1.00 µM at -10 Hz and -17 Hz versus PC and POPC:POPG, respectively. If these values were 
instead used as the observed Δf to compare predictions of ΔfMIN associated with water-filled pore 
formation they provide a more realistic fit of 13 and 8 peptides per pore. Indeed, other pore-
forming AMPs, (e.g. Melittin, Magainin 2, Protegrin, Alamethicin) form pores comprising of 4-7 
peptides [45]. Using neutron in-plane scattering, Lee et al. estimated 5 LL37 peptides per toroidal 
pore [52]. 
The observed ΔfP of -10 and -17 Hz versus PC and POPC:POPG correspond to 1.33x1013 
and 2.26x1013 cCBD-LL37 molecules on each bilayer, respectively. These numbers are 
approximately 1.5x and 2.6x higher than the required number of cCBD-LL37 molecules needed 
for bilayer saturation (8.7x1012), respectively. This could have occurred for several reasons. First, 
one may expect multiple peptides would be required to self-assemble prior to forming pores, which 
would increase the number of surface-associated cCBD-LL37. Second, the reduced amphiphilicity 
(µH) of cCBD-LL37 compared with LL37 would reduce the propensity for monomeric cCBD-
LL37 to traverse lipid hydrophobic cores without oligomerization; however, this would have a 
higher effect on the interactions with zwitterionic PC [59]. Third, the FLAG domain within cCBD 
has a high density of negative charges produced by glutamic acid residues. This, particularly in 
the case of POPC:POPG bilayers would render some electrostatic repulsion, which would in turn 
require higher µH to overcome. If FLAGs were repelled and assumed perpendicular orientation to 
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the bilayer (corresponds to the 2.8 nm thickness in Fig. 5) and the LL37 portions of cCBD-LL37 
were adsorbed with parallel orientation to the bilayer, then the number of molecules required for 
bilayer saturation the bilayers would instead be 1.2x1013 cCBD-LL37 molecules, an improved fit 
of ΔfP. Indeed, MD simulations demonstrated that the combination of FLAG and cCBD caused an 
overall “W-like” kinked shape of cCBD-LL37 in water (Chapter 5) which may drive unique 
conformations on the bilayer compared with LL37. 
 
Figure 8: Analyses of cCBD-LL37 peak values and interaction times with PC only and 
POPC:POPG bilayers. A, Peak thicknesses (nm) and B, local minima in Δf (Hz) and C, time to 
reach equilibrium thickness (s) and D, time to reach local minima in Δf (s) all versus concentration 
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(µM) of cCBD-LL37 against PC only (circles) and POPC:POPG (triangles) bilayers. All values 
represent mean ± S.E. of n>4 replicates. 
While bilayer charge did not alter the overall interaction mechanism of cCBD-LL37, it did 
appear to modulate the time required to reach an equilibrium, defined as the time to achieve 
unchanging thickness (Fig. 8C) and the time to reach ΔfP (Fig. 8D), both of which were more rapid 
against POPC:POPG than against PC. Both of the times appeared linearly correlated (log-log plot) 
with concentration against POPC:POPG; however, against PC there was an abrupt drop in time to 
reach equilibrium between 2.00-5.00 µM (Fig. 8C) and time to reach ΔfP between 1.00-2.00 µM 
(Fig. 8D).  
 
3.4. Time- and concentration-dependence of the fCBD-LL37 interactions with different 
bilayers 
We hypothesized that the properties of fCBD caused an inability of fCBD-LL37 to 
permeate membranes and instead, left a “carpet-like” layer of peptides adsorbed to the bilayer 
surface. However, the mismatch of experimental Δf and ΔfMIN predictions for surface association 
suggests that there were additional influences in the bilayer interactions of fCBD-LL37. To 
determine what these influences were, we first used Voigt-Kelvin modeling for thickness and 
density and then investigated the dependence of QCM-D and model parameters with time on 
different bilayers. 
3.4.1. Overall thickness and density changes with fCBD-LL37 concentration were affected by 
bilayer composition 
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We first modeled the overall thickness (Fig. 9) and calculated overall density (Fig. 10) 
changes induced in the different bilayers with fCBD-LL37 concentration. Over PC and 
POPC:POPG, thickness increased with concentration starting at 1.00 µM (Fig. 9A), while there 
was thinning observed with fCBD-LL37 concentration on saturated DMPC:DMPG bilayers (Fig. 
9B). The thickness of fCBD-LL37 layers physically adsorbed onto the SiO2 sensor crystals also 
increased with concentration, up to 15.5 and 11.2 nm at 10.0 µM in MOPS and Tris buffers, 
respectively (Fig. 9C). This corresponds to the thickness at 10.0 µM fCBD-LL37 on PC (11.4 nm 
above the bilayer original thickness), but not with POPC:POPG (20.5 nm above the bilayer original 
thickness). Based on these results, it is possible that fCBD-LL37 had the same affinity for SiO2 
and zwitterionic PC, but a stronger, charge-facilitated affinity for POPC:POPG. 
 
Figure 9: Thickness changes as a function of fCBD-LL37 concentration against different 
bilayer compositions. The overall changes in modeled thickness (nm) versus fCBD-LL37 
concentration (µM) versus A, PC only and 4:1 POPC:POPG bilayers and B, 4:1 DMPC:DMPG 
bilayers. C, for comparison, the thickness of fCBD-LL37 at different concentrations physically 
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adsorbed onto SiO2 sensor crystals. Each original bilayer thickness and density values are 
represented by dotted lines; in (A) only PC (7.43 nm) is shown; note that POPC:POPG is 6.48 nm 
thick. All values represent mean ± S.E. of n>4 replicates. 
The calculated density changes against the three different bilayers reflected much of what 
was observed with the overall thickness data (Fig. 10). Against PC and POPC:POPG, the bilayers 
became more dense at the surface versus further within the bilayer at concentrations greater than 
1.00 µM, as represented by the higher magnitudes of the 3rd vs. 11th overtones (Fig. 10A-B). 
However, the density appeared to have a predictable trend with concentration, whereas it did not 
appear to have a trend against POPC:POPG. This is reflected in the relatively lower density 
observed at 5.00 µM compared to both 2.00 and 10.0 µM of fCBD-LL37 against POPC:POPG. 
Despite this, the density at higher penetration depths (e.g. 11th overtone) was higher against 
POPC:POPG than PC only. Against saturated DMPC:DMPG, density decreased with increased 
concentration and there was no significant effects between the 3rd and 11th overtones (Fig. 10C). 
Thus, fCBD-LL37 strongly effected the density of charged membranes compared to cCBD-LL37, 
depending on both charge and saturation. 
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Figure 10: Density changes as a function of fCBD-LL37 concentration against different 
bilayer compositions. The calculated density (kg/m3) at the 3rd (purple) and 11th (orange) 
overtones versus fCBD-LL37 concentration (µM) against A, PC only, B, 4:1 POPC:POPG and C, 
4:1 DMPC:DMPG bilayers. Dotted lines represent each original bilayer thickness and density 
values. All values represent mean ± S.E. of n>4 replicates. 
 
3.4.2. Molecular signatures of fCBD-LL37 demonstrated single-step adsorption on zwitterionic 
lipids but two-step dynamic adsorption on charged lipids 
As expected, the ΔD vs. Δf molecular signatures for fCBD-LL37 demonstrated continuous 
mass adsorption and increased viscoelasticity (-Δf, +ΔD), but interestingly, it occurred at different 
rates depending on both bilayer composition and peptide concentration (Fig. 11). In addition to 
having much more adsorption on POPC:POPG, there was a noticeably faster “first” mass 
adsorption process against POPC:POPG (blue i), followed by a “second” slower mass adsorption 
(blue ii) that was not observed for PC (inset; Fig. 11A-B). A similar two-step process was also 
observed on DMPC:DMPG (green i and ii in Fig. 11C), suggesting that the appearance of a slower 
second adsorption step was charge-dependent for fCBD-LL37. 
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Figure 11: Dynamics of fCBD-LL37 interactions with different bilayers. Representative ΔD 
vs. Δf plots of fCBD-LL37 at concentrations ranging from 0.25 – 10.0 µM against A, PC only, B, 
4:1 POPC:POPG and C, 4:1 DMPC:DMPG bilayers. Numbered and colored arrows indicate the 
progression of membrane interactions with time, and “R” represents the processes associated with 
the final buffer rinse. For simplicity, plots of the 3rd overtones only are presented; all overtones 
demonstrated similar ΔD vs. Δf signatures. 
 
For all peptides at all concentrations against both bilayer types, the final buffer rinse (R) 
demonstrated decreased viscoelasticity (-ΔD), suggesting that adsorbed fCBD-LL37 may alter 
bilayer order during the rinse. For all two-step mechanisms vs. charged bilayers, mass loss (+Δf) 
also occurred during the rinse (R), indicting some reversibility of binding, possibly due to 
electrostatic repulsion of the negatively charged fCBD with the negative charges of PG lipids.  
An interesting observation was that the maximum ΔD achieved for fCBD-LL37 was 10E-
06 for both PC and POPC:POPG bilayers at 10.0 µM. When fCBD-LL37 was physically adsorbed 
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onto SiO2 sensor crystals at 10 µM, the maximum ΔD achieved was 3E-06 in Tris buffer (PC 
bilayer buffer, Fig. S10B) and 6E-06 in MOPs buffer (POPC:POPG buffer, Fig. S10A). This 
suggests that the observed ΔD on PC is primarily due to its interaction with the bilayer itself, but 
most of the observed ΔD on POPC:POPG is due to fCBD-LL37 self-association and solvent 
interactions [57]. This suggests that fCBD-LL37 has a different propensity for self-association and 
interaction with buffers of different ionic strengths than both cCBD-LL37 and LL37, driven by 
the fCBD domain. 
 
3.4.3. The speed of fCBD-LL37 adsorption depends the number of fCBD-LL37 on the bilayer 
We wondered why two of the same mechanistic processes would happen at different rates 
against charged membranes, and postulated that the rate of each process was determined by the 
number of fCBD-LL37 adsorbed onto the bilayers at any particular time. Thus, we looked closer 
at the changes in Δf (Fig. 2B) and in modeled thickness (Fig. S11) versus time against 
POPC:POPG and PC only, and realized that they appeared to have different slopes at different 
times at high concentrations only (2.00 – 10.0 µM), which are not apparent at first glance.  
Thus, we overlaid thickness (Fig. 12A-B) and Δf (Fig. 12C-D) versus time responses of 
SiO2 adsorbed (solid line) versus bilayer adsorbed (dotted line) fCBD-LL37 at 10.0 µM for 
zwitterionic PC and charged POPC:POPG. When overlaid, it is clear that in MOPS 
7.0/POPC:POPG bilayers, there is nearly perfect overlap in the rapid “first” mass adsorption which 
does not occur in Tris 7.8/PC only bilayers, in both thickness and Δf. We also noticed that the 
separation of MOPS 7.0/POPC:POPG profiles consistently occurred at -7.5 Hz, which 
corresponded to 9.51x1012 molecules on the surface. This is very similar to the estimated bilayer 
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saturation for fCBD-LL37, 9.43x1012 molecules. This suggests that rapid bilayer saturation is a 
mechanistic process on charged bilayers, but does not occur on zwitterionic bilayers. Since this 
saturation occurred at concentrations where fCBD-LL37 is antimicrobial, this saturation may be 
required for fCBD-LL37 to kill bacteria. 
 
Figure 12: Comparison of physically adsorbed and bilayer adsorbed fCBD-LL37 peptides. 
Representative A-B, thickness (nm) and C-D, Δf (Hz) versus time of fCBD-LL37 peptides at 10.0 
µM when physically adsorbed onto SiO2 (solid lines) and when adsorbed onto a bilayer (dashed 
line), in (A,C) MOPS 7.0 and (B,D) Tris 7.8 buffers. MOPS 7.0 and Tris 7.8 buffers are used for 
making POPC:POPG and PC only bilayers, respectively. 
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3.5. Proposed mechanisms and the influence of intrinsic CBD properties on bilayer 
interactions 
3.5.1. Proposed mechanisms of cCBD-LL37 and fCBD-LL37 versus zwitterionic and charged 
bilayers 
The results for both concentration- and time-dependent properties for cCBD-LL37 
(Section 3.3) and fCBD-LL37 (Section 3.4) led us to propose interaction mechanisms for cCBD-
LL37 (Fig. 13A) and fCBD-LL37 (Fig. 13B) driven by the presence of different CBD domains 
and lipid types. For both peptides, the first step (I) involved bilayer surface adsorption driven by 
the LL37 portion of each molecule. The negatively charged FLAG domain contributed to 
electrostatic repulsion of both CBDs, particularly against anionic charged membranes. In the case 
of cCBD; however, positively charged cCBD compensated for this repulsion, while the negative 
charges in fCBD domain contributed to it. 
The bioactivity and structural similarities between LL37 and cCBD-LL37 led us to propose 
a similar, pore formation interaction for cCBD-LL37. Adsorption onto the bilayers to 
approximately double bilayer saturation led to a threshold “exchange” event at concentrations 
higher than 1.00 µM, where the lipid film transitioned from being primarily lipid to a proteolipid 
film with cCBD-LL37-lined transmembrane pores, which occurred faster and at a lower 
concentration on charged versus zwitterionic bilayers (II). We did question whether the film was 
comprised of proteolipids or just protein (e.g. the peptides caused complete bilayer removal). 
However, we recently visualized fluorescent PC and POPC:POPG lipid bilayers after their 
interactions with cCBD-LL37 at high concentrations, and determined that lipids remained on the 
sensor crystal surface (Chapter 5). We postulated mechanistic reasons behind why the time of 
cCBD-LL37 interactions correlated differently with concentration against charged versus 
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uncharged membranes at high concentrations (e.g. linear vs. piecewise, respectively, Fig. 8). From 
the data on thickness against PC only, it appeared that cCBD-LL37 re-oriented perpendicular to 
the bilayer for insertion, which only occurred after re-orientation of a threshold number of peptides. 
On POPC:POPG, re-orientation occurred to some degree, but perpendicular orientation was not a 
requirement. We envision the pore formation of cCBD-LL37 on charged membranes similar to a 
time-dependent curling intercalation within the lipids. Further studies would be required to 
determine the orientation of FLAG during (II); however, its negative charges may contribute to 
electrostatic repulsion in the case of anionic bilayers. After the initial time-dependent lipid 
insertion at high concentration, cCBD-LL37 contributed to stable transmembrane pore formation 
with distribution of charged residues at the N-terminus and cCBD anchored to the polar parts of 
the bilayer (III). Further peptide adsorption led to collapse of the proteolipid film at the highest 
concentrations, where cCBD-LL37 trapped some lipids on the surface (also demonstrated with 
fluorescent imaging, Chapter 5) while interacting with the SiO2 sensor crystals (IV).  
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Figure 13: Proposed interaction mechanisms of CBD-LL37 peptides with different bilayers 
at different concentrations. The proposed mechanism of A, cCBD-LL37 involved surface 
adsorption (I) and peptide re-orientation (II) followed by the rapid transition into transmembrane 
pore formation (III) and equilibration as a rigid proteolipid film adsorbed onto SiO2 (IV). The 
proposed mechanism of B, fCBD-LL37 involved surface adsorption (I), bilayer saturation (II) and 
slow buildup of surface-adsorbed peptides (III). In the case of POPC:POPG, bilayer saturation 
occurred rapidly (dotted arrow). 
 
In contrast to cCBD-LL37, interactions of fCBD-LL37 began with adsorption at low 
concentrations (I), followed by continued adsorption. Against zwitterionic PC, membrane thinning 
at low concentrations suggested some interaction with polar head groups of the lipids (II). Against 
POPC:POPG, rapid bilayer saturation (II) was a threshold for allowing continued adsorption with 
time and concentration. In the case of PC, adsorption and increased viscoelasticity suggest that 
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relatively strong interactions between fCBD-LL37, polar lipid head groups and possibly the lipid 
hydrophobic core occurred, while against POPC:POPG, the lower viscoelasticity similar to that of 
physically adsorbed fCBD-LL37 on SiO2 indicate that peptide-peptide and peptide-solvent 
interactions were more prominent (III). We found that in contrast to cCBD-LL37 and LL37, the 
binding strength of fCBD-LL37 on SiO2 increased with pH, as indicated by decreasing binding 
constant (KD) (Fig. S12). This correlates with the different adsorption behaviors on PC versus 
POPC:POPG bilayers, which are formed at different ionic strengths. 
3.5.2. Implications for the design of novel CBD-LL37 sequences 
By adding short cCBD and fCBD sequences onto the C-terminus of LL37 for collagen-
tethering purposes, we created unintentional – and even surprising – effects on not only tethered 
CBD-LL37 [25], but also soluble CBD-LL37 leading to very different bioactivities and 
mechanisms (Fig. 13). We wondered which particular residues or physicochemical features of 
each CBD were primarily responsible for the observed mechanistic differences, and whether that 
information could allow the development of a structure-function relationship of CBD-mediated 
changes in LL37 bioactivity. Such a relation could be used to predict bioactivity and bilayer 
interactions of hypothetical CBD-LL37 based on other known sequences, and would be crucial in 
the further development of CBD-mediated tethering as a platform. To test this we designed two 
novel CBD-LL37 with CBDs derived from fibromodulin (fmCBD-LL37 [60]) and Von Willebrand 
Factor (vCBD-LL37 [61]). The projected physicochemical properties of all CBD-LL37 are listed 
in Table 1 to identify property and structural trends. 
 
 
254 
 
Table 1: Sequence and physicochemical characteristics of various CBD-LL37 
 
aLL37 sequence and properties provided in row 1 for comparison; bCharge at pH 7.0 estimated 
with Heliquest [62]; cHydrophobicity, on the Liu-Deber scale [63], dHydrophobic moment (µH) 
was calculated with Heliquest [62]; eHelicity was estimated using AGADIR [64, 65] rather than 
helical propensities (Pα). Pα estimated using Liu-Deber scale [63] were nearly identical for all 
CBD peptides; fThe 19-residue hydrophobic face of the molecule was estimated using Heliquest 
[62] and helical wheel diagrams and its hydrophobicity was reported using Liu-Deber [63]. 
 
Charge allows for faster interactions with anionic lipids and antimicrobial activity, which 
explains the rapid interactions of cCBD-LL37 (+6) and LL37 (+6) with charged lipids [54]. Charge 
distribution is also important for electrostatic interactions. Though the overall charge of fCBD is 
+2 which facilitated its initial electrostatic adsorption onto bilayers, the domain itself is -4; the 
high density of negative charge at the C-terminus may explain different affinities observed of 
fCBD-LL37 for solvent and other fCBD-LL37 rather than bilayers. Though fCBD-LL37 was 
relatively less antimicrobial than cCBD-LL37 and LL37, it was less specific toward Gram-positive 
vs. Gram-negative bacteria [25], suggesting that the charge density in fCBD-LL37 also affects its 
specificity toward different membranes. Both of the hypothetical peptides have positive charge 
higher than fCBD-LL37; thus, we predict they would both electrostatically adsorb onto charged 
255 
 
bilayers. The charge distribution in fmCBD-LL37 is interesting with two KR residues in its 
sequence, which may facilitate a higher specificity toward Gram-negative bacteria, similar to 
cCBD-LL37. 
Liu and Deber identified a threshold hydrophobicity (H) of 0.4 and a threshold length of 
~18-19 residues, above which a large percent of helical peptides formed transmembrane pores [63, 
66]. We observed that both cCBD- and fCBD-LL37 are helical in a lipid environment (Chapter 
5); however, they demonstrate H below the threshold. For peptides below the threshold, helicity 
and charge become more important for pore formation [67]. This is the case for LL37, which forms 
transmembrane pores based on literature reports [2] and our previous studies (Chapter 6) with a 
charge of +6 and helicity of 6.83. cCBD-LL37 has the same change and an even higher helicity of 
7.08. However, the combination of a low charge and low helicity (4.93) for fCBD-LL37 did not 
allow for pore formation. Both fmCBD- and vCBD-LL37 are below the threshold H; the relatively 
high helicity and charge of fmCBD-LL37 may allow it to permeate bilayers. Indeed, Chrysophsin-
3 forms pores in membranes with only +3 charge and helicity of 5.91 [31], both of which are lower 
than properties of fmCBD-LL37. The question of which portion of the molecules drives insertion, 
may be answered by the observation that all CBD-LL37 peptides have a similar hydrophobic face, 
comprised of residues from the LL37 portion of the molecule. This suggests that the LL37 portion 
of the all of the CBDs, despite having a long enough sequence to permeate bilayers on their own 
(~18-19 residues), would drive insertion. 
Amphiphilicity (µH) is critical for the cytotoxic action (or, interactions with zwitterionic 
bilayers) of helical peptides [59, 68]. Both LL37 and cCBD-LL37 demonstrated cytotoxicity at 
concentrations >10 µM [25], which correlates well with their high µH. In contrast, fCBD-, fmCBD- 
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and vCBD-LL37 all have lower, similar µH, which would demonstrate lower cytotoxicity (which 
is true in vitro for fCBD-LL37 [25]). 
Specific residues can also be highly influential toward mechanistic phenomena. For 
instance, the KK and KR clusters in cCBD and fmCBD would deter peptide-peptide interactions 
and strengthen bilayer-peptide electrostatic interactions, making them more antimicrobial [55, 66]. 
Cysteine in fCBD and vCBD would encourage dimerization, as observed before in other cysteine-
containing peptides [32, 69], which may also render them too large to permeate bilayers. Despite 
a high H in vCBD which supports pore formation, its proline residue would cause structural and 
helical disruption. Combined with a low µH, it unlikely that vCBD would be able to traverse 
bilayers [55, 59, 70]. Aromatic residues in fCBD and vCBD would be involved in bilayer anchoring 
important for adsorption-based mechanisms [56].  
No prediction for peptide mechanism could replace the validity of testing newly designed 
peptide bioactivities and membrane activities in vitro as we have done here and previously for 
cCBD-LL37 and fCBD-LL37. However, we postulate mechanisms for fmCBD- and vCBD-LL37 
based on the mechanistic findings and sequence properties of cCBD- and fCBD-LL37. We predict 
that fmCBD-LL37 would be able to adsorb preferentially to charged membranes and form 
transmembrane pores, similar to cCBD-LL37; however, at a slower rate than cCBD-LL37 given 
its lower H and µH [71]. In contrast, vCBD would be unable to fully permeate bilayers to fCBD-
LL37; however, its higher charge, µH and H compared to fCBD-LL37 would allow more intimate 
interactions with lipid head groups into the bilayer hydrophobic core, more reflective of a “sinking 
raft” mechanism [56]. Based on these mechanisms and physicochemical properties, fmCBD- and 
vCBD-LL37 would not be as effective against bacteria as cCBD-LL37 but most importantly would 
be less cytotoxic than cCBD-LL37.  
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4. Conclusions 
In this study, we determined the time- and concentration-dependent interactions of cCBD-
LL37 and fCBD-LL37 with different lipid bilayers using QCM-D and Voigt-Kelvin modeling, and 
determined how these interactions were modulated by CBD sequence properties. We found that 
similar to LL37, cCBD-LL37 had similar time- and concentration-dependent interactions with all 
of the bilayers, but its interactions were more rapid and involved different orientation preferences 
prior to insertion. fCBD-LL37 did not traverse bilayers due to its low charge and µH; instead, it 
rapidly saturated charged bilayers or slowly adsorbed onto zwitterionic bilayers, followed by self- 
and solvent-associations slowly with time and concentration. With this knowledge, we predicted 
the interactions of two newly designed chimeric LL37.  
Typically, chimera designed for reducing AMP cytotoxicity minimize the overall changes 
to sequence and length to avoid excess peptide synthesis costs. However, our studies demonstrate 
that the addition of longer sequences such as CBDs may also exhibit the desired effects on 
bioactivity. The ability to predict new sequence structure-function relationships greatly broadens 
the potential impact of not only CBD-mediated collagen tethering to other CBDs, but also the idea 
of using other binding domains to mediate tethering onto other biopolymers. With new ways to 
predict the effects of different CBDs on LL37 bioactivities by linking structure, sequence, and 
both concentration- and time-dependent function, CBD-LL37 can be designed as a platform 
toward not only reducing infection of chronic wounds, but also toward developing new, non-
cytotoxic and stable alternative antimicrobial therapies. 
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Chapter 8 
 
 
Future Directions 
 
Part I: Introduction and Overview 
Part II data is in preparation for publication. 
Part III is under investigation. 
Part IV: A Discussion of Future Directions 
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Future Directions 
Part I 
Introduction and Overview 
The studies in this thesis serve as the foundation for development of a new platform 
technology that enables the delivery of non-cytotoxic antimicrobial alternatives to chronic wounds 
to promote healing without promoting resistance. The results from this thesis open a wide number 
of future studies that could be pursued to better understand and develop this platform. 
Two major knowledge gaps regarding collagen tethering of CBD-LL37 are most urgent to 
address in future work, which are described in detail below. First, studies to quantitatively 
determine CBD-LL37 loading concentrations on collagen substrates must be performed to 
optimize clinical application of CBD-LL37 on collagen-based wound dressings. Second, reducing 
the costs of producing long, custom peptides such as cCBD-LL37 and fCBD-LL37 is crucial for 
both fundamental and clinical development of CBD-based peptide therapeutics.  
The development of a collagen substrate and method to study collagen-tethered 
antimicrobial peptide binding and activity is important for optimizing loading 
concentrations and determining effective therapeutic doses. We propose the use of solubilized 
collagen type I films deposited on quartz crystal sensors in QCM-D as substrates for studying the 
concentration-dependent tethering and orientation of CBD-LL37 peptides. In this section, we 
describe the viscoelastic deposition of collagen type I at different concentrations over silicon 
dioxide (SiO2) or gold (Au) substrates and present a technique for the quantitative study of peptide 
binding onto these collagen films. Then, we propose a method for determining antimicrobial 
activity of the collagen-tethered peptides. Successful development of this QCM-D-based method 
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will allow accurate quantification of effective CBD-LL37 loading concentrations, which will be 
required for their cost-effective tethering and clinical implementation. Preliminary results are 
described in Part II. 
Costs of peptide production may decrease with the design and implementation of a 
new CBD-LL37 production method, based on recombinant production in a mammalian-
based expression system. We propose the development of a recombinant system for the 
expression of full-length LL37 precursor (hCAP-18) and production of cleaved and active CBD-
LL37 in mammalian cells. Here, we provide a preliminary description of the design and 
verification of recombinant CBD-LL37 expressed in human lung carcinoma cells, and present data 
that suggests the proper cleavage of bioactive CBD-LL37. Recombinant expression of CBD-LL37 
may provide a more cost-efficient production method, and demonstrates promise toward making 
inherently antimicrobial, pro-healing wound scaffolds with cells expressing CBD-LL37 peptides. 
Preliminary findings are described in Part III. 
 The results within this thesis also catalyzed questions and new discussion toward future 
studies of CBD-mediated collagen tethering of LL37. These future directions, along with short 
discussions guided by the thesis review committee are presented in Part IV. 
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Part II 
Development of a collagen substrate and method to study collagen-tethered antimicrobial 
peptide binding and activity. 
Data in this section is in preparation for publication. 
Contributing Authors: L.D. Lozeau, E.B. Jayapurna, N.R. Bergstrom, C.J. Lujuo, A.G. Connor, 
M.F. Frare, M.W. Rolle, T.A. Camesano 
Collagen tethering of antimicrobial peptides (AMPs) using CBDs has demonstrated 
promise for delivering novel, non-cytotoxic, antimicrobial and pro-healing therapies to chronic 
wounds that will not promote bacterial resistance. Previously, we designed two chimeric versions 
of human-derived LL37 with C-terminal CBDs derived from collagenase (cCBD-LL37) and 
fibronectin (fCBD-LL37) and tested their binding, retention, antimicrobial activity and 
cytotoxicity on native 100% collagen type I scaffolds [1]. An interesting finding was that the 
peptides (including unmodified LL37) were antimicrobial but not cytotoxic when adsorbed onto 
collagen, despite being adsorbed at concentrations 30 times higher than the reported cytotoxic 
threshold of LL37, 13 µM [2]. The peptide loading concentrations were purely theoretical, 
rationalized based on the assumption of a 1:1 binding ratio of collagen monomers in the scaffold 
to collagenase binding domains [3]. However, we hypothesize that the optimized loading 
concentrations will depend on CBD affinity for collagen, peptide soluble bioactivities, scaffold 
composition and available binding sites, as well as other tethering parameters such as binding 
orientation [4], conformation [5] and surface charge density [6]. Unfortunately testing these 
parameters is a challenge, as there are no well-established techniques to quantify collagen tethering 
and activity of CBD-LL37. Previously, we found that QCM-D was a powerful technique for 
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measuring density and thickness of covalently tethered Chrysophsin-1, which allowed 
determination of binding orientation and antimicrobial mechanisms [7]. Thus, QCM-D may 
provide a sensitive platform to study CBD-LL37 tethering parameters and calculate loading 
concentrations for delivery on collagen-based biopolymer scaffolds. Our goal is to create a 
method to study CBD-LL37 collagen binding, retention, concentration, density, orientation 
and antimicrobial activity in QCM-D. Toward this goal, we: 
1. studied the concentration- and source-dependent viscoelastic deposition of collagen type I 
films onto SiO2 or Au substrates in QCM-D, 
2. quantified binding of cCBD-LL37, fCBD-LL37, and unmodified LL37 onto collagen, and 
3. developed a method to study ex situ antimicrobial activity of bound peptides. 
QCM-D is an acoustic flow technique designed to measure surface phenomena in films 
deposited on an oscillating piezoelectric quartz crystal sensor. Frequency (Δf) is inversely related 
to mass adsorption (decreased Δf indicates mass adsorption, increased Δf indicates mass loss), and 
dissipation (ΔD) is related to the viscoelastic property of the film (increased ΔD indicates a flexible 
film, decreased ΔD indicates a rigid film). The Δf and ΔD are measured along various overtones 
(3rd, 5th, 7th, 9th and 11th), which are multiples of the fundamental frequency, f0 = 5 MHz, and 
indicate phenomena that occur at different penetration depths in the film [8]. For example, low 
overtones indicate phenomena that occur closest to the bulk solution and high overtones indicate 
phenomena that occur deeper within the film. When a film is rigid (ΔD≈0), Δf is related to mass 
deposition using the Sauerbrey relation [9]. When ΔD is not zero, the viscoelastic character of the 
film must be accounted for, and more complex models such as Voigt-Kelvin must be used [10]. 
We postulated that QCM-D would be suitable for creating reproducible and homogeneous collagen 
type I films with a controlled number of binding sites to study CBD-LL37 tethering. 
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First, we studied the concentration- and substrate-dependent deposition of collagen in 
QCM-D, by flowing bovine hide type I collagen (Advanced BioMatrix, San Diego, CA) at 0.1 
mL/min from 0.001 to 1 mg/mL diluted in phosphate buffered saline, pH 7.4 (PBS) over SiO2 or 
Au crystal sensor substrates. With increasing concentration on both substrates, Δf decreased (Fig. 
1A) and ΔD increased (Fig. 1B) until reaching plateaus after 0.1 mg/mL. Overall, Δf and ΔD were 
much larger in magnitude on Au than SiO2. Thickness, modeled on Au using the Voigt-Kelvin 
Viscoelastic Extended model [10], also increased with concentration up to 0.1 mg/mL, reaching 
≈100 nm (Fig. 1C). On SiO2 (not shown), the film thickness at 0.1 mg/mL was ≈30 nm. Deposition 
on SiO2 also appeared dependent on the collagen source; although additional replicates are 
required to support this observation. Rat tail (BD Biosciences, Bedford, MA) and calf skin 
(SigmaAldrich, St. Louis, MO) collagen type I films demonstrated higher deposition (negative Δf) 
and viscoelasticity (increased ΔD) than bovine hide collagen (Fig. 1D). Interestingly, Δf for calf 
skin and rat tail collagen films were similar, but calf skin demonstrated higher ΔD. Higher ΔD 
could indicate a higher degree of swelling and hydration, which may influence CBD-LL37 
binding.  
Immunohistochemistry (IHC) of collagen-coated SiO2 films with anti-collagen antibody 
(Cat. No. MA1-26771; Invitrogen, Rockford IL) demonstrated fluorescent string-like structures 
that were most prevalent at 0.1 mg/mL (Fig. 1E). These structures may indicate that in the time 
tested, polymerization of the collagen films had begun. According to the manufacturer, the suitable 
amount of time for gelation of this collagen at pH 7.2-7.6 is 90 to 120 min. The time of a typical 
experiment (approximately 180 min) plus the time for IHC preparation is thus more than enough 
time for potential collagen gelation or polymerization in these samples. 
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Figure 1: Concentration-, substrate-, and source-dependent deposition of collagen type I 
films. The average Δf (A), ΔD (B) and film thickness (C) versus concentration (mg/mL) of bovine 
hide type I collagen deposited over SiO2 (circles) or Au (triangles) substrates. (D) Δf (left) and ΔD 
(right) at all overtones for different collagen sources, bovine hide (top), rat tail (middle) and calf 
skin (bottom). For A-C, values represent mean ± S.E. of n=4 replicates. Thickness on SiO2 is not 
shown in (C), since only 0.1 mg/mL was modeled in preliminary studies. For D, values represent 
responses from n=1 replicate. (E) Representative images of collagen at 0.01, 0.05 and 0.1 mg/mL 
on SiO2 compared with PBS only SiO2 visualized with anti-collagen antibodies; bar = 50 µm.  
 
 For studies on peptide binding, we chose films comprised of 0.1 mg/mL bovine hide 
collagen type I, due to the plateaus observed in ΔD, Δf and thickness (Fig. 1A-C) on SiO2, due to 
the overall lower viscoelasticity of collagen on SiO2. Future studies should focus on deposited 
films with appropriate number of binding sites compared to 3D scaffolds studied previously [1]. 
A full collagen tethering experiment (Fig. 2A) involved a number of steps in QCM-D, each 
separated with vertical dotted lines. First, collagen was deposited and rinsed at 0.1 mL/min. Then, 
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1% wt/vol bovine serum albumin (BSA) was introduced as a blocking agent to limit non-specific 
peptide adsorption onto SiO2. Collagen films were highly viscoelastic, demonstrated by high ΔD 
and separation of the individual overtones (Fig. 2B). For example, Δf at the 3rd overtone was 
significantly more negative than all other overtones, and separated from the 11th overtone by -40 
Hz. BSA had the opposite effect, where a large loss of mass (+Δf) was accompanied by an increase 
in film rigidity (-ΔD) (Fig. 2C). BSA may have introduced ionic gradients leading to film collapse, 
reflected by the large change in rigidity. The 3rd overtone reflected higher changes due to BSA 
overall, and by the end of the BSA step, the film was more homogeneous in terms of 
viscoelasticity, indicated by nearly overlapping overtones.  
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Figure 2: Studying CBD Peptide Binding in Real-Time with QCM-D. (A) Full representative 
peptide binding experiment in QCM-D, showing Δf (Hz; blue, primary y-axis) and ΔD (1E-06; 
red, secondary y-axis) at all overtones 3rd through 11th versus time (min), starting at 0 with collagen 
introduction, followed by BSA, peptide, and bacteria introduction, indicated by vertical dotted 
lines at 135, 170 and 270 min, respectively. The average Δf and ΔD versus overtone for (B) 
collagen deposition and (C) 1% BSA flow. (D) Representative Δf and ΔD versus time profiles 
starting at peptide flow for PBS buffer, LL37, cCBD-LL37 and fCBD-LL37 including a buffer 
rinse at approximately 45 min. (E) The average Δf and ΔD for PBS or peptide samples resulting 
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from E. coli introduction and incubation. (B-E) Plots for Δf and ΔD are on the top and bottom, 
respectively, and values represent mean ± S.E. of n=4 replicates. Statistical significance (one-way 
ANOVA, post-hoc Tukey test, p<0.05) is represented for an individual overtone versus **all other 
overtones, or *the 9th and 11th overtones, and for a sample versus ^all other samples or ^^other 
samples as indicated. 
 
Peptides (LL37, cCBD-LL37 or fCBD-LL37) at 5 µM or PBS buffer only were flown over 
the blocked collagen, incubated under static condition for 30 min, and rinsed with buffer (Fig. 2D). 
There was a clear decrease in Δf for all peptides versus PBS, indicating that LL37, cCBD-LL37, 
and fCBD-LL37 all adsorbed onto collagen, which corresponds with what we found previously 
[1]. Initially, fCBD-LL37 adsorbed the most onto collagen, but then demonstrated the highest mass 
loss with the buffer rinse. If binding is mediated by CBD, then we suspect this mass loss is due to 
the relatively weaker collagen affinity of fCBD (KD = 5 µM [11]) versus cCBD (KD = 0.3 µM 
[12]). A small decrease in ΔD indicates increased rigidity upon peptide introduction. A 
crosslinking effect of cationic peptides within biopolymers has been observed before [13]. Indeed, 
a mild electrostatic-mediated collagen crosslinking would cause the film to de-swell, increasing 
its rigidity. Future studies to quantify the thickness change during peptide addition will give useful 
information toward elucidating the structure and orientation of bound peptides [7]. In the final 
step, 1x106 colony forming units per mL (CFU/mL) Escherichia coli were introduced and 
incubated for 1 hour to match the time of peptide exposure on 3D scaffolds [1, 14]. The effect of 
bacteria on QCM-D responses was relatively small, with a slight adsorption over cCBD-LL37 and 
LL37, and slight mass loss for PBS and fCBD-LL37 (Fig. 2E). 
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To further quantify the number of peptides bound onto collagen, we used the 3rd overtone 
responses to calculate the adsorbed mass (Δm), number of molecules bound (NBOUND) and the 
percent of binding sites on the collagen film occupied by each peptide (Table 1). At 5 µM, none 
of the peptides fully saturated the available area on the crystal indicating that a monolayer of 
peptides were attached onto the surface. However, we estimated that 1.22x1012 binding sites were 
available on 0.1 mg/mL collagen, indicating that there were more peptides on the surface than 
binding sites available. ΔD during peptide introduction is close to 0; thus, Sauerbrey was used for 
calculations. In the future, Voigt-Kelvin modeling may help determine a more accurate adsorption. 
Then, different concentrations can be introduced to tune peptide surface binding, which can be 
translated to binding onto 3D surfaces. 
Table 1: Quantification of Peptide Collagen Binding for the 3rd Overtone. 
 
aThe number of peptides required to saturate the crystal geometrically, assuming molecular 
lengths modeled with Molecular Dynamics simulations; bMass estimated using Sauerbrey [9]; 
cEstimated number of binding sites available on 0.1 mg/mL collagen is 1.22x1012 molecules; dThe 
percentage of binding sites occupied by a peptide, assuming 1:1 ratio of peptide to collagen 
monomer available on the surface.  
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The last step was to develop an activity assay for studying antimicrobial action of the 
tethered peptides. In a different tethered peptide system, we used ex situ fluorescent imaging of 
the bacteria using LIVE/DEAD BacLight staining (LifeTechnologies, Carlsbad, CA) [7]; however, 
this kit produced a high signal to noise ratio on collagen substrates. Thus, we developed an ex situ 
method based on log reduction of viable colonies harvested from the surfaces (Fig. 3). The new ex 
situ method, was found to be more quantitative than imaging-based methods: 
1. After the full QCM-D experiment (Fig. 2A), carefully take the sensor crystals out of the 
QCM-D and place in a small Petri dish. Do not let the samples dry out; add 90 µL of PBS 
onto the surface (considered as an additional 10-fold dilution, as the sensor crystal holds a 
thin film of approximately 10 µL liquid when removed). 
2. Using a sterile cell scraper, gently scrape all materials from the surface of the sensor and 
mix with the added PBS. 
3. Dilute the scraped solution 100-fold, and then 10-fold in two different tubes. Ensure 
contents are well mixed. 
4. Spread 100 µL of each dilution onto an agar plate, and incubate at 37°C for 12-16 hours. 
Ensure at least three replicate plates per sample. 
5. After incubation, count the number of colonies on the plate and calculate the number of 
CFU/mL. 
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Figure 3: Assay for Determining Antimicrobial Activity of Collagen-Tethered CBD-LL37. 
After the QCM-D experiment, a sterile cell scraper is used to thoroughly remove the collagen film 
and tethered peptides (1), followed by serial dilution of the samples (2) and culture on an agar 
plate for 12-16 hours at 37°C (3). The last step is to count colonies to determine the concentration 
of bacteria for each sample. A significant reduction (*p<0.05) of CFU/mL was observed for 10 
µM LL37 and cCBD-LL37 samples compared to the PBS- and broth medium-only (GC) controls, 
y-axis spans 0 to 3E09 CFU/mL E. coli, one-way ANOVA and post-hoc Tukey test. 
 
Using this method we were able to determine a statistically significant reduction in 
CFU/mL E. coli after exposure to collagen films treated with 10 µM LL37 and cCBD-LL37 
compared to PBS over collagen and an ex situ GC of the original bacterial culture diluted directly 
in broth medium (Fig. 3). Future work at 5 µM, including fCBD-LL37, and against other bacterial 
strains will further assess proof-of-concept of using this method to determine activity.  
Results presented in Part II demonstrate proof-of-concept toward using QCM-D to better 
quantify peptide binding and activity when adsorbed to collagen surfaces. If successful, QCM-D 
studies will aid to optimize CBD- and concentration-dependent tethering of CBD-LL37 onto 
different collagen-based biopolymers substrates, provide insight into orientation and other 
tethering parameters and considerably advance development of collagen-tethered peptides as an 
antimicrobial surface technology.  
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Part III 
Design of a mammalian-based expression system for recombinant production of CBD-LL37. 
Contributions from the following report are derived from the following publications and authors: 
 [FIGURE 4A-B] Prifti, F. Fabrication of a Novel Matrix-Associating Antimicrobial Peptide 
for Enhanced Wound Healing (2013), WPI MQP Report [15]. 
Gasper, R., Miller, C.R. Localization, Concentration, and Antimicrobial Activity of Human 
Cathelicidin LL-37 from H1299 Human Lung Carcinoma Cells to be applied to Dermal Wound 
Healing (2013), WPI MQP Report [16]. 
 [FIGURE 4C, FIGURE 5] Preliminary antimicrobial work by Lozeau, L.D., Kole, D., 
Dominko, T., Camesano, T.A., Rolle, M.W. 
 Ongoing studies on a different recombinant method for studying recombinant production of 
CBD-LL37 (NSF STTR IIP 1660301) investigated by: Shendi, D.M., Rolle, M.W., and 
Zimber, M. 
Successful alternative antimicrobial therapies must have four major attributes for their 
successful clinical implementation: biocompatibility, broad antimicrobial activity, effective 
delivery strategy, and low costs. In this thesis, we have developed collagen-tethered AMPs as a 
potential strategy that achieves three of the four attributes: a unique delivery on collagen scaffolds, 
low cytotoxicity to human fibroblasts and retained antimicrobial activity. Unfortunately, the high 
cost of synthetic AMPs has severely hindered their clinical success. Cost reduction of AMPs is an 
active research area [17, 18]; one promising strategy is their recombinant production [19, 20]. 
Thus, our overall goal is to develop a recombinant expression system for producing CBD-
LL37 peptides toward reducing the costs of synthesis. We hypothesize that a mammalian-based 
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expression system will allow the simultaneous production of CBD-LL37 peptides with collagen 
and other extracellular matrix (ECM) materials that will enable the in situ biofabrication of 
inherently antimicrobial CBD-LL37-tethered, collagen-based scaffolds [21]. Preliminary testing 
of this hypothesis demonstrated: 
1. the design and verification of recombinant CBD-LL37 peptides in a mammalian expression 
system, and 
2. that recombinant CBD-LL37 peptides were antimicrobial. 
The cCBD-LL37 and fCBD-LL37 peptides were designed as the C-terminal part of the 
full-length cathelicidin hCAP-18 precursor sequence [22-25] to allow for expression in 
mammalian cells (Fig. 4A). cCBD- and fCBD-LL37 constructs were transformed into E. coli, 
validated with restriction assays, and then ligated to p3xFLAG-Myc-CMV-25 vectors, 
transformed into E. coli again, and transfected into H1299 human lung carcinoma cells (ATCC 
CRL-5803) [15]. The p3xFLAG was incorporated to aid in affinity purification [26]. The 
transfected cells did not appear morphologically different from wild type (WT) cells despite being 
cultured under 500 µg/mL G418 selection pressure (Fig. 4B).  
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Figure 4: Design of recombinant hCAP-18 in mammalian cells. (A) The full design and 
sequence of CBD-LL37 peptides, which includes 3xFLAG sequences for purification [26] and the 
cathelicidin hCAP-18 precursor [22, 27]: a signal peptide, conserved cathelin-like [28] domain, 
and active LL37 domain, and modified with CBDs from collagenase [12, 29] or fibronectin [11, 
30]. (B) The predicted cleaved and active CBD-LL37 peptide (C) Phase contrast images of 
transfected and WT H1299 human lung carcinoma cells at 40-50% confluence; bar = 10 µM. 
 
Two major questions of this system were (1) whether the correct proteins were expressed 
in the H1299 cells and (2) whether the recombinant inactive hCAP-18 was cleaved correctly by 
proteinase-3 [27] to produce full and active CBD-LL37. Evidence of expression and cleavage was 
observed with Western Blots [15, 16]. Because the AMP localization was not known, whole cell 
lysate (cellular contents but no media), soluble fractions (whole cells suspended in lysis buffer 
prior to mechanical lysis and centrifugation), conditioned media (CM), and trichloroacetic acid-
concentrated CM from WT cells were compared to CM from transfected cells with cCBD-LL37 
or fCBD-LL37. Bands demonstrated expression at two molecular weights. The first was at the 
expected full-length preprotein weight in lysed cell contents (~25 kDa), indicating preprotein 
synthesis [16]. The second was at a lower molecular weight in concentrated CM (~15 and 20 kDa 
for cCBD and fCBD respectively), suggesting extracellular cleavage into active CBD-LL37 [16]. 
To determine the antimicrobial activity of the proteins produced from the cultures, CM 
from transfected and WT cells was collected and purified. In this procedure, confluent cultures 
were aspirated, rinsed, and replaced with fresh media without G418 and without serum. Cells were 
grown for 12 hours after which media was collected. CM (5 mL) was FLAG affinity purified [26] 
with ANTI-FLAG M2 Affinity Gel and 3X FLAG Peptide (Sigma Aldrich) by D. Kole. Samples 
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were dialyzed overnight in PBS at 4°C before collection. Zone of inhibition (ZOI) tests, as utilized 
commonly for antibiotic susceptibility testing [31], were used to determine activity of the purified 
CM against E. coli (Fig. 5). In short, paper disks were soaked in CM and control solutions for 2 
hours and then dropped directly onto an agar plate coated with 1x106 CFU/mL E. coli in broth 
medium. Plates were incubated at 37°C for 12-16 hours to allow a lawn of bacteria to grow around 
the disks. ZOI diameters were measured to quantify activity. Purified cCBD-LL37 (Fig. 5A) and 
fCBD-LL37 (Fig. 5B) CM demonstrated similar ZOI as 100 µg/mL G418, demonstrating that 
active CBD peptides had been produced by transfected H1299 cells. Minimum inhibitory activity 
tests (data not shown) of cCBD-LL37 and fCBD-LL37 CM [32] also demonstrated inhibitory 
action against E. coli as well as S. aureus, P. aeruginosa and S. epidermidis strains over time. 
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Figure 5: Antimicrobial activity of recombinant CBD-LL37 peptides against E. coli. The 
average ZOI (~15 mm) produced by purified cCBD-LL37 CM (A) and fCBD-LL37 CM (B) 
compared with WT CM, 100 µg/mL G418, and PBS pH 7.4 and 4.0 (labeled “HCl”) controls. 
 
Results from this study demonstrate proof-of-concept toward utilizing a mammalian 
expression system to produce active and properly cleaved CBD-LL37 peptides from the hCAP-18 
precursor. Future studies to quantify the production, collagen-binding activity, cytotoxicity of 
recombinant CBD-LL37 peptides are needed to better understand its promise toward the cost-
efficient production of CBD-LL37. 
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Part IV 
A Discussion of Future Directions 
The fundamental design and study of collagen-tethered cCBD-LL37 and fCBD-LL37 for 
chronic wound healing applications described in this thesis has done just this, leading to a number 
of questions, discussion points, and future projects. The following is a short discussion, guided by 
questions from the review committee for this thesis, of future directions that will answer some of 
these questions and elicit even more.  
 For chronic wound applications, LL37’s ability to promote wound healing is a crucial 
differentiation over competing products such as silver. The multifaceted immunomodulatory 
activities of LL37 are well known [2, 33]. For example, it has chemoattractant properties [34], 
induces fibroblast proliferation and migration [2], binds and neutralizes endotoxin [34], contributes 
to signal transduction involved in wound healing [33] and upregulates many important genes 
involved in immunomodulatory pathways [35]. We briefly investigated this ability in soluble 
cCBD-LL37 and fCBD-LL37 using a scratch assay in CRL-2352 fibroblasts, where a single 
scratch was made with a pipette tip over a confluent layer of cells [36]. Then, the cells were 
exposed to synthetic and recombinant versions of each peptide and the time to scratch closure was 
measured over time with phase contrast imaging [36]. Preliminary results indicated that neither 
cCBD-LL37 nor fCBD-LL37 had significant influence over the time it took for the scratch to heal 
compared with unmodified LL37, but further studies would need to be implemented [37]. As for 
collagen-tethered CBD-LL37, cell infiltration with time was qualitatively observed on PURACOL 
(Chapter 3) and FIBRACOL (Chapter 4) scaffolds during cytotoxicity studies. From these results, 
it appeared that scaffolds loaded with fCBD-LL37 may have had increased infiltration of cells both 
in cell number and depth into the scaffold, particularly at longer time points on FIBRACOL (7 
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days). Future studies should be specifically designed to study immunomodulatory function, using 
common in vitro methods such as immunocytochemistry (ICC) in immune cells (e.g. 
macrophages). Alternatively, proliferation markers may also be studied with ICC. Cell infiltration 
studies should be designed to be quantitative, and over longer periods of time. In vivo assays are 
also common for studying wound healing [12, 38], and are currently under investigation (NSF IIP 
1660301). Together, the effect of CBD addition on soluble peptide immunomodulatory actions 
and mechanisms by which collagen tethered CBD-LL37 peptides impart immunomodulatory 
actions are vastly important for creating clinically relevant wound healing therapeutics.  
The addition of sequences such as CBDs onto AMPs is very rare, given the substantially 
increased cost of peptide synthesis that comes with additional amino acids, as discussed in Part 
III. Thus, all studies of CBD-LL37, regardless of tethering them onto collagen, propagated new 
discoveries throughout this thesis. Elucidating a relationship between primary amino acid 
sequence and soluble mechanisms of AMP antimicrobial activity and cytotoxicity (discussed in 
Chapters 5-7), would be a “holy grail” in advancing AMP development and studies of added 
sequences. Many databases attempt sequence-structure-function predictions of AMPs, but are still 
incomplete. This is likely due to the immense variation in studies on peptide structure-function, 
which have led to contrasting results for even the most well-known AMPs, such as the mechanisms 
of LL37 interactions with lipid bilayers (Chapter 6). In the case of tethered AMPs, such databases 
do not exist.  
Unfortunately, studies on the mechanisms of tethered AMPs is filled with contradictions 
and debate, and rules for designing tethered AMPs with certain structure-function relationships are 
lacking. Further, most studies involve covalent rather than non-covalent tethering methods. No 
systematic strategies have been developed to study several different tethering parameters 
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simultaneously. Current techniques are destructive, complicated and often require complementary 
techniques. Significant technological advancement must occur for improved studies of binding, 
bioactivity, and mechanisms of surface-tethered AMPs. While QCM-D is powerful for studies of 
rigid systems such as covalently tethered AMPs [4, 7] or lipid bilayers [8], it has not been utilized 
in the capacity of studying non-covalent or dissipative tethering systems, as discussed in Part II. 
In this respect, scanning electron microscopy (SEM) and other advanced imaging techniques may 
become quite significant in examining morphological effects on microbes as a result of particular 
mechanisms (Chapter 3 addendum). A unique idea is the use of atomic force microscopy (AFM) 
to study nano-level forces on substrates in both liquid and air environments [39]. It is possible that 
collagen-coated AFM cantilevers could be loaded with CBD-LL37 and then used to probe planar 
lipid bilayers or bacteria to determine tethered CBD-LL37 mechanisms of interactions with model 
lipid bilayers. 
 QCM-D provides a wealth of mechanistic information toward soluble peptide activities 
with lipid bilayer models; however, every model system has several pros and cons. The method of 
spontaneous vesicle rupture in QCM-D [40] is only consistent with certain, more simplistic lipid 
compositions, such as those described here. In creating more physiologically relevant model 
systems such as those with phosphatidylethanolamine or cholesterol lipids, QCM-D bilayer 
formation becomes inconsistent and difficult [41]. No model membrane could accurately replicate 
a real E. coli or S. aureus membrane. Indeed, even MIC studies of the same type of bacteria have 
demonstrated deviations from literature due to nuances such as the use of slightly different strains 
(Chapter 3). Though no simple task, future research should be directed toward this goal of creating 
in situ membranes in QCM-D directly from real bacterial membranes. Such an ability would create 
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more realistic models to enable understanding of the mechanisms of not only AMPs, but also all 
new anti-infective therapies in the pipeline. 
 Through CBD-mediated tethering of LL37 onto collagen-based wound dressings, we have 
created a new platform that will help to quench the antibiotic resistance crisis. Interestingly, we 
found that even without tethering onto collagen, both cCBD-LL37 and fCBD-LL37 were still 
broad and effective antimicrobials. They may also promote wound healing, based on previous 
studies of LL37. We asked whether there were other strategies that could be used to deliver 
accurate and bioactive doses of soluble cCBD-LL37 or fCBD-LL37 to combat infection in other 
applications. The delivery of LL37 via poly(lactic-co-glycolic acid) (PLGA) microcapsules was 
found to modulate the delivery of LL37 over time [42]. Further, an interesting finding is that some 
peptides are synergistic with silver [43, 44]. If synergistic, the combination of silver and CBD-
LL37 could effectively eradicate infection, require smaller dosages of expensive peptide, and help 
to heal wounds, thereby overcoming a major problem with silver-based therapeutics [45]. We 
began to investigate this possibility, by studying and investigating different particle formulations 
involving silver nanoparticles, such as Pickering emulsions [46] and coated microspheres for 
delivery to hyaluronic acid-based scaffolds. Results were gathered by: Lozeau, L.D., Shendi, D.M., 
Aquino, A.K. (NSF IGERT CIIF DGE 1144804). However, we did not study the loading of these 
microspheres with either cCBD-LL37 or fCBD-LL37, which would be an immediate next step to 
demonstrate feasibility. Interestingly, this project may broaden the number of binding domains 
studied for LL37 tethering into other biopolymers, such as hyaluronic acid.  
 It is said that a good project has a clear start and a clear end with rational experiments and 
sensible discussion in between. However, the “end” of a great project is instead a new start, with 
a multitude of exciting new questions, applications and projects brought about by the results 
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described within it. Such projects translate to innovation and impact. The results in this thesis 
induced a number of new interesting questions and projects that all have the potential for high 
impact. This includes the potential reduction of CBD-LL37 costs using recombinant production, 
techniques to study collagen-tethered AMP mechanisms, new strategies of AMP delivery and 
exploration of the effect CBD addition has on peptide functionality in the immune system. The 
novelty of CBD-mediated tethering and rarity of the addition of new amino acid sequences onto 
AMPs ensures that every new study of CBD-LL37 will result in exciting new discoveries. Most 
importantly, the answers to these new questions also have far-reaching implications in advancing 
the entire field of AMPs, from reducing costs and developing unique new models, to the 
development of new databases and expanding the biopolymer-tethering platform. The new 
knowledge brought from each study will create a foundation for tethered AMP development that 
will bring us closer solving the antimicrobial resistance threat.  
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Conclusions 
Amidst the antibiotic resistance crisis, the call for antimicrobial alternatives is more urgent 
than ever [1]. Particularly for chronic wound patients, the threat of an infection with resistant 
pathogens severely complicates treatments and significantly increases morbidity. Current 
alternatives for combating chronic wound infection, such as wound dressings coated in silver or 
chemical-based antiseptics are effective at killing bacteria, but prevent the wounds from healing 
which further perpetuates the threat of infection [2, 3]. Antimicrobial peptides (AMPs) are among 
the most promising alternatives to antibiotics currently under development that do not promote 
resistance in bacteria [4, 5]. Specifically, human-derived LL37 demonstrates the broad 
antimicrobial [6] and pro-healing immunomodulatory activities [7] sorely needed by chronic 
wound patients. Unfortunately, its cytotoxicity leading to narrow therapeutic ratio (the ratio of 
antimicrobial efficacy to cytotoxicity) combined with low in vivo stability of LL37 has kept it from 
the clinic. In this thesis, we addressed these shortcomings by developing new chimeric versions of 
LL37 with collagen binding domains (CBD-LL37) for tethering onto collagen-based wound 
scaffolds, for the stable, non-cytotoxic delivery to chronic wounds. 
Herein we have described the design and fundamental studies of two novel chimeric LL37 
with CBDs from collagenase (cCBD-LL37) and fibronectin (fCBD-LL37) for tethering onto 
collagen-based scaffolds for chronic wound healing applications. We began by studying whether 
CBD could mediate collagen tethering in wound scaffolds and then further analyzed how the 
addition of CBDs with different physicochemical properties led to large changes in the observed 
bioactivities implemented by soluble CBD-LL37. 
In summary, we first designed two chimeric LL37 with CBDs and found that they 
effectively bound to and were retained on 100% collagen type I scaffolds. The CBD peptides 
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retained stable antimicrobial activity against common wound pathogens for 14 days and were not 
cytotoxic, thus, collagen binding significantly widened the therapeutic ratio (Chapter 3) [8]. Both 
peptides also bound highly to 90% collagen type I plus 10% calcium alginate composite scaffolds 
over 14 days, but only demonstrated activity against P. aeruginosa, indicating that the presence of 
particular biopolymers such as calcium alginate could alter the bioactivities of CBD-LL37 
(Chapter 4). CBD modification appeared to have large effects on the soluble CBD-LL37 
bioactivities, which we attributed to CBD structural characteristics, such as CBD sequence, charge, 
helicity and amphiphilicity using a combination of modeling and experimental techniques 
(Chapter 5). To develop a mechanistic basis for the observed CBD-mediated changes in 
bioactivity, we first determined the time- and concentration-dependent interactions of unmodified 
LL37 with model mammalian lipid bilayers using quartz crystal microbalance with dissipation 
(QCM-D), since its mechanisms are still controversial in literature [9-13]. This allowed us to 
propose a mechanistic model that corresponded with the bioactive concentrations of LL37 
(Chapter 6). Finally, using the mechanistic insight gained for LL37 as a comparative baseline, we 
used QCM-D and viscoelastic modeling to determine concentration-, time-, CBD structure-, and 
lipid composition-dependent interaction mechanisms of the two CBD-LL37 (Chapter 7). The 
conclusions drawn from this in-depth study regarding CBD-LL37 peptide mechanisms allowed us 
to make predictions for the interactions of two newly designed CBD-LL37, which is powerful in 
the development of this platform. 
The need to discover new ways to utilize QCM-D to maximize its outputs has been 
previously identified [14]. Through our QCM-D studies, we were able to expand on previous 
QCM-D studies in our lab [15-17] by studying additional QCM-D outputs, notably in Chapters 5 
through 7. We did this by forming two different stable anionic planar bilayers, analyzing outputs 
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with viscoelastic modeling, studying time-dependent QCM-D properties, comparing molecular 
signatures of three different but related AMPs, making mechanistic predictions, and corroborating 
findings from peptide-bilayer interactions with other techniques. Indeed, throughout these works, 
the combination of QCM-D with other techniques such as molecular modeling, fluorescent 
imaging, spectroscopy and viscoelastic modeling proved to be powerful in determining details of 
peptide-bilayer interactions. 
Based on all of these studies, we made suggestions for many future directions as well as 
provided some preliminary results for creating a new technique for studying and a new system for 
producing collagen tethered LL37 (Chapter 8). These studies are still under active investigation 
and will considerably advance our current understanding CBD-LL37 as well as encourage the 
development of new CBD-modified AMPs. 
With their immense diversity and functionality, AMPs will demonstrate clinical utility in 
the “post antibiotic era” far beyond that of antibiotics, particularly for chronic wound patients, if 
only their shortcomings can be addressed. The results in this thesis not only demonstrate the 
viability overcoming these shortcomings for LL37 using CBD-mediated collagen tethering, but 
also show promise toward using CBD tethering as a platform AMP delivery strategy. If successful, 
collagen-tethered AMPs could provide a foundation for the successful clinical implementation of 
thousands of new antimicrobial therapeutics that will quench the antibiotic resistance crisis. 
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Table S1: Short Literature Summary of Tethered Antimicrobial Peptides 
Peptidea Substrate Conjugation Method Ref. 
4K-C16 lipopeptide SS 
Allyl glycidyl ether plasma 
polymerization via amine 
groups 
[1] 
6K8L synthetic peptide Polystryene packaging PEG [2] 
Apidaecin 1B 
Anionic photosensitizer 
porphyrin cTTP 
Light activation [3] 
Arginine, lysine, 
tryptophan rich synthetics 
PDMS 
Allyl glycidyl ether polymer 
brush 
[4] 
BMAP-27 
Epoxy, aldehyde, NHS, 
PDITC functionality 
Amine chemistry [5] 
Buforin II 
Epoxy, aldehyde, NHS, 
PDITC functionality 
Amine chemistry [5] 
Cathelin-derived sC18 Amide resin 
Carboxy-functionalized 
imidazolium cations 
[6] 
Cecropin P1 
 Polystyrene 
 Gold 
 Gold 
 Polystyrene 
 Biosensor 
 Maleimide + Cysteine 
 Cysteine 
 Cysteine 
 Maleimide + Cysteine 
 Maleimide + Cysteine 
[7] 
[8] 
[9] 
[10] 
[11] 
Cecropin-Melittin hybrid  Gold NPs  PEG, thiol chemistry [12] 
Chrysophsin-1 
 SiO2 
 SiO2, Gold 
 PEG + Cysteine 
 PEG + Cysteine 
[13] 
[14] 
Chrysophsin-1, truncated 
versions 
Aluminum Acrylate resin brushes [15] 
Chrysophsin-3, truncated 
versions 
Aluminum Acrylate resin brushes [15] 
Defensin Polyelectrolyte films Incorporation [16] 
DP18L Platinum Diaminopropoinic aicd [17] 
Gramicidin A 
 Gold 
 Poly(L-lysine) coating 
 Cystamine SAMs 
 Carboxymethylpullulan 
[18] 
[19] 
Histatin polypeptide --b 
Silver-chlorhexidine 
complex 
[20] 
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IDR-1010cys Polymer brushes Cysteine [21] 
Indolicidin --b 
Levofloxacin via glycolic 
acid 
[22] 
LL37 
 Polyelectrolyte films 
 Titanium 
 Nickel NPs 
 Collagen 
 Magnetic NPs 
 Epoxy, aldehyde, NHS, 
PDITC functionality 
 Amide resin 
 Carbodiimide chemistry 
 Silane with PEG 
 Nanolayer of Polyacrylic 
acid using plasma 
 Collagen Binding Domains 
 Electrostatic adsorption 
 Amine chemistry 
 Carboxy-functionalized 
imidazolium cations 
[23] 
[24] 
[25] 
[26] 
[27] 
[5] 
[6] 
Magainin-KLAL hybrid Resins PEG polymers [28] 
Magainin 2 deletions Resins 
Ethylenediamine-carboxylic 
acid chemistry 
[29] 
Magainin I 
 Gold 
 Silica microparticles 
 Silicon Wafers 
 Mercaptuondecanoic aicd 
+ mercaptohexanol 
 Copolymer brushes of 
oligo(ethylene 
glycol)methacrylates 
 Methacrylate brushes 
[30] 
[31] 
[32] 
Magainin I SS Chitosan polymeric layer [33] 
Melimine Glass ABA, FNA azide linkages [34] 
Melittin-protamine hybrid Contact Lenses Carbodiimide chemistry [35] 
MSI-78 SiO2 Silane chemistry [36] 
Nisin 
 SS 
 SS 
 SS 
 Layer-by-layer 
poly(methacylamide) and 
dihydroxyphenylalinine 
 Chitosan polymeric layer 
 Allyl glycidyl ether plasma 
polymerization via amine 
groups 
[37] 
[33] 
[1] 
Tritrpticin SS 
Allyl glycidyl ether plasma 
polymerization via amine 
groups 
[1] 
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Pep-4 --b Levofloxacin [38] 
Polymyxin B Glass Sol-gel tech, silane coating [39] 
Ponericin P1 Polyelectrolyte films Incorporation [40] 
PGQ Biosensor Cysteine + maleimide [11] 
RRWRIVVIRVRRC Polyurethane Cysteine [41] 
SMAP-29 Biosensor Cysteine + maleimide [11] 
Tet213 Titanium 
Maleimide + cysteine with 
polymer brushes 
[42] 
Tritrpticin SS 
Allyl glycidyl ether plasma 
polymerization via amine 
groups 
[1] 
 
aNote that this is not a comprehensive list. For excellent reviews on antimicrobial peptide tethering 
and conjugation consult [43-45]. 
bIndicates physisorption of the peptide as a means of conjugation.  
 
Table Abbreviations: SS-Stainless steel; PEG-Poly(ethylene glycol); PDMS-
polydimethylsiloxane; SAMs-Self-assembled monolayers; SiO2-Silicon dioxide; NHS-N-
Hydroxysuccinimide; PDITC-p-Phenylene diisothiocyanate; NPs-Nanoparticles; ABA-4-
azidobenzoic acid; FNA-4-fluoro-3-nitrophenyl azide; Pep-Peptide; PGQ-Three residue peptide 
of a proline, glycine and glutamine. 
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Table S1: Minimum inhibitory concentrations of LL37, cCBD-LL37 and fCBD-LL37 against 
different bacteria strains, with µM values (from Table 1) provided in bold lettering, and values 
converted to µg/mL in parentheses. 
 Microbe 
Published 
MIC for 
LL37, µM 
(µg/mL) [1] 
LL37 
µM 
(µg/mL) 
cCBD-LL37 
µM 
(µg/mL) 
fCBD-LL37 
µM 
(µg/mL) 
 E. coli HB101 
0.42 
(1.89) 
0.77 ± 0.12 
(3.46±0.54) 
0.67 ± 0.20 
(4.23±1.26) 
2.92 ± 1.10* 
(19.3±7.28) 
 E. coli B78 -- 
1.67 ± 0.42 
(7.51 1.89) 
1.15 ± 0.10 
(7.26±0.63) 
6.46 ± 3.03 
(47.8±20.1) 
 P. aeruginosa 
1.27 
(5.71) 
0.69 ± 0.07 
(3.10±0.31) 
0.49 ± 0.06 
(3.10±0.38) 
9.17 ± 1.67* 
(60.7±11.1) 
 S. epidermidis 
0.56 
(2.52) 
0.50 ± 0.04 
(2.25±0.18) 
0.53 ± 0.22 
(3.35±1.39) 
10.0 ± 2.50* 
(66.2±16.6) 
 S. aureus 
0.80 
(3.60) 
0.45 ± 0.05 
(2.02±0.22) 
0.64 ± 0.27 
(4.04±1.71) 
6.67 ± 0.83* 
(44.2±5.49) 
 
Methicillin-resistant 
S. aureus (MRSA) 
0.76 
(3.42) 
0.68 ± 0.07 
(3.06±0.31) 
8.13 ± 0.68* 
(51.36±4.30) 
5.83 ± 0.83* 
(38.6±5.49) 
 
Methicillin-, 
Gentamycin-
resistant S. aureus 
(M/GRSA) 
2.34 
(10.52) 
7.50 ± 0.00 
(33.7±0.00) 
8.33 ± 0.83 
(52.6±5.24) 
5.83 ± 0.83 
(38.6±5.49) 
 B. subtilis 
0.60 
(2.70) 
0.53 ± 0.09 
(2.38±0.40) 
2.25 ± 0.49 
(14.2±3.10) 
5.83 ± 1.10** 
(38.6±7.28) 
Mean is significantly different from mean for LL37; *p<0.001 or **p<0.05 (n=3). 
Values in bold are in µM, values in parentheses are given in µg/mL for comparison. 
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Figure S1: Antimicrobial peptide cytotoxicity in CT1005 fibroblasts. Relative fluorescent units 
(x103), indicating the level of viable CT1005 primary human fibroblasts, based on AlamarBlue® 
reduction when exposed to LL37, cCBD-LL37 and fCBD-LL37 in solution after 8 hours. All 
values represent standard error from at least three experimental replicates. The dotted line 
represents the average medium-only fluorescence; the vertical line represents the reported 
cytotoxic threshold of soluble LL37 [2]; statistical significance is indicated by: *All treatments 
different from untreated, no AMP control, p<0.001, **fCBD-LL37 is different from all other 
AMPs, p<0.001; ***cCBD-LL37 is different from fCBD-LL37, p<0.01.  
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Figure S2: Peptide localization on collagen scaffolds during controlled release studies. 
Representative immunohistochemistry images of scaffold sections harvested at different time 
points during the controlled release study. Sections were stained using anti-human LL37 and 
visualized with AlexaFluor®488-conjugated secondary antibody (LL37; green). (a) PBS-, (b) 
LL37-, (c) cCBD-LL37- and (d) fCBD-LL37-adsorbed scaffolds; bar = 100 µm.   
(a)
1 hour 1 day 4 days 7 days 14 days
(b)
(c)
(d)
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Figure S3: Fibroblast distribution on peptide-loaded and control scaffolds. Representative 
immunohistochemistry images of scaffold sections harvested 24 hours after seeding with 
fibroblasts. Sections were stained with anti(human)-LL37, visualized with AlexaFluor®488-
conjugated secondary antibody (LL37; green) and counterstained with Hoechst 33342 (DNA; 
blue). Scaffolds without cells (a) were compared to cell-seeded scaffolds adsorbed with (b) PBS, 
(c) LL37, (d) cCBD-LL37 and (e) fCBD-LL37; bar = 100 µm. 
 
  
(c) LL37
(b) PBS
(d) cCBD-LL37 (e) fCBD-LL37
(a) PURACOL® (--) Cells
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Figure S1: Visualizing additional morphological characteristics of FIBRACOL (left) and 
PURACOL (right) scaffolds. Scanning electron micrographs of dry, sterile and sputter-coated 
scaffolds (A-B) taken at 10 kV; bar = 500 µm. Representative histological images of scaffold 
sections at a higher magnification than in Fig. 1, first with PicroSirius red/Fast Green staining for 
collagen (C-D) and second with Toluidine blue staining for alginate (E-F); bar = 100 µM. 
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SUPPLEMENTARY MATERIAL S2 
Calculation of FIBRACOL and PURACOL Loading 
The same loading concentrations were used on both of the scaffolds described in the text. However, 
it was necessary to estimate the maximum loading on both scaffolds to determine whether or not 
there were large discrepancies in the amount of peptide loaded on FIBRACOL versus PURACOL 
scaffolds. Calculations described here were carried out in a similar manner to what was described 
previously [1, 2]. 
FIBRACOL® Plus (Acelity, San Antonio, TX) came packaged in square sheets, 26.01 cm2 
(5.1 x 5.1 cm). The mass of a single sheet was 0.0777 g was measured by an Explorer analytical 
balance (Ohaus Corporation, Parsippany, NJ), thus, each sheet had a superficial density of 0.0030 
g/cm2, or 3.0 mg/cm2. In contrast, the superficial density of PURACOL® (Medline Industries, 
Mansfield, MA), was 2.4 mg/cm2. 
Each scaffold was then cut into 5 mm circular disks, sterilized and loaded as described in 
Section 2.2. The surface area of each disk was thus 0.196 cm2, the same as that of PURACOL. 
Using this and the superficial density, the mass of a single 5 mm disk was estimated to be 0.59 mg 
for FIBRACOL, compared with 0.47 mg for PURACOL. This value is similar to the mass of 
FIBRACOL disks measured experimentally, where 7 disks were measured simultaneously to 
calculate 0.64 mg per disk. In FIBRACOL, 90% of the scaffold composition is bovine collagen 
type I and 10% is calcium alginate, thus the mass of collagen was assumed as 0.53 mg. 
The mass of a collagen triple helix is estimated to be 280 kDa, which corresponds to a mass 
of 4.65x10-19 g per collagen molecule. It is estimated that binding of collagenase molecules to 
collagen triple helices occurs in a 1:1 ratio [3], thus, we assumed this ratio for cCBD-LL37 and 
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fCBD-LL37. Thus, the number of binding sites (N) available in FIBRACOL for peptides to bind, 
would be equivalent to the number of triple helix monomers in FIBRACOL. To calculate N, we 
used the masses (m) of collagen and triple helices in Eq. 1. 
𝑁 =
𝑚𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛
𝑚𝑡𝑟𝑖𝑝𝑙𝑒 ℎ𝑒𝑙𝑖𝑥
=
0.00053 𝑔
4.65𝑥10−19𝑔
        Eq. 1 
Thus, N was 1.13x1015 in FIBRACOL compared to 9.93x1014 in PURACOL. This makes 
sense because the superficial density of FIBRACOL was higher than that of PURACOL. To 
determine the density of peptides required for maximum loading, the mass of each peptide, 
7.46x10-21, 1.04x10-20 and 1.10x10-20 g per LL37, cCBD-LL37 and fCBD-LL37 molecule, 
respectively, was used to calculate the mass required to saturate N binding sites. These masses 
were 8.47, 11.9 and 12.5 µg for LL37, cCBD-LL37 and fCBD-LL37, respectively. 
A volume that was suitable to completely wet PURACOL disks was 5 µL. Despite the 
much larger swelling ratio of FIBRACOL, 5 µL was also sufficient to wet the entire scaffold. 
Based on this volume and the masses of each peptide required to saturate FIBRACOL binding 
sites, the loading concentrations were calculated and compared with FIBRACOL (Table S2.1). 
Table S2.1: Comparison of the maximum peptide loading concentrations on FIBRACOL 
and PURACOL. 
Peptide 
FIBRACOL 
(µg/mL) 
PURACOL 
(µg/mL) 
LL37 1694 1478 
cCBD-LL37 2382 2078 
fCBD-LL37 2496 2178 
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Using the volume of each scaffold, the concentrations of loaded peptides are 329 µM on 
PURACOL and 377 µM on FIBRACOL. FIBRACOL was loaded at 329 µM, in the same manner 
as PURACOL. Unsaturation of 14% of N could be another reason for discrepancy observed in 
peptides bioactivities on FIBRACOL versus PURACOL. Further consideration of the higher 
swelling capacity (Q) of FIBRACOL would further decrease the concentration of each peptide 
within FIBRACOL scaffolds per unit volume and reduce concentrations of released, soluble 
peptides, also reducing bioactivity. Results from this loading calculation clearly demonstrate a 
need for a future systematic study of CBD-LL37 loading concentrations on different biopolymer 
scaffolds, to optimize their binding and desired bioactivities. This will further enable the cost 
calculations and feasibility analyses for implementing CBD-LL37 peptides in clinical wound 
healing applications. 
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Figure S3: Cytotoxicity of LL37, cCBD-LL37 and fCBD-LL37 on FIBRACOL against 
human dermal fibroblasts at 8 hours and 7 days. The relative fluorescent units (x103) produced 
by AlamarBlue® reagent reduction, correlated to the number of viable CRL-2352 fibroblasts after 
8 hours’ (A) and 7 days’ (B) exposure to peptide-loaded scaffolds. Bars represent the mean ± S.D 
of n=3 replicates. Statistically significant difference of PBS-, LL37-, cCBD-LL37- and fCBD-
LL37-loaded scaffolds versus medium-only and cell-only controls, *p<0.001 (post-hoc Tukey 
test), and of PBS-, cCBD-LL37- and fCBD-LL37- vs. LL37-loaded scaffolds, **p<0.05 (post-hoc 
Tukey test). (C) Representative IHC images of scaffold sections harvested after 7 days’ exposure 
of fibroblasts to PBS only, LL37, cCBD-LL37 and fCBD-LL37, stained with LL37 (green) and 
DNA (blue); bar = 100 µm.  
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Figure S4: Cellular infiltration on collagen-based FIBRACOL scaffolds at 24 hours and 7 
days. Representative images of PBS-, LL37-, cCBD-LL37-, and fCBD-LL37-loaded scaffold 
sections stained with Hematoxylin and Eosin, showing collagen (red) and cytosolic components 
(purple) after seeding with human fibroblasts for 24 hours (A) and 7 days (B); bar = 100 µM. 
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Figure S5: Visualizing LL37 and CBD-LL37 peptides on FIBRACOL after interactions with 
bacteria. Representative IHC images of FIBRACOL scaffold sections after 12 hours’ exposure to 
Gram-negative strains (A) E. coli and (B) P. aeruginosa and Gram-positive strains, (C) S. aureus 
and (D) S. epidermidis, stained with anti(human)-LL37 antibody; bar = 100 µm. 
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Figure S6: Visualizing the localization of different bacterial strains on loaded FIBRACOL 
and PURACOL scaffolds. Representative histological images of PBS- or peptide-loaded 
FIBRACOL (top panels A-D) and PURACOL (bottom panels, A-D) sections after 12 hours’ 
interaction with Gram-negative strains (A) E. coli and (B) P. aeruginosa and Gram-positive strains 
(C) S. aureus and (D) S. epidermidis. Scaffolds were stained with differential Hucker-Twort, 
staining scaffolds in (light and dark purple and red), Gram-negative (red) and Gram-positive (blue) 
bacteria; bar = 20 µM with oil immersion. 
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Figure S7: Co-localization of LL37, cCBD-LL37 and fCBD-LL37 and collagen on 
FIBRACOL compared to PURACOL. Representative IHC images scaffold sections after 12 
hours’ exposure to Gram-negative strains (A) E. coli and (B) P. aeruginosa and  Gram-positive 
strains (C) S. aureus and (D) S. epidermidis, and compared to (E) PURACOL scaffold sections 
after 12 hours of exposure to S. epidermidis, stained with anti(human)-LL37, green, and 
anti(collagen), red, antibodies; bar = 100 µm. 
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Figure S8: The distribution of LL37, cCBD-LL37 and fCBD-LL37 peptides loaded onto 
PURACOL after interaction with different bacteria**. Representative IHC images of 
PURACOL sections after 12 hours’ exposure to Gram-negative strains (A) E. coli and (B) P. 
aeruginosa and Gram-positive strains (C) S. aureus and (D) S. epidermidis, stained with 
anti(human)-LL37 antibody; bar = 100 µm. 
 
**Data outline in pink boxes has been reproduced with permission for comparison from: [1] 
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Figure S1. LL37, cCBD-LL37 and fCBD-LL37 Sequence Dimensions and Overall Lengths. The 
dimensions and lengths of LL37 (A), cCBD-LL37 (B) and fCBD-LL37 (C) modeled in 100% 
water, from CN terminus, and the estimated overall peptide lengths in both 100% water (left) 
and 50% v/v trifluoroethanol (TFE) (right), and (D), all calculated using MD simulations. 
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Figure S2. Peptide Hydrophobicity Profiles in Different Simulated Solvents. The hydrophobicity 
profiles of the final conformations of LL37 (A), cCBD-LL37 (B) and fCBD-LL37 (C) in simulated 
100% water (left) and 50% v/v TFE (right) solutions with hydrophobic residues (brown) and 
hydrophilic residues (blue) demonstrated on a scale from 3 (most hydrophobic) to -3 (most 
hydrophilic). 
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Figure S3. Experimental Secondary Structure at 37°C. Representative CD spectra (θ, mdeg versus 
wavelength, nm) at 37°C for 20 µM LL37 (triangles), cCBD-LL37 (circles), and fCBD-LL37 
(squares) in 100% water (black symbols) and 50% v/v TFE (white symbols) (A). From CD spectra, 
the content of secondary structures in the form of helices, beta strands, turns and unordered 
percentages was determined using CDSSTR modeling with SMP180 reference protein set in 
DICHROWEB (B). Statistical analyses were performed to compare between peptides within 100% 
water and 50% v/v TFE groups, and also between 100% water and 50% v/v TFE. All comparisons 
demonstrated statistical significance, one-way ANOVA, p<0.05, except for (1) the content of 
unordered structure of cCBD-LL37 and LL37 in 100% water, (2) all structural content between 
peptides in 50% v/v TFE and (3) the content of turn structures in fCBD-LL37 between 100% water 
and 50% v/v TFE. 
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Figure S4. Helicity Predicted in 100% Water using MD Simulations. Ribbon diagrams for LL37 
(A), cCBD-LL37 (B) and fCBD-LL37 (C) modeled in 100% water, constructed by MD 
simulations, highlighting helical resides in red, beta turn residues in green, and random coils in 
gray. Using the ribbon diagrams, the percent of helical residues (D) in the whole peptides and just 
the LL37 portion of the peptides was estimated. 
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Figure S5. Overall Frequency and Dissipation Changes due to PC Interactions with Low and High 
Concentrations of Peptides. The overall changes in Δf (Hz) (A) and ΔD (1E-06) (B) for the 3rd 
through 11th overtones at very low concentrations of LL37, cCBD-LL37 and fCBD-LL37 (0.01-
0.1 µM) against PC only bilayers. A comparison of Δf and ΔD for the 3rd through 11th overtones 
of interactions of high concentrations, 15 µM for LL37 and 20 µM for cCBD-LL37 and fCBD-
LL37 with PC bilayers (C). Values represent the mean ± S.E. of n>3 replicates per peptide, per 
concentration. The data for LL37 vs. PC only bilayers at 0.10 µM and 15.0 µM is described and 
discussed in more detail elsewhere [1]. 
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Figure S6. QCM-D Profiles of Different Bilayers with Fluorescent Lipids. Comparison of the Δf 
(Hz, blue) and ΔD (1E-06, red) versus time (min) profiles at all overtones for the formation of PC 
only (A) versus PC plus 1% NBD-PC lipids (B), and the formation of 4:1 (mole percent) 
POPC:POPG (C) versus 4:1 POPC:POPG plus 1% NBD-PC lipids incorporated into the POPC 
portion (D). Time stamps are indicated by vertical dotted lines. PC was formed in Tris buffer, pH 
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7.8; Tris rinses are represented by (i) highlighted in yellow in A-B. 4:1 POPC:POPG was formed 
in MOPS buffer, pH 7.0 with CaCl2, MOPS(+). Rinses with MOPS(+) are represented in C-D by 
(i) highlighted in green, followed by rinses with MOPS(-), without CaCl2, represented in C-D by 
(ii) highlighted in yellow.  
 
 
Figure S7. Control Images of Fluorescent Bilayers and Physically Adsorbed Peptide Layers. 
Representative fluorescent images of PC bilayers plus 1% (wt/vol) NBD-PC alone (A), 4:1 
POPC:POPG bilayers 1% NBD-PC alone (B) and physically adsorbed LL37 (C), cCBD-LL37 (D) 
and fCBD-LL37 (E), all at 10 µM, directly adsorbed onto SiO2 crystal sensors. Bar = 100 µm. 
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Figure S1: Physicochemical properties, bioactive concentrations and amphiphilicitya of 
LL37. 
 
aHelical wheel diagram [1] drawn with Heliquest (http://heliquest.ipmc.cnrs.fr/) [2], represents a 
view parallel to the LL37 alpha-helix, with charged polar (blue/red), uncharged polar 
(gray/pink/purple), and non-polar (yellow/green) residues, and hydrophobic moment (arrow).  
bIndicates a concentration range where LL37 kills red blood cells, and demonstrates some 
cytotoxic but not lethal activities against other types of mammalian cells [3-5]. 
cIndicates concentrations where LL37 kills mammalian cells [3]. 
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Figure S2: Representative QCM-D Δf and ΔD profiles with time at different concentrations 
and overtones. Representative Δf (blue) and ΔD (red) versus time profiles after the introduction 
of LL37 to PC lipid bilayers (at time 0). LL37 (0.10 – 15.0 µM) was introduced, followed by a 
static incubation and a final Tris rinse (at time 70 min). 
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Figure S3: Concentration-dependent physical adsorption of LL37 on SiO2. The average 
equilibrium values of A, Δf, B, ΔD, C, mass adsorption (Δm), and D, thickness (nm) and 
calculation of KD (inset), all versus concentration (µM) of LL37 physically adsorbed onto SiO2 
crystal sensors. In A-C, dark circles and light triangles represent the equilibrium values before and 
after the final Tris buffer rinses, respectively. High and low concentrations are separated by a 
vertical dotted line. All values represent means ± S.E of n>4 replicates. 
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Figure S4: Removal of PC bilayers with detergent at the 11th overtone. The Δf and ΔD QCM-
D versus time profiles after interaction of different film compositions with 0.1% (w/v) SDS at the 
11th overtone, which is more closely associated with phenomena closer to the sensor crystal 
surface. The Δf that predicts full SLB removal (25 Hz) is marked by a horizontal dotted line. All 
other overtones demonstrated similar Δf and ΔD responses. 
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Figure S5: Molecular signatures of LL37 at the 7th and 11th overtones. Representative ΔD vs. 
Δf plots of the LL37-PC interactions at A, low concentrations (0.25 – 1.00 µM) and B, high 
concentrations (2.00 – 15.0 µM). C, Representative ΔD vs. Δf plots of physically adsorbed LL37 
on SiO2 (0.10 – 10.0 µM). Numbered arrows indicate the progression of the interactions with time 
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and arrows labeled “R” indicate processes associated with the final Tris rinse. Signatures at the 7th 
and 11th overtones are presented; all overtones demonstrated similar profiles. 
 
 
 
Figure S6. Molecular signatures of LL37 at concentrations lower than 0.25 µM. 
Representative ΔD vs. Δf plots of the LL37-PC interactions at 0.01 µM (red), 0.05 µM (blue), 0.10 
µM (green) at the A, 3rd, B, 7th and C, 11th overtones. Insets are provided with different scales. 
 
360 
 
 
Figure S7: Changes in film thickness versus time due to rinses and interactions with low 
LL37 concentrations. A, representative profiles of thickness (nm) versus time (min) at all LL37 
concentrations (0.10 – 15.0 µM) during the final buffer rinse (indicated with an arrow) and B, 
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representative profiles of thickness versus time at the lowest tested LL37 concentrations (0.01 – 
0.10 µM), during peptide introduction (top) and the final Tris rinse (bottom). 
 
 
Figure S8: Graphical depiction of the peak values in QCM-D measurements (summarized in 
Table 1) at high and low concentrations. The local peak values of A, ΔfMIN, B, ΔDMAX, C, 
corresponding mass change, ΔmMAX (ng) and D, modeled maximum thickness (nm), all versus 
LL37 concentration (µM). High and low concentrations are separated by a vertical dashed line; 
peak values appeared at high concentrations. Peaks were not observed at low concentrations (0.10-
1.00 µM); thus, peak values were equivalent to overall values in these concentration ranges 
(presented in Fig. 2A). Concentrations from 0.10 – 1.00 µM correlate with 2nd order polynomials 
(R2>0.999). For A-C, the 3rd, 7th and 11th overtones are shown, connected by dotted lines for ease 
of visualization; however, it should be noted that they are discreet values with concentration and 
should not be used to illustrate changes at concentrations between the discreet points. All values 
represent means ± S.E of n>4 replicates. 
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Figure S9: Biophysical properties of the QCM-D model system at different LL37 
concentrations, including the velocity (v), Peclet Number (NPe) and flux values in the x- and y-
directions. Calculations in the x- and y-directions utilize the crystal sensor diameter and height of 
the chamber above the bilayer, respectively. NPe was calculated assuming an extended helix 
monomer of LL37 as well as a 20-mer peptide aggregate. Flux calculations were calculated 
assuming an extended helix monomer only.  
 
 
 
  
363 
 
Appendix 6 References 
[1] M. Schiffer, A.B. Edmundson, Use of helical wheels to represent the structures of proteins and 
to identify segments with helical potential, Biophysical journal, 7 (1967) 121. 
[2] R. Gautier, D. Douguet, B. Antonny, G. Drin, HELIQUEST: a web server to screen sequences 
with specific α-helical properties, Bioinformatics, 24 (2008) 2101-2102. 
[3] Y. Kai-Larsen, B. Agerberth, The role of the multifunctional peptide LL-37 in host defense, 
Frontiers in bioscience: a journal and virtual library, 13 (2007) 3760-3767. 
[4] M.J. Oudhoff, M.E. Blaauboer, K. Nazmi, N. Scheres, J.G. Bolscher, E.C. Veerman, The role 
of salivary histatin and the human cathelicidin LL-37 in wound healing and innate immunity, 
Biological chemistry, 391 (2010) 541-548. 
[5] A.J. Duplantier, M.L. Van Hoek, The human cathelicidin antimicrobial peptide LL-37 as a 
potential treatment for polymicrobial infected wounds, Fronteirs in immunology, 4 (2013) 
10.3389. 
 
364 
 
Appendix 7 
 
 
Chapter 7 Supplementary Material  
365 
 
Mechanistic Predictions of the Influence of Collagen-Binding Domain Sequences on Human 
LL37 Interactions with Model Lipids using QCM-D 
Lindsay D. Lozeaua, Marsha W. Rolleb and Terri A. Camesanoa* 
 
aDepartment of Chemical Engineering, bDepartment of Biomedical Engineering, Worcester 
Polytechnic Institute, Worcester, MA 01609 USA 
 
SUPPLEMENTARY MATERIAL 
 
*Corresponding Author 
Terri A. Camesano 
100 Institute Road 
Worcester, MA 01609 
(O): 1(508)831-5380 
(E): terric@wpi.edu 
  
366 
 
 
Figure S1: Representative QCM-D Δf and ΔD profiles of LL37 with time and concentration. 
Representative Δf (left) and ΔD (right) versus time profiles after the introduction of LL37 to 
charged bilayers, A-B, 4:1 POPC:POPG and C, 4:1 DMPC:DMPG (molar ratios). For 
POPC:POPG, the concentrations are separated into A, low LL37 concentrations (0.25 – 1.00 µM) 
and B, high LL37 concentrations (2.00 – 10.0 µM). The 3rd overtones only are shown normalized 
to the equilibrated bilayer Δf and ΔD values; all overtones had similar profiles. 
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Figure S2: The large QCM-D profiles Δf and ΔD for 20.0 µM fCBD-LL37 against PC. 
Representative Δf (left) and ΔD (right) versus time profiles after the introduction of 20.0 µM 
fCBD-LL37 to zwitterionic PC only. The 3rd overtones only are shown normalized to the 
equilibrated bilayer Δf and ΔD values; all overtones had similar profiles. 
 
 
Figure S3: Predicted ΔfMIN versus actual Δf for a carpet-like, surface adsorption model for 
cCBD-LL37. A, The predicted ΔfMIN (Hz) for cCBD-LL37 adsorption onto bilayer surfaces. These 
predictions may be compared to B, the overall average Δf observed in QCM-D. The 3rd overtone 
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for Δf is presented to allow for maximum Δf magnitudes to be compared with predicted values. 
Other overtones are reported elsewhere (Chapter 5). Predicted ΔfMIN for cCBD-LL37 adsorption 
is not a good match at concentrations >1.00 µM. 
 
 
Figure S4: Predicted ΔfMIN versus actual Δf for two different pore-forming mechanisms for 
fCBD-LL37. The predicted ΔfMIN (Hz) for fCBD-LL37 inserting into bilayers as A, monomers or 
dimer clusters or B, water-filled transmembrane pores comprised of different participating 
numbers of peptides. These predictions may be compared to C, the overall average Δf observed in 
QCM-D. The 3rd overtone for Δf is presented to allow for maximum Δf magnitudes to be compared 
with predicted values. Other overtones are reported elsewhere (Chapter 5). Predicted ΔfMIN for 
either mechanism are not good fits; the prediction is too high in magnitude for monomers or 
clusters, and is too low in magnitude for water-filled pores. 
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Figure S5: Predictions of ΔfMIN compared to actual Δf for pore-forming and adsorption 
mechanisms for LL37. The predicted ΔfMIN (Hz) for LL37 A, insertion into bilayers as monomers 
or dimer clusters, B, insertion into bilayers as water-filled transmembrane pores comprised of 
different participating numbers of peptides, or C, adsorption onto bilayer surfaces. These 
predictions may be compared to D, the overall average Δf observed in QCM-D. The 3rd overtone 
for Δf is presented to allow for maximum Δf magnitudes to be compared with predicted values. 
Other overtones are reported elsewhere (Chapter 5). Predicted ΔfMIN are a better fit past the 
“threshold concentration” between 1.00 and 2.00 µM for water-filled transmembrane pores. 
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Figure S6: Thickness of physically adsorbed LL37 and cCBD-LL37 in different buffers. The 
thickness (nm) versus concentration (µM) for A, LL37 and B, cCBD-LL37 in MOPS buffer, pH 
7.0, phosphate-buffered saline buffer (PBS), pH 7.4, and Tris buffer, pH 7.8 and C, a comparison 
of buffer composition. In A-B all values represent mean ± S.E. of n>4 replicates for each 
concentration. 
 
 
Figure S7: Density as a function of LL37 concentration against different bilayer 
compositions. The overall changes in calculated density (kg/m3) at the 3rd (purple) and 11th 
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(orange) overtones due to LL37, all versus peptide concentration (µM) against A, PC only*, B, 
4:1 POPC:POPG, and C, 4:1 DMPC:DMPG bilayers. Dotted lines represent original bilayer 
densities. All values represent mean ± S.E. of n>4 replicates. 
*Note that the thickness values reported here for LL37 on PC bilayers were recently submitted for 
publication in Colloids and Surfaces B: Biointerfaces (See Chapter 6). 
 
 
Figure S8: Dynamics of LL37 interactions with charged** bilayers. Representative ΔD vs. Δf 
plots of LL37 at concentrations ranging from 0.25 – 10.0 µM against A, 4:1 POPC:POPG and B, 
4:1 DMPC:DMPG bilayers. C, representative ΔD vs. Δf plots of physically adsorbed LL37 on 
SiO2 substrates (0.50 – 10.0 µM) in MOPS 7.0 (charged bilayer buffer; top) and Tris 7.8 (PC only 
buffer; bottom). Numbered and colored arrows indicate the progression of membrane interactions 
with time, and “R” represents the processes associated with the final buffer rinse. For simplicity, 
plots of the 3rd overtones only are presented; all overtones demonstrated similar ΔD vs. Δf 
signatures. 
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**Note that the molecular signatures for LL37 on PC bilayers were recently submitted for 
publication in Colloids and Surfaces B: Biointerfaces (see Chapter 6). 
 
 
Figure S9: Changes in film thickness with time due to LL37-charged*** bilayer interactions. 
Representative profiles of thickness (nm) versus time at different concentrations of LL37 (ranging 
from 0.10 – 10.0 µM) against A, 4:1 POPC:POPG and B, DMPC:DMPG bilayers.  
***Note that the thickness versus time profiles for LL37 on PC bilayers were recently submitted 
for publication in Colloids and Surfaces B: Biointerfaces (See Chapter 6). 
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Figure S10: Dynamics of fCBD-LL37 physical adsorption on SiO2 in different buffers. 
Representative ΔD vs. Δf plots of fCBD-LL37 physically adsorbed onto SiO2 sensor crystals at 
concentrations ranging from 0.50 – 10.0 µM in A, MOPS 7.0 buffer (charged bilayer buffer) and 
B, Tris 7.8 (PC only buffer). Numbered and colored arrows indicate the progression of the 
interactions with time, and “R” represents the processes associated with the final buffer rinse. For 
simplicity, plots of the 3rd overtones only are presented; all overtones demonstrated similar ΔD vs. 
Δf signatures. 
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Figure S11: Changes in film thickness with time due to interactions of fCBD-LL37. With 
different bilayers. Representative profiles of thickness (nm) versus time at different 
concentrations of fCBD-LL37 (ranging from 0.10 – 20.0 µM) against A, PC only, B, 4:1 
POPC:POPG and C, DMPC:DMPG bilayers. D, for comparison, the thickness vs. time at different 
concentrations (0.50 – 10.0 µM) of fCBD-LL37 physically adsorbed onto SiO2 in MOPS 7.0 (left) 
and Tris 7.8 (right). 
 
 
Figure S12: Dissociation constant of CBD-LL37 peptides compared to LL37 in buffers with 
different compositions. The calculated dissociation constant (KD; nM) of LL37, cCBD-LL37 and 
fCBD-LL37 in MOPS, PBS, and Tris buffers at three different pHs. Values represent the mean ± 
S.E. of n>4 replicates. 
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